UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form
(Mark One)
| | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
| FOR THE QUARTERLY PERIOD ENDED | |
| OR | |
| | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
FOR THE TRANSITION PERIOD FROM _____TO
COMMISSION FILE NUMBER:
HORIZON TECHNOLOGY FINANCE CORPORATION
(Exact name of registrant as specified in its charter)
| | | |
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | |
| | ||
| | | |
| (Address of principal executive offices) | (Zip Code) |
(
(Registrant’s telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b‑2 of the Exchange Act.
| Large accelerated filer | ☐ | Accelerated filer | ☐ | |
| | ☒ | Smaller reporting company | | |
| Emerging growth company | |
| If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act | ☐ |
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b‑2 of the Exchange Act). Yes
The number of shares of the registrant’s common stock traded under the symbol “HRZN” on the Nasdaq Global Select Market, $0.001 par value per share, outstanding as of October 29, 2024 was
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Ticker symbol(s) | Name of each exchange on which registered | ||
| | | The | ||
| | | The | ||
| | | The |
HORIZON TECHNOLOGY FINANCE CORPORATION
FORM 10‑Q
TABLE OF CONTENTS
Item 1. Consolidated Financial Statements
Horizon Technology Finance Corporation and Subsidiaries
Consolidated Statements of Assets and Liabilities
(Dollars in thousands, except share and per share data)
| September 30, | December 31, | |||||||
| 2024 | 2023 | |||||||
| (Unaudited) | ||||||||
| Assets | ||||||||
| Non-affiliate investments at fair value (cost of $ and $, respectively) | $ | $ | ||||||
| Non-controlled affiliate investments at fair value (cost of $ and $, respectively) (Note 5) | ||||||||
| Controlled affiliate investments at fair value (cost of $ and $, respectively) (Note 5) | ||||||||
| Total investments at fair value (cost of $ and $, respectively) (Note 4) | ||||||||
| Cash | ||||||||
| Investments in money market funds | ||||||||
| Restricted investments in money market funds | ||||||||
| Interest receivable | ||||||||
| Other assets | ||||||||
| Total assets | $ | $ | ||||||
| Liabilities | ||||||||
| Borrowings (Note 7) | $ | $ | ||||||
| Distributions payable | ||||||||
| Base management fee payable (Note 3) | ||||||||
| Other accrued expenses | ||||||||
| Total liabilities | ||||||||
| Commitments and contingencies (Notes 3 and 8) | ||||||||
| Net assets | ||||||||
| Preferred stock, par value $ per share, shares authorized, shares issued and outstanding as of September 30, 2024 and December 31, 2023 | ||||||||
| Common stock, par value $ per share, shares authorized, and shares issued and and shares outstanding as of September 30, 2024 and December 31, 2023, respectively | ||||||||
| Paid-in capital in excess of par | ||||||||
| Distributable loss | ( | ) | ( | ) | ||||
| Total net assets | ||||||||
| Total liabilities and net assets | $ | $ | ||||||
| Net asset value per common share | $ | $ | ||||||
See Notes to Consolidated Financial Statements
Consolidated Statements of Operations (Unaudited)
(Dollars in thousands, except share and per share data)
| For the Three Months Ended |
For The Nine Months Ended |
|||||||||||||||
| September 30, |
September 30, |
|||||||||||||||
| 2024 |
2023 |
2024 |
2023 |
|||||||||||||
| Investment income |
||||||||||||||||
| From non-affiliate investments: |
||||||||||||||||
| Interest income |
$ | $ | $ | $ | ||||||||||||
| Fee income |
||||||||||||||||
| Payment-in-kind interest income |
||||||||||||||||
| From non-controlled affiliate investments: |
||||||||||||||||
| Interest income |
||||||||||||||||
| From controlled affiliate investments: |
||||||||||||||||
| Interest income |
||||||||||||||||
| Payment-in-kind interest income |
||||||||||||||||
| Total investment income |
||||||||||||||||
| Expenses |
||||||||||||||||
| Interest expense |
||||||||||||||||
| Base management fee (Note 3) |
||||||||||||||||
| Performance based incentive fee (Note 3) |
||||||||||||||||
| Administrative fee (Note 3) |
||||||||||||||||
| Professional fees |
||||||||||||||||
| General and administrative |
||||||||||||||||
| Total expenses |
||||||||||||||||
| Net investment income before excise tax |
||||||||||||||||
| Provision for excise tax |
||||||||||||||||
| Net investment income |
||||||||||||||||
| Net realized and unrealized loss |
||||||||||||||||
| Net realized loss on non-affiliate investments |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
| Net realized gain on non-controlled affiliate investments |
||||||||||||||||
| Net realized loss on investments |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
| Net unrealized appreciation (depreciation) on non-affiliate investments |
( |
) | ( |
) | ||||||||||||
| Net unrealized (depreciation) appreciation on non-controlled affiliate investments |
( |
) | ( |
) | ( |
) | ||||||||||
| Net unrealized appreciation (depreciation) on controlled affiliate investments |
( |
) | ||||||||||||||
| Net unrealized appreciation (depreciation) on investments |
( |
) | ( |
) | ||||||||||||
| Net realized and unrealized loss |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
| Net increase (decrease) in net assets resulting from operations |
$ | $ | ( |
) | $ | $ | ( |
) | ||||||||
| Net investment income per common share |
$ | $ | $ | $ | ||||||||||||
| Net increase (decrease) in net assets resulting from operations per common share |
$ | $ | ( |
) | $ | $ | ( |
) | ||||||||
| Distributions declared per share |
$ | $ | $ | $ | ||||||||||||
| Weighted average shares outstanding |
||||||||||||||||
See Notes to Consolidated Financial Statements
Consolidated Statements of Changes in Net Assets (Unaudited)
(Dollars in thousands, except share data)
| Paid-In Capital |
||||||||||||||||||||
| Common Stock |
in Excess of |
Distributable |
Total Net |
|||||||||||||||||
| Shares |
Amount |
Par |
Loss |
Assets |
||||||||||||||||
| Balance at June 30, 2023 |
$ | $ | ( |
) | $ | |||||||||||||||
| Issuance of common stock, net of offering costs |
||||||||||||||||||||
| Net increase in net assets resulting from operations, net of excise tax: |
||||||||||||||||||||
| Net investment income, net of excise tax |
— | |||||||||||||||||||
| Net realized loss on investments |
— | ( |
) | ( |
) | |||||||||||||||
| Net unrealized depreciation on investments |
— | ( |
) | ( |
) | |||||||||||||||
| Issuance of common stock under dividend reinvestment plan |
||||||||||||||||||||
| Distributions declared |
— | ( |
) | ( |
) | |||||||||||||||
| Balance at September 30, 2023 |
( |
) | ||||||||||||||||||
| Balance at June 30, 2024 |
( |
) | ||||||||||||||||||
| Issuance of common stock, net of offering costs |
||||||||||||||||||||
| Net increase in net assets resulting from operations, net of excise tax: |
||||||||||||||||||||
| Net investment income, net of excise tax |
— | |||||||||||||||||||
| Net realized loss on investments |
— | ( |
) | ( |
) | |||||||||||||||
| Net unrealized appreciation on investments |
— | |||||||||||||||||||
| Issuance of common stock under dividend reinvestment plan |
||||||||||||||||||||
| Distributions declared |
— | ( |
) | ( |
) | |||||||||||||||
| Balance at September 30, 2024 |
$ | $ | $ | ( |
) | $ | ||||||||||||||
| Paid-In Capital |
||||||||||||||||||||
| Common Stock |
in Excess of |
Distributable |
Total Net |
|||||||||||||||||
| Shares |
Amount |
Par |
Loss |
Assets |
||||||||||||||||
| Balance at December 31, 2022 |
$ | $ | $ | ( |
) | $ | ||||||||||||||
| Issuance of common stock, net of offering costs |
||||||||||||||||||||
| Net increase in net assets resulting from operations, net of excise tax: |
||||||||||||||||||||
| Net investment income, net of excise tax |
— | |||||||||||||||||||
| Net realized loss on investments |
— | ( |
) | ( |
) | |||||||||||||||
| Net unrealized depreciation on investments |
— | ( |
) | ( |
) | |||||||||||||||
| Issuance of common stock under dividend reinvestment plan |
||||||||||||||||||||
| Distributions declared |
— | ( |
) | ( |
) | |||||||||||||||
| Balance at September 30, 2023 |
( |
) | ||||||||||||||||||
| Balance at December 31, 2023 |
( |
) | ||||||||||||||||||
| Issuance of common stock, net of offering costs |
||||||||||||||||||||
| Net increase in net assets resulting from operations, net of excise tax: |
||||||||||||||||||||
| Net investment income, net of excise tax |
— | |||||||||||||||||||
| Net realized loss on investments |
— | ( |
) | ( |
) | |||||||||||||||
| Net unrealized appreciation on investments |
— | |||||||||||||||||||
| Issuance of common stock under dividend reinvestment plan |
||||||||||||||||||||
| Distributions declared |
— | ( |
) | ( |
) | |||||||||||||||
| Balance at September 30, 2024 |
$ | $ | $ | ( |
) | $ | ||||||||||||||
See Notes to Consolidated Financial Statements
Consolidated Statements of Cash Flows (Unaudited)
(Dollars in thousands)
| For the nine months ended September 30, |
||||||||
| 2024 |
2023 |
|||||||
| Cash flows from operating activities: |
||||||||
| Net increase (decrease) in net assets resulting from operations |
$ | $ | ( |
) | ||||
| Adjustments to reconcile net increase (decrease) in net assets resulting from operations to net cash provided by (used in) operating activities: |
||||||||
| Amortization of debt issuance costs |
||||||||
| Net realized loss on investments |
||||||||
| Net unrealized (appreciation) depreciation on investments |
( |
) | ||||||
| Purchase of investments |
( |
) | ( |
) | ||||
| Principal payments received on investments |
||||||||
| Payment-in-kind interest on investments |
( |
) | ( |
) | ||||
| Proceeds from sale of investments |
||||||||
| Equity received in settlement of fee income |
( |
) | ||||||
| Warrants received in settlement of fee income |
( |
) | ( |
) | ||||
| Changes in assets and liabilities: |
||||||||
| (Increase) decrease in interest receivable |
( |
) | ||||||
| Increase in end-of-term payments |
( |
) | ( |
) | ||||
| Decrease in unearned income |
( |
) | ( |
) | ||||
| Increase in other assets |
( |
) | ( |
) | ||||
| (Decrease) increase in other accrued expenses |
( |
) | ||||||
| (Decrease) increase in base management fee payable |
( |
) | ||||||
| Decrease in incentive fee payable |
( |
) | ||||||
| Net cash provided by (used in) operating activities |
( |
) | ||||||
| Cash flows from financing activities: |
||||||||
| Repayment of 2022 Asset-Backed Notes |
( |
) | ||||||
| Repayment of 2019 Asset-Backed Notes |
( |
) | ||||||
| Proceeds from issuance of common stock, net of offering costs |
||||||||
| Advances on Credit Facilities |
||||||||
| Repayment of Credit Facilities |
( |
) | ( |
) | ||||
| Debt issuance costs |
( |
) | ( |
) | ||||
| Distributions paid |
( |
) | ( |
) | ||||
| Net cash (used in) provided by financing activities |
( |
) | ||||||
| Net increase in cash, cash equivalents and restricted cash |
||||||||
| Cash, cash equivalents and restricted cash: |
||||||||
| Beginning of period |
||||||||
| End of period |
$ | $ | ||||||
| Supplemental disclosure of cash flow information: |
||||||||
| Cash paid for interest |
$ | $ | ||||||
| Supplemental non-cash investing and financing activities: |
||||||||
| Refinanced debt investment balances |
$ | $ | ||||||
| Warrant investments received and recorded as unearned income |
$ | $ | ||||||
| Distributions payable |
$ | $ | ||||||
| End-of-term payments receivable |
$ | $ | ||||||
| Non-cash income |
$ | $ | ||||||
| September 30, |
||||||||
| 2024 |
2023 |
|||||||
| Cash |
$ | $ | ||||||
| Investments in money market funds |
||||||||
| Restricted investments in money market funds |
||||||||
| Total cash, cash equivalents and restricted cash |
$ | $ | ||||||
See Notes to Consolidated Financial Statements
Consolidated Schedule of Investments (Unaudited)
September 30, 2024
(Dollars in thousands)
| Portfolio Company (1)(3) | Sector | Type of Investment (7) | Cash Rate (4) | Index | Margin | Floor | Ceiling | ETP (10) | Maturity Date | Principal Amount | Cost of Investments (6)(9) | Fair Value (9) | ||||||||||||||||||||||||||
| Non-Affiliate Investments — % (8) | ||||||||||||||||||||||||||||||||||||||
| Non-Affiliate Debt Investments — % (8) | ||||||||||||||||||||||||||||||||||||||
| Non-Affiliate Debt Investments — Life Science — % (8) | ||||||||||||||||||||||||||||||||||||||
| Castle Creek Biosciences, Inc. (2)(12) | Biotechnology | Term Loan | % | Prime | % | % | % | % | | $ | $ | $ | ||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | % | | |||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | % | | |||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | % | | |||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | % | | |||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | % | | |||||||||||||||||||||||||||||||
| Emalex Biosciences, Inc. (2)(12) | Biotechnology | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Greenlight Biosciences, Inc. (2)(12) | Biotechnology | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| KSQ Therapeutics, Inc. (2)(12) | Biotechnology | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Native Microbials, Inc (2)(12) | Biotechnology | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| PDS Biotechnology Corporation (2)(5)(12) | Biotechnology | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Provivi, Inc. (2)(12) | Biotechnology | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Stealth Biotherapeutics Inc. (2)(12) | Biotechnology | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Tallac Therapeutics, Inc. (2)(12) | Biotechnology | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Aerobiotix, LLC (2)(12) | Medical Device | Term Loan | % | Fixed | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Fixed | % | | ||||||||||||||||||||||||||||||||||
| Term Loan | % | Fixed | % | | ||||||||||||||||||||||||||||||||||
See Notes to Consolidated Financial Statements
Consolidated Schedule of Investments (Unaudited)
September 30, 2024
(Dollars in thousands)
| Portfolio Company (1)(3) | Sector | Type of Investment (7) | Cash Rate (4) | Index | Margin | Floor | Ceiling | ETP (10) | Maturity Date | Principal Amount | Cost of Investments (6)(9) | Fair Value (9) | ||||||||||||||||||||||||||
| Candesant Biomedical, Inc. (2)(12) | Medical Device | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Ceribell, Inc. (2)(12) | Medical Device | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Cognoa, Inc. (2)(12) | Medical Device | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Conventus Orthopaedics, Inc. (2)(12) | Medical Device | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Infobionic, Inc. (2)(12) | Medical Device | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| MicroTransponder, Inc. (2)(12) | Medical Device | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Scientia Vascular, Inc. (2)(12) | Medical Device | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Sonex Health, Inc. (2)(12) | Medical Device | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Spineology, Inc. (2)(12) | Medical Device | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Swift Health Systems Inc. (2)(12)(14) | Medical Device | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
See Notes to Consolidated Financial Statements
Consolidated Schedule of Investments (Unaudited)
September 30, 2024
(Dollars in thousands)
| Portfolio Company (1)(3) | Sector | Type of Investment (7) | Cash Rate (4) | Index | Margin | Floor | Ceiling | ETP (10) | Maturity Date | Principal Amount | Cost of Investments (6)(9) | Fair Value (9) | ||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | | |||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | | |||||||||||||||||||||||||||||||||
| Vero Biotech, Inc. (2)(12) | Medical Device | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Total Non-Affiliate Debt Investments — Life Science | ||||||||||||||||||||||||||||||||||||||
| Non-Affiliate Debt Investments — Sustainability — % (8) | ||||||||||||||||||||||||||||||||||||||
| Pivot Bio, Inc.(2)(12) | Energy Efficiency | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| New Aerofarms, Inc. assignee of Aerofarms, Inc. (2)(12)(15) | Other Sustainability | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Soli Organic, Inc. (2)(12) | Other Sustainability | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Temperpack Technologies, Inc. (2)(12) | Other Sustainability | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Total Non-Affiliate Debt Investments — Sustainability | ||||||||||||||||||||||||||||||||||||||
| Non-Affiliate Debt Investments — Technology — % (8) | ||||||||||||||||||||||||||||||||||||||
| Axiom Space, Inc. (2)(12) | Communications | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| CAMP NYC, Inc. (2)(12) | Consumer-related Technologies | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
See Notes to Consolidated Financial Statements
Consolidated Schedule of Investments (Unaudited)
September 30, 2024
(Dollars in thousands)
| Portfolio Company (1)(3) | Sector | Type of Investment (7) | Cash Rate (4) | Index | Margin | Floor | Ceiling | ETP (10) | Maturity Date | Principal Amount | Cost of Investments (6)(9) | Fair Value (9) | ||||||||||||||||||||||||||
| Clara Foods Co. (2)(12) | Consumer-related Technologies | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Havenly, Inc. (2)(12) | Consumer-related Technologies | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Lyrical Foods, Inc. (2)(12) | Consumer-related Technologies | Term Loan | % (11) | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| NextCar Holding Company, Inc. (2)(12)(13) | Consumer-related Technologies | Term Loan | % (11) | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % (11) | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % (11) | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % (11) | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % (11) | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % (11) | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % (11) | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % (11) | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Optoro, Inc. (2)(12) | Consumer-related Technologies | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Standvast Holdings, LLC (2)(12) | Consumer-related Technologies | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Unagi, Inc. (2)(12)(13) | Consumer-related Technologies | Term Loan | % (11) | Prime | % | % | | |||||||||||||||||||||||||||||||
| Term Loan | % (11) | Prime | % | % | | |||||||||||||||||||||||||||||||||
| Term Loan | % (11) | Prime | % | % | | |||||||||||||||||||||||||||||||||
| Fictiv, Inc. (2)(12) | Networking | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| BriteCore Holdings, Inc. (2)(12) | Software | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Dropoff, Inc. (2)(12) | Software | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
See Notes to Consolidated Financial Statements
Consolidated Schedule of Investments (Unaudited)
September 30, 2024
(Dollars in thousands)
| Portfolio Company (1)(3) | Sector | Type of Investment (7) | Cash Rate (4) | Index | Margin | Floor | Ceiling | ETP (10) | Maturity Date | Principal Amount | Cost of Investments (6)(9) | Fair Value (9) | ||||||||||||||||||||||||||
| Kodiak Robotics, Inc. (2)(12) | Software | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Lytics, Inc. (2)(12) | Software | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Mirantis, Inc. (2)(12) | Software | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Noodle Partners, Inc. (2)(12) | Software | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Reputation Institute, Inc. (2)(12) | Software | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Supply Network Visibility Holdings LLC (2)(12) | Software | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Viken Detection Corporation (2)(12) | Software | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Total Non-Affiliate Debt Investments — Technology | ||||||||||||||||||||||||||||||||||||||
| Non-Affiliate Debt Investments — Healthcare information and services — % (8) | ||||||||||||||||||||||||||||||||||||||
| Hound Labs Inc. (12)(13) | Diagnostics | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Fixed | % | | ||||||||||||||||||||||||||||||||||
| Term Loan | % | Fixed | % | | ||||||||||||||||||||||||||||||||||
| Parse Biosciences, Inc. (2)(12) | Diagnostics | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
See Notes to Consolidated Financial Statements
Consolidated Schedule of Investments (Unaudited)
September 30, 2024
(Dollars in thousands)
| Portfolio Company (1)(3) | Sector | Type of Investment (7) | Cash Rate (4) | Index | Margin | Floor | Ceiling | ETP (10) | Maturity Date | Principal Amount | Cost of Investments (6)(9) | Fair Value (9) | ||||||||||||||||||||||||||
| BrightInsight, Inc. (2)(12) | Software | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Elligo Health Research, Inc. (2)(12) | Software | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| SafelyYou, Inc. (2)(12) | Software | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| GT Medical Technologies, Inc. (2)(12) | Other Healthcare Services | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Hometeam Technologies, Inc. (2)(12) | Other Healthcare Services | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Total Non-Affiliate Debt Investments — Healthcare information and services | $ | $ | ||||||||||||||||||||||||||||||||||||
| Total Non- Affiliate Debt Investments | $ | $ | ||||||||||||||||||||||||||||||||||||
| Cost of | Fair | |||||||||||||||
| Portfolio Company (1)(3) | Sector | Type of Investment (7) | Number of Shares | Investments (6)(9) | Value (9) | |||||||||||
| Non-Affiliate Warrant Investments — % (8) | ||||||||||||||||
| Non-Affiliate Warrants — Life Science — % (8) | ||||||||||||||||
| Avalo Therapeutics, Inc. (2)(5)(12) | Biotechnology | Common Stock Warrant | $ | $ | ||||||||||||
| Castle Creek Biosciences, Inc. (2)(12) | Biotechnology | Preferred Stock Warrant | ||||||||||||||
| Emalex Biosciences, Inc. (2)(12) | Biotechnology | Preferred Stock Warrant | ||||||||||||||
| Imunon, Inc. (2)(5)(12) | Biotechnology | Common Stock Warrant | ||||||||||||||
| KSQ Therapeutics, Inc. (2)(12) | Biotechnology | Preferred Stock Warrant | ||||||||||||||
| Mustang Bio, Inc. (2)(5)(12) | Biotechnology | Common Stock Warrant | ||||||||||||||
| Native Microbials, Inc (2)(12) | Biotechnology | Preferred Stock Warrant | ||||||||||||||
| PDS Biotechnology Corporation (2)(5)(12) | Biotechnology | Common Stock Warrant | ||||||||||||||
| Provivi, Inc. (2)(12) | Biotechnology | Common Stock Warrant | ||||||||||||||
| Provivi, Inc. (2)(12) | Biotechnology | Preferred Stock Warrant | ||||||||||||||
| Stealth Biotherapeutics Inc. (2)(12) | Biotechnology | Common Stock Warrant | ||||||||||||||
| Tallac Therapeutics, Inc. (2)(12) | Biotechnology | Preferred Stock Warrant | ||||||||||||||
| Xeris Pharmaceuticals, Inc. (2)(5)(12) | Biotechnology | Common Stock Warrant | ||||||||||||||
| AccuVein Inc. (2)(12) | Medical Device | Common Stock Warrant | ||||||||||||||
| Aerin Medical, Inc. (2)(12) | Medical Device | Preferred Stock Warrant | ||||||||||||||
| Aerobiotix, LLC (2)(12) | Medical Device | Preferred Stock Warrant | ||||||||||||||
| Canary Medical Inc. (2)(12) | Medical Device | Preferred Stock Warrant | ||||||||||||||
| Candesant Biomedical, Inc. (2)(12) | Medical Device | Preferred Stock Warrant | ||||||||||||||
| Ceribell, Inc. (2)(12) | Medical Device | Preferred Stock Warrant | ||||||||||||||
| Cognoa, Inc. (2)(12) | Medical Device | Common Stock Warrant | ||||||||||||||
| Cognoa, Inc. (2)(12) | Medical Device | Preferred Stock Warrant | ||||||||||||||
| Conventus Orthopaedics, Inc. (2)(12) | Medical Device | Preferred Stock Warrant | ||||||||||||||
| CSA Medical, Inc. (2)(12) | Medical Device | Preferred Stock Warrant | ||||||||||||||
| CVRx, Inc. (2)(5)(12) | Medical Device | Common Stock Warrant | ||||||||||||||
| Infobionic, Inc. (2)(12) | Medical Device | Preferred Stock Warrant | ||||||||||||||
See Notes to Consolidated Financial Statements
Consolidated Schedule of Investments (Unaudited)
September 30, 2024
(Dollars in thousands)
| Cost of | Fair | |||||||||||||||
| Portfolio Company (1)(3) | Sector | Type of Investment (7) | Number of Shares | Investments (6)(9) | Value (9) | |||||||||||
| Magnolia Medical Technologies, Inc. (2)(12) | Medical Device | Preferred Stock Warrant | | | | |||||||||||
| Meditrina, Inc. (2)(12) | Medical Device | Preferred Stock Warrant | | | | |||||||||||
| MicroTransponder, Inc. (2)(12) | Medical Device | Preferred Stock Warrant | | | | |||||||||||
| Scientia Vascular, Inc (2)(12) | Medical Device | Preferred Stock Warrant | | | | |||||||||||
| Sonex Health, Inc. (2)(12) | Medical Device | Preferred Stock Warrant | | | | |||||||||||
| VERO Biotech LLC (2)(12) | Medical Device | Preferred Stock Warrant | | | | |||||||||||
| Spineology, Inc. (2)(12) | Medical Device | Common Stock Warrant | | | | |||||||||||
| Spineology, Inc. (2)(12) | Medical Device | Preferred Stock Warrant | | | | |||||||||||
| Swift Health Systems Inc. (2)(12) | Medical Device | Preferred Stock Warrant | | | — | |||||||||||
| Total Non-Affiliate Warrants — Life Science | | | ||||||||||||||
| Non-Affiliate Warrants — Sustainability — % (8) | ||||||||||||||||
| New Aerofarms, Inc. assignee of Aerofarms, Inc. (2)(12)(15) | Other Sustainability | Preferred Stock Warrant | | | | |||||||||||
| LiquiGlide, Inc. (2)(12) | Other Sustainability | Preferred Stock Warrant | | | | |||||||||||
| Soli Organic, Inc. (2)(12) | Other Sustainability | Common Stock Warrant | | | | |||||||||||
| Soli Organic, Inc. (2)(12) | Other Sustainability | Preferred Stock Warrant | | | | |||||||||||
| Temperpack Technologies, Inc. (2)(12) | Other Sustainability | Preferred Stock Warrant | | | | |||||||||||
| Pivot Bio, Inc. (2)(12) | Energy Efficiency | Preferred Stock Warrant | | | | |||||||||||
| Total Non-Affiliate Warrants — Sustainability | | | ||||||||||||||
| Non-Affiliate Warrants — Technology — % (8) | ||||||||||||||||
| Axiom Space Holdings, Inc. (2)(12) | Communications | Common Stock Warrant | | | | |||||||||||
| Intelepeer Holdings, Inc. (2)(12) | Communications | Preferred Stock Warrant | | | | |||||||||||
| Alula Holdings, Inc. (2)(12) | Consumer-related Technologies | Preferred Stock Warrant | | | | |||||||||||
| CAMP NYC, Inc. (2)(12) | Consumer-related Technologies | Preferred Stock Warrant | | | | |||||||||||
| Clara Foods Co. (2)(12) | Consumer-related Technologies | Preferred Stock Warrant | | | | |||||||||||
| Divergent Technologies, Inc. (2)(12) | Consumer-related Technologies | Common Stock Warrant | | | | |||||||||||
| Divergent Technologies, Inc. (2)(12) | Consumer-related Technologies | Preferred Stock Warrant | | | | |||||||||||
| Havenly, Inc. (2)(12) | Consumer-related Technologies | Common Stock Warrant | | | | |||||||||||
| MyForest Foods Co. (2)(12) | Consumer-related Technologies | Preferred Stock Warrant | | | | |||||||||||
| NextCar Holding Company, Inc. (2)(12) | Consumer-related Technologies | Common Stock Warrant | | | — | |||||||||||
| NextCar Holding Company, Inc. (2)(12) | Consumer-related Technologies | Preferred Stock Warrant | | | — | |||||||||||
| Optoro, Inc. (2)(12) | Consumer-related Technologies | Preferred Stock Warrant | | | | |||||||||||
| Primary Kids, Inc. (2)(12) | Consumer-related Technologies | Preferred Stock Warrant | | | | |||||||||||
| Quip NYC Inc. (2)(12) | Consumer-related Technologies | Preferred Stock Warrant | | | — | |||||||||||
| Standvast Holdings, LLC (2)(12) | Consumer-related Technologies | Preferred Stock Warrant | | | | |||||||||||
| Unagi, Inc. (2)(12) | Consumer-related Technologies | Preferred Stock Warrant | | | — | |||||||||||
| Updater, Inc.(2)(12) | Consumer-related Technologies | Preferred Stock Warrant | | | | |||||||||||
| CPG Beyond, Inc. (2)(12) | Data Storage | Preferred Stock Warrant | | | | |||||||||||
| Silk, Inc. (2)(12) | Data Storage | Preferred Stock Warrant | | | | |||||||||||
| Global Worldwide LLC (2)(12) | Internet and Media | Preferred Stock Warrant | | | — | |||||||||||
| Rocket Lawyer Incorporated (2)(12) | Internet and Media | Preferred Stock Warrant | | | | |||||||||||
| Skillshare, Inc. (2)(12) | Internet and Media | Preferred Stock Warrant | | | | |||||||||||
| Liqid, Inc. (2)(12) | Networking | Preferred Stock Warrant | | | | |||||||||||
| Fictiv, Inc. (2)(12) | Networking | Common Stock Warrant | | | | |||||||||||
| Halio, Inc. (2)(12) | Power Management | Common Stock Warrant | | | | |||||||||||
| Avalanche Technology, Inc. (2)(12) | Semiconductors | Preferred Stock Warrant | | | — | |||||||||||
| BriteCore Holdings, Inc. (2)(12) | Software | Preferred Stock Warrant | | | | |||||||||||
| Dropoff, Inc. (2)(12) | Software | Common Stock Warrant | | | | |||||||||||
| E La Carte, Inc. (2)(5)(12) | Software | Common Stock Warrant | | | — | |||||||||||
| Everstream Holdings, LLC (2)(12) | Software | Preferred Stock Warrant | | | | |||||||||||
| Kodiak Robotics, Inc. (2)(12) | Software | Preferred Stock Warrant | | | | |||||||||||
| Lemongrass Holdings, Inc. (2)(12) | Software | Preferred Stock Warrant | | | | |||||||||||
| Lotame Solutions, Inc. (2)(12) | Software | Preferred Stock Warrant | | | | |||||||||||
| Lytics, Inc. (2)(12) | Software | Preferred Stock Warrant | | | — | |||||||||||
| Mirantis, Inc. (2)(12) | Software | Common Stock Warrant | | | | |||||||||||
See Notes to Consolidated Financial Statements
Consolidated Schedule of Investments (Unaudited)
September 30, 2024
(Dollars in thousands)
| Cost of | Fair | |||||||||||||||
| Portfolio Company (1)(3) | Sector | Type of Investment (7) | Number of Shares | Investments (6)(9) | Value (9) | |||||||||||
| Noodle Partners, Inc. (2)(12) | Software | Preferred Stock Warrant | | | — | |||||||||||
| Reputation Institute, Inc. (2)(12) | Software | Preferred Stock Warrant | | | | |||||||||||
| Revinate Holdings, Inc. (2)(12) | Software | Preferred Stock Warrant | | | | |||||||||||
| SIGNiX, Inc. (12) | Software | Preferred Stock Warrant | | | — | |||||||||||
| Slingshot Aerospace, Inc. (2)(12) | Software | Preferred Stock Warrant | | | | |||||||||||
| Supply Network Visibility Holdings LLC (2)(12) | Software | Preferred Stock Warrant | | | | |||||||||||
| Topia Mobility, Inc. (2)(12) | Software | Preferred Stock Warrant | | | — | |||||||||||
| Viken Detection Corporation (2)(12) | Software | Preferred Stock Warrant | | | | |||||||||||
| xAd, Inc. (2)(12) | Software | Preferred Stock Warrant | | | | |||||||||||
| Total Non-Affiliate Warrants — Technology | | | ||||||||||||||
| Non-Affiliate Warrants — Healthcare information and services — % (8) | ||||||||||||||||
| Hound Labs, Inc (12) | Diagnostics | Preferred Stock Warrant | | | — | |||||||||||
| Parse Biosciences, Inc. (2)(12) | Diagnostics | Common Stock Warrant | | | | |||||||||||
| Parse Biosciences, Inc. (2)(12) | Diagnostics | Preferred Stock Warrant | | | | |||||||||||
| Kate Farms, Inc. (2)(12) | Other Healthcare | Preferred Stock Warrant | | | | |||||||||||
| GT Medical Technologies, Inc. (2)(12) | Other Healthcare | Preferred Stock Warrant | | | | |||||||||||
| BrightInsight, Inc. (2)(12) | Software | Preferred Stock Warrant | | | — | |||||||||||
| Elligo Health Research, Inc. (2)(12) | Software | Preferred Stock Warrant | | | | |||||||||||
| Medsphere Systems Corporation (2)(12) | Software | Preferred Stock Warrant | | | — | |||||||||||
| SafelyYou, Inc. (2)(12) | Software | Preferred Stock Warrant | | | | |||||||||||
| Total Non-Affiliate Warrants — Healthcare information and services | | | ||||||||||||||
| Total Non-Affiliate Warrants | | | ||||||||||||||
| Non-Affiliate Other Investments — Life Science — % (8) | ||||||||||||||||
| Lumithera, Inc. (12) | Medical Device | Royalty Agreement | | | ||||||||||||
| Robin Healthcare, Inc. (2)(12) | Medical Device | Royalty Agreement | | | ||||||||||||
| ZetrOZ, Inc. (12) | Medical Device | Royalty Agreement | — | — | ||||||||||||
| Total Non-Affiliate Other Investments | | | ||||||||||||||
| Non-Affiliate Equity — % (8) | ||||||||||||||||
| Cadrenal Therapeutics, Inc. (5) | Biotechnology | Common Stock | | — | | |||||||||||
| Castle Creek Biosciences, Inc. (12) | Biotechnology | Common Stock | | | | |||||||||||
| Emalex Biosciences, Inc. (12) | Biotechnology | Common Stock | | | | |||||||||||
| Axiom Space, Inc. (12) | Communications | Preferred Stock | | | | |||||||||||
| PebblePost, Inc. (2)(12) | Communications | Preferred Stock | | | | |||||||||||
| Caastle, Inc. (2)(12) | Consumer-related Technologies | Preferred Stock | | | | |||||||||||
| Getaround, Inc. (2)(5) | Consumer-related Technologies | Common Stock | | | | |||||||||||
| NextCar Holding Company, Inc. (2)(12) | Consumer-related Technologies | Preferred Stock | | | — | |||||||||||
| SnagAJob.com, Inc. (12) | Consumer-related Technologies | Common Stock | | | | |||||||||||
| Lumithera, Inc. (12) | Medical Device | Common Stock | | | | |||||||||||
| Tigo Energy, Inc. (5) | Other Sustainability | Common Stock | | | | |||||||||||
| Decisyon, Inc. (12) | Software | Preferred Stock | | | | |||||||||||
| Lotame, Inc. (12) | Software | Preferred Stock | | | | |||||||||||
| Total Non-Affiliate Equity | | | ||||||||||||||
| Total Non-Affiliate Portfolio Investment Assets | $ | $ | ||||||||||||||
See Notes to Consolidated Financial Statements
Consolidated Schedule of Investments (Unaudited)
September 30, 2024
(Dollars in thousands)
| Portfolio Company (1)(3) | Sector | Type of Investment (7) | Cash Rate (4) | Index | Margin | Floor | Ceiling | ETP (10) | Maturity Date | Principal Amount | Cost of Investments (6)(9) | Fair Value (9) | ||||||||||||||||||||||||||
| Non-Controlled Affiliate Investments — % (8) | ||||||||||||||||||||||||||||||||||||||
| Non-Controlled Affiliate Other Investments — % (8) | ||||||||||||||||||||||||||||||||||||||
| Evelo Holdings, Inc. (2)(5)(12)(17) | Biotechnology | Other Investment | % (11) | Prime | % | % | % | | $ | $ | $ | |||||||||||||||||||||||||||
| Other Investment | % (11) | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Other Investment | % (11) | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Other Investment | % (11) | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Other Investment | % (11) | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Other Investment | % (11) | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Total Non-Controlled Affiliate Other Investments | ||||||||||||||||||||||||||||||||||||||
| Cost of | Fair | |||||||||||||||
| Portfolio Company (1)(3) | Sector | Type of Investment (7) | Number of Shares | Investments (6)(9) | Value (9) | |||||||||||
| Non-controlled Affiliate Equity — % (8) | ||||||||||||||||
| Aulea Medical, Inc. (12) | Medical Device | Common Stock | $ | $ | ||||||||||||
| Evelo Holdings, Inc. (2)(5)(12) | Biotechnology | Common Stock | ||||||||||||||
| Total Non-Controlled Affiliate Equity | ||||||||||||||||
| Non-controlled Affiliate Warrants — % (8) | ||||||||||||||||
| Evelo Holdings, Inc. (2)(5)(12) | Biotechnology | Common Stock | ||||||||||||||
| Total Non-Controlled Affiliate Warrants | ||||||||||||||||
| Total Non-Controlled Affiliate Portfolio Investment Assets | $ | $ | ||||||||||||||
| Portfolio Company (1)(3) | Sector | Type of Investment (7) | Cash Rate (4) | Index | Margin | Floor | Ceiling | ETP (10) | Maturity Date | Principal Amount | Cost of Investments (6)(9) | Fair Value (9) | ||||||||||||||||||||||||||
| Controlled Affiliate Investments — % (8) | ||||||||||||||||||||||||||||||||||||||
| Controlled Affiliate Debt Investments — % (8) | ||||||||||||||||||||||||||||||||||||||
| Better Place Forests Co. (12) | Consumer-related Technologies | Term Loan | % (11) | Prime | % | % | % | | $ | $ | $ | |||||||||||||||||||||||||||
| Term Loan | % (11) | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % (11) | Prime | % | % | | |||||||||||||||||||||||||||||||||
| Term Loan | % (11) | Prime | % | % | | |||||||||||||||||||||||||||||||||
| Term Loan | % (11) | Prime | % | % | | |||||||||||||||||||||||||||||||||
| Nexii, Inc. (12) | Other Sustainability | Term Loan | % | Fixed | | |||||||||||||||||||||||||||||||||
| Total Controlled Affiliate Debt Investments | ||||||||||||||||||||||||||||||||||||||
| Cost of | Fair | |||||||||||||||
| Portfolio Company (1)(3) | Sector | Type of Investment (7) | Number of Shares | Investments (6)(9) | Value (9) | |||||||||||
| Controlled Affiliate Equity — % (8) | ||||||||||||||||
| Better Place Forests Co. (12) | Consumer-related Technologies | Common Stock | ||||||||||||||
| Better Place Forests Co. (12) | Consumer-related Technologies | Preferred Stock | ||||||||||||||
| Nexii, Inc. (2)(12) | Other Sustainability | Common Stock | ||||||||||||||
| Nexii, Inc. (2)(12) | Other Sustainability | Preferred Stock | ||||||||||||||
| Total Controlled Affiliate Equity | ||||||||||||||||
| Controlled Affiliate Other Investments — % (8) | ||||||||||||||||
| HIMV LLC (12)(16) | Biotechnology | Other Investment | ||||||||||||||
| Total Controlled Affiliate Other | ||||||||||||||||
| Total Controlled Affiliate Portfolio Investment Assets | $ | $ | ||||||||||||||
| Total Portfolio Investment Assets — % (8) | $ | $ | ||||||||||||||
| Short Term Investments - Unrestricted Investments - % (8) | ||||||||
| US Bank Money Market Deposit Account | ||||||||
| Total Short Term Investments - Unrestricted Investments | $ | $ | ||||||
| Short Term Investments - Restricted Investments - % (8) | ||||||||
| US Bank Money Market Deposit Account | ||||||||
| Total Short Term Investments - Restricted Investments | $ | $ |
See Notes to Consolidated Financial Statements
Consolidated Schedule of Investments (Unaudited)
September 30, 2024
(Dollars in thousands)
| (1) | All investments of the Company are in entities which are organized under the laws of the United States and have a principal place of business in the United States, unless otherwise noted. |
| (2) | Has been pledged as collateral under the revolving credit facility (the “Key Facility”) with KeyBank National Association (“Key”), a credit facility (the “NYL Facility”) led by New York Life Insurance Company, a credit facility (the “Nuveen Facility”, together with the Key Facility and the NYL Facility, the “Credit Facilities”) led by Nuveen Alternatives Advisors LLC, and/or the term debt securitization in connection with which an affiliate of the Company made an offering of $ |
| (3) | All non-affiliate investments are investments in which the Company owns less than 5% of the voting securities of the portfolio company. All non-controlled affiliate investments are investments in which the Company owns 5% or more of the voting securities of the portfolio company but not more than 25% of the voting securities of the portfolio company. All controlled affiliate investments are investments in which the Company owns more than 25% of the portfolio company’s outstanding voting securities or has the power to exercise control over management or policies of such portfolio company (including through a management agreement). |
| (4) | All interest is payable in cash due monthly in arrears, unless otherwise indicated, and applies only to the Company’s debt investments. Interest rate is the annual interest rate on the debt investment and does not include end-of-term payments (“ETPs”), and any additional fees related to the investments, such as deferred interest, commitment fees or prepayment fees. Debt investments are at variable rates for the term of the debt investment, unless otherwise indicated. For each debt investment, the current interest rate in effect as of September 30, 2024 is provided. |
| (5) | Portfolio company is a public company. |
| (6) | For debt investments, represents principal balance less unearned income. |
| (7) | Warrants, Equity and Other Investments are non-income producing. |
| (8) | Value as a percent of net assets. |
| (9) | The Company did not have any non-qualifying assets under Section 55(a) of the 1940 Act as of September 30, 2024. Under the 1940 Act, the Company may not acquire any non-qualifying assets unless, at the time the acquisition is made, qualifying assets represent at least 70% of the Company’s total assets. |
| (10) | ETPs are contractual fixed-interest payments due in cash at the maturity date of the applicable debt investment, including upon any prepayment, and are a fixed percentage of the original principal balance of the debt investments unless otherwise noted. Interest will accrue during the life of the debt investment on each ETP and will be recognized as non-cash income until it is actually paid. Therefore, a portion of the incentive fee the Company may pay its Advisor will be based on income that the Company has not yet received in cash. |
| (11) | Investment has a payment-in-kind (“PIK”) feature in which the accrued interest is added to the then-outstanding principal amount of the investment. |
| (12) | The fair value of the investment was valued using significant unobservable inputs. |
| (13) | Debt investment is on non-accrual status as of September 30, 2024. |
| (14) | Debt investment is on non-accrual status as of September 30, 2024 and interest payments received will be recognized as income on a cash basis. |
| (15) | On or about September 13, 2023, in connection with New Aerofarms, Inc.’s purchase of substantially all of the assets of Aerofarms, Inc.in a bankruptcy process, New Aerofarms, Inc. assumed all of the debt investments of the Company in Aerofarms, Inc. |
| (16) | By an Order of the Supreme Court of Nova Scotia made May 1, 2023, as amended and restated by an Order of the Court made May 5, 2023, IMV, Inc. (“IMV”) commenced proceedings (the “CCAA Proceedings”) under the Companies' Creditors Arrangement Act, R.S.C. 1985, c. C-36, as amended to seek creditor protection for IMV and on June 2, 2023, IMV obtained recognition of the CCAA Proceedings under Chapter 15 of the United States Bankruptcy Code in proceedings before the United States Bankruptcy Court for the District of Delaware. In September 2023, the Company, with its co-lender to IMV, credit-bid and acquired substantially all of the assets of IMV through HIMV LLC, an entity formed to acquire the assets of IMV. The assets of IMV were sold for (i) the right to receive certain payments, if any, in connection with the potential future development and licensing of the assets sold and (ii) equity in the buyer of such assets. HIMV LLC is 70% owned by the Company and 30% owned by a third-party co-lender. |
| (17) | The investment originally consisted of debt investments in Evelo Biosciences Inc. (“Evelo”). Evelo was a clinical stage life science company that was unable to raise additional capital to continue as a going concern and, through a series of transactions, Evelo became a subsidiary of Evelo Holdings, Inc. (“Evelo Holdings”) and Evelo Holdings assumed the indebtedness of Evelo to the Company. Evelo Holdings is not an operating company but holds certain contractual rights to contingent payments and owns equity in Evelo, as well as certain assets it seeks to sell. The Company has a first priority security interest in the assets of Evelo Holdings, so if any payments are received by Evelo Holdings or any of its equity holdings or other assets are sold, the Company will receive substantially all of the proceeds from the same, until such time, if ever, that all of the indebtedness is repaid. Accordingly, the Company characterizes this investment as an “Other Investment” rather than a “Debt Investment”. |
See Notes to Consolidated Financial Statements
Consolidated Schedule of Investments
December 31, 2023
(Dollars in thousands)
| Portfolio Company (1)(3) | Sector | Type of Investment (7) | Cash Rate (4) | Index | Margin | Floor | Ceiling | ETP (10) | Maturity Date | Principal Amount | Cost of Investments (6)(9) | Fair Value (9) | ||||||||||||||||||||||||||
| Non-Affiliate Investments — % (8) | ||||||||||||||||||||||||||||||||||||||
| Non-Affiliate Debt Investments — % (8) | ||||||||||||||||||||||||||||||||||||||
| Non-Affiliate Debt Investments — Life Science — % (8) | ||||||||||||||||||||||||||||||||||||||
| Castle Creek Biosciences, Inc. (2)(12) | Biotechnology | Term Loan | % | Prime | % | % | % | % | | $ | $ | $ | ||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | % | | |||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | % | | |||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | % | | |||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | % | | |||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | % | | |||||||||||||||||||||||||||||||
| Emalex Biosciences, Inc. (2)(12) | Biotechnology | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Greenlight Biosciences, Inc. (2)(12) | Biotechnology | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| KSQ Therapeutics, Inc. (2)(12) | Biotechnology | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Native Microbials, Inc (2)(12) | Biotechnology | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| PDS Biotechnology Corporation (2)(5)(12) | Biotechnology | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Provivi, Inc. (2)(12) | Biotechnology | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Stealth Biotherapeutics Inc. (2)(12) | Biotechnology | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Tallac Therapeutics, Inc. (2)(12) | Biotechnology | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Aerobiotix, LLC (2)(12) | Medical Device | Term Loan | % | Fixed | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Fixed | % | | ||||||||||||||||||||||||||||||||||
| Term Loan | % | Fixed | % | | ||||||||||||||||||||||||||||||||||
| Candesant Biomedical, Inc. (2)(12) | Medical Device | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Ceribell, Inc. (2)(12) | Medical Device | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Cognoa, Inc. (2)(12) | Medical Device | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Conventus Orthopaedics, Inc. (2)(12) | Medical Device | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| CSA Medical, Inc. (2)(12) | Medical Device | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| MicroTransponder, Inc. (2)(12) | Medical Device | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
See Notes to Consolidated Financial Statements
Consolidated Schedule of Investments
December 31, 2023
(Dollars in thousands)
| Portfolio Company (1)(3) | Sector | Type of Investment (7) | Cash Rate (4) | Index | Margin | Floor | Ceiling | ETP (10) | Maturity Date | Principal Amount | Cost of Investments (6)(9) | Fair Value (9) | ||||||||||||||||||||||||||
| Robin Healthcare, Inc. (2)(12)(13) | Medical Device | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Scientia Vascular, Inc. (2)(12) | Medical Device | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Sonex Health, Inc. (2)(12) | Medical Device | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Spineology, Inc. (2)(12) | Medical Device | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Swift Health Systems Inc. (2)(12) | Medical Device | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Vero Biotech, Inc. (2)(12) | Medical Device | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Total Non-Affiliate Debt Investments — Life Science | ||||||||||||||||||||||||||||||||||||||
| Non-Affiliate Debt Investments — Sustainability — % (8) | ||||||||||||||||||||||||||||||||||||||
| New Aerofarms, Inc. assignee of Aerofarms, Inc. (2)(12)(15) | Other Sustainability | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Nexii Building Solutions, Inc. (2)(12)(13)(14)(18) | Other Sustainability | Term Loan | % (11) | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % (11) | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % (11) | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % (11) | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % (11) | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % (11) | Prime | % | % | | |||||||||||||||||||||||||||||||||
| Term Loan | % (11) | Prime | % | % | | |||||||||||||||||||||||||||||||||
| Term Loan | % (11) | Prime | % | % | | |||||||||||||||||||||||||||||||||
| Term Loan | % (11) | Prime | % | % | | |||||||||||||||||||||||||||||||||
| Term Loan | % (11) | Prime | % | % | | |||||||||||||||||||||||||||||||||
| Term Loan | % (11) | Prime | % | % | | |||||||||||||||||||||||||||||||||
| Term Loan | % (11) | Prime | % | % | | |||||||||||||||||||||||||||||||||
| Soli Organic, Inc. (2)(12) | Other Sustainability | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Temperpack Technologies, Inc. (2)(12) | Other Sustainability | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Total Non-Affiliate Debt Investments — Sustainability | ||||||||||||||||||||||||||||||||||||||
See Notes to Consolidated Financial Statements
Consolidated Schedule of Investments
December 31, 2023
(Dollars in thousands)
| Portfolio Company (1)(3) | Sector | Type of Investment (7) | Cash Rate (4) | Index | Margin | Floor | Ceiling | ETP (10) | Maturity Date | Principal Amount | Cost of Investments (6)(9) | Fair Value (9) | ||||||||||||||||||||||||||
| Non-Affiliate Debt Investments — Technology — % (8) | ||||||||||||||||||||||||||||||||||||||
| Axiom Space, Inc. (2)(12) | Communications | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| CAMP NYC, Inc. (2)(12) | Consumer-related Technologies | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Clara Foods Co. (2)(12) | Consumer-related Technologies | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Divergent Technologies, Inc. (2)(12) | Consumer-related Technologies | Term Loan | % | Prime | % | % | % | % | | |||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | % | | |||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | % | | |||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | % | | |||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | % | | |||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | % | | |||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | % | | |||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | % | | |||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | % | | |||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | % | | |||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | % | | |||||||||||||||||||||||||||||||
| Havenly, Inc. (2)(12) | Consumer-related Technologies | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Lyrical Foods, Inc. (2)(12) | Consumer-related Technologies | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| MyForest Foods Co. (2)(12) | Consumer-related Technologies | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| NextCar Holding Company, Inc. (2)(12) | Consumer-related Technologies | Term Loan | % (11) | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % (11) | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % (11) | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % (11) | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % (11) | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % (11) | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % (11) | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % (11) | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Optoro, Inc. (2)(12) | Consumer-related Technologies | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Unagi, Inc. (2)(12)(13) | Consumer-related Technologies | Term Loan | % (11) | Prime | % | % | | |||||||||||||||||||||||||||||||
| Term Loan | % (11) | Prime | % | % | | |||||||||||||||||||||||||||||||||
| Term Loan | % (11) | Prime | % | % | | |||||||||||||||||||||||||||||||||
| Liqid, Inc. (2)(12) | Networking | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| BriteCore Holdings, Inc. (2)(12) | Software | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
See Notes to Consolidated Financial Statements
Consolidated Schedule of Investments
December 31, 2023
(Dollars in thousands)
| Portfolio Company (1)(3) | Sector | Type of Investment (7) | Cash Rate (4) | Index | Margin | Floor | Ceiling | ETP (10) | Maturity Date | Principal Amount | Cost of Investments (6)(9) | Fair Value (9) | ||||||||||||||||||||||||||
| Dropoff, Inc. (2)(12) | Software | Term Loan | % (19) | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % (19) | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % (19) | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Engage3, LLC (2)(12) | Software | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Kodiak Robotics, Inc. (2)(12) | Software | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Lemongrass Holdings, Inc. (2)(12) | Software | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Lytics, Inc. (2)(12) | Software | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Mirantis, Inc. (2)(12) | Software | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Noodle Partners, Inc. (2)(12) | Software | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Reputation Institute, Inc. (2)(12) | Software | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Slingshot Aerospace, Inc. (2)(12) | Software | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Supply Network Visibility Holdings LLC (2)(12) | Software | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Viken Detection Corporation (2)(12) | Software | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Total Non-Affiliate Debt Investments — Technology | ||||||||||||||||||||||||||||||||||||||
| Non-Affiliate Debt Investments — Healthcare information and services — % (8) | ||||||||||||||||||||||||||||||||||||||
| Hound Labs inc. (2) (12) | Diagnostics | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Parse Biosciences, Inc. (2)(12) | Diagnostics | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| BrightInsight, Inc. (2)(12) | Software | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Elligo Health Research, Inc. (2)(12) | Software | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| SafelyYou, Inc. (2)(12) | Software | Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Total Non-Affiliate Debt Investments — Healthcare information and services | ||||||||||||||||||||||||||||||||||||||
| Total Non- Affiliate Debt Investments | ||||||||||||||||||||||||||||||||||||||
See Notes to Consolidated Financial Statements
Consolidated Schedule of Investments
December 31, 2023
(Dollars in thousands)
| Cost of | Fair | |||||||||||||||
| Portfolio Company (1)(3) | Sector | Type of Investment (7) | Number of Shares | Investments (6)(9) | Value (9) | |||||||||||
| Non-Affiliate Warrant Investments — % (8) | ||||||||||||||||
| Non-Affiliate Warrants — Life Science — % (8) | ||||||||||||||||
| Avalo Therapeutics, Inc. (2)(5)(12) | Biotechnology | Common Stock Warrant | | | — | |||||||||||
| Castle Creek Biosciences, Inc. (2)(12) | Biotechnology | Preferred Stock Warrant | | | | |||||||||||
| Emalex Biosciences, Inc. (2)(12) | Biotechnology | Preferred Stock Warrant | | | | |||||||||||
| Imunon, Inc. (2)(5)(12) | Biotechnology | Common Stock Warrant | | | — | |||||||||||
| KSQ Therapeutics, Inc. (2) (12) | Biotechnology | Preferred Stock Warrant | | | | |||||||||||
| Mustang Bio, Inc. (2)(5)(12) | Biotechnology | Common Stock Warrant | | | — | |||||||||||
| Native Microbials, Inc (2)(12) | Biotechnology | Preferred Stock Warrant | | | | |||||||||||
| PDS Biotechnology Corporation (2)(5)(12) | Biotechnology | Common Stock Warrant | | | | |||||||||||
| Provivi, Inc. (2)(12) | Biotechnology | Common Stock Warrant | | | — | |||||||||||
| Provivi, Inc. (2)(12) | Biotechnology | Preferred Stock Warrant | | | | |||||||||||
| Stealth Biotherapeutics Inc. (2)(12) | Biotechnology | Common Stock Warrant | | | | |||||||||||
| Tallac Therapeutics, Inc. (2)(12) | Biotechnology | Preferred Stock Warrant | | | | |||||||||||
| Xeris Pharmaceuticals, Inc. (2)(5)(12) | Biotechnology | Common Stock Warrant | | | | |||||||||||
| AccuVein Inc. (2)(12) | Medical Device | Common Stock Warrant | | | — | |||||||||||
| Aerin Medical, Inc. (2)(12) | Medical Device | Preferred Stock Warrant | | | | |||||||||||
| Aerobiotix, LLC (2)(12) | Medical Device | Preferred Stock Warrant | | | | |||||||||||
| Canary Medical Inc. (2)(12) | Medical Device | Preferred Stock Warrant | | | | |||||||||||
| Candesant Biomedical, Inc. (2)(12) | Medical Device | Preferred Stock Warrant | | | | |||||||||||
| Ceribell, Inc. (2)(12) | Medical Device | Preferred Stock Warrant | | | | |||||||||||
| Cognoa, Inc. (2)(12) | Medical Device | Preferred Stock Warrant | | | | |||||||||||
| Conventus Orthopaedics, Inc. (2)(12) | Medical Device | Preferred Stock Warrant | | | | |||||||||||
| CSA Medical, Inc. (2)(12) | Medical Device | Preferred Stock Warrant | | | | |||||||||||
| CVRx, Inc. (2)(5)(12) | Medical Device | Common Stock Warrant | | | | |||||||||||
| Infobionic, Inc. (2)(12) | Medical Device | Preferred Stock Warrant | | | | |||||||||||
| Magnolia Medical Technologies, Inc. (2)(12) | Medical Device | Preferred Stock Warrant | | | | |||||||||||
| Meditrina, Inc. (12) | Medical Device | Preferred Stock Warrant | | | | |||||||||||
| MicroTransponder, Inc. (2)(12) | Medical Device | Preferred Stock Warrant | | | | |||||||||||
| Scientia Vascular, Inc (2)(12) | Medical Device | Preferred Stock Warrant | | | | |||||||||||
| Sonex Health, Inc. (2)(12) | Medical Device | Preferred Stock Warrant | | | | |||||||||||
| VERO Biotech LLC (2)(12) | Medical Device | Preferred Stock Warrant | | | | |||||||||||
| Swift Health Systems Inc. (2)(12) | Medical Device | Preferred Stock Warrant | | | | |||||||||||
| Total Non-Affiliate Warrants — Life Science | | | ||||||||||||||
See Notes to Consolidated Financial Statements
Consolidated Schedule of Investments
December 31, 2023
(Dollars in thousands)
| Cost of | Fair | |||||||||||||||
| Portfolio Company (1)(3) | Sector | Type of Investment (7) | Number of Shares | Investments (6)(9) | Value (9) | |||||||||||
| Non-Affiliate Warrants — Sustainability — % (8) | ||||||||||||||||
| New Aerofarms, Inc. assignee of Aerofarms, Inc. (2)(12)(15) | Other Sustainability | Preferred Stock Warrant | | | | |||||||||||
| LiquiGlide, Inc. (2)(12) | Other Sustainability | Common Stock Warrant | | | | |||||||||||
| Nexii Building Solutions, Inc. (2)(12)(14)(18) | Other Sustainability | Common Stock Warrant | | | — | |||||||||||
| Soli Organic, Inc. (2)(12) | Other Sustainability | Preferred Stock Warrant | | | | |||||||||||
| Temperpack Technologies, Inc. (2)(12) | Other Sustainability | Preferred Stock Warrant | | | | |||||||||||
| Total Non-Affiliate Warrants — Sustainability | | | ||||||||||||||
| Non-Affiliate Warrants — Technology — % (8) | ||||||||||||||||
| Axiom Space, Inc. (2)(12) | Communications | Common Stock Warrant | | | | |||||||||||
| Intelepeer Holdings, Inc. (2)(12) | Communications | Preferred Stock Warrant | | | | |||||||||||
| PebblePost, Inc. (2)(12) | Communications | Preferred Stock Warrant | | | | |||||||||||
| Alula Holdings, Inc. (2)(12) | Consumer-related Technologies | Preferred Stock Warrant | | | — | |||||||||||
| Aterian, Inc. (2)(5)(12) | Consumer-related Technologies | Common Stock Warrant | | | — | |||||||||||
| Caastle, Inc. (2)(12) | Consumer-related Technologies | Preferred Stock Warrant | | | | |||||||||||
| CAMP NYC, Inc. (2)(12) | Consumer-related Technologies | Preferred Stock Warrant | | | | |||||||||||
| Clara Foods Co. (2)(12) | Consumer-related Technologies | Preferred Stock Warrant | | | | |||||||||||
| CZV, Inc. (2)(12) | Consumer-related Technologies | Common Stock Warrant | | | | |||||||||||
| Divergent Technologies, Inc. (2)(12) | Consumer-related Technologies | Preferred Stock Warrant | | | | |||||||||||
| Havenly, Inc. (2)(12) | Consumer-related Technologies | Common Stock Warrant | | | | |||||||||||
| MyForest Foods Co. (2)(12) | Consumer-related Technologies | Preferred Stock Warrant | | | | |||||||||||
| NextCar Holding Company, Inc. (2)(12) | Consumer-related Technologies | Common Stock Warrant | | | — | |||||||||||
| NextCar Holding Company, Inc. (2)(12) | Consumer-related Technologies | Preferred Stock Warrant | | | — | |||||||||||
| Optoro, Inc. (2)(12) | Consumer-related Technologies | Preferred Stock Warrant | | | | |||||||||||
| Primary Kids, Inc. (2)(12) | Consumer-related Technologies | Preferred Stock Warrant | | | | |||||||||||
| Quip NYC Inc. (2)(12) | Consumer-related Technologies | Preferred Stock Warrant | | | | |||||||||||
| Unagi, Inc. (2)(12) | Consumer-related Technologies | Preferred Stock Warrant | | | — | |||||||||||
| Updater, Inc. (2)(12) | Consumer-related Technologies | Preferred Stock Warrant | | | — | |||||||||||
| CPG Beyond, Inc. (2)(12) | Data Storage | Preferred Stock Warrant | | | | |||||||||||
| Silk, Inc. (2)(12) | Data Storage | Preferred Stock Warrant | | | | |||||||||||
| Global Worldwide LLC (2)(12) | Internet and Media | Preferred Stock Warrant | | | | |||||||||||
| Rocket Lawyer Incorporated (2)(12) | Internet and Media | Preferred Stock Warrant | | | | |||||||||||
| Skillshare, Inc. (2)(12) | Internet and Media | Preferred Stock Warrant | | | | |||||||||||
| Liqid, Inc. (2)(12) | Networking | Preferred Stock Warrant | | | | |||||||||||
| Halio, Inc. (2)(12) | Power Management | Common Stock Warrant | | | | |||||||||||
| Avalanche Technology, Inc. (2)(12) | Semiconductors | Preferred Stock Warrant | | | — | |||||||||||
| BriteCore Holdings, Inc. (2)(12) | Software | Preferred Stock Warrant | | | | |||||||||||
| Dropoff, Inc. (2)(12) | Software | Common Stock Warrant | | | | |||||||||||
| E La Carte, Inc. (2)(5)(12) | Software | Common Stock Warrant | | | — | |||||||||||
| Everstream Holdings, LLC (2)(12) | Software | Preferred Stock Warrant | | | | |||||||||||
| Kodiak Robotics, Inc. (2)(12) | Software | Preferred Stock Warrant | | | | |||||||||||
| Lemongrass Holdings, Inc. (2)(12) | Software | Preferred Stock Warrant | | | | |||||||||||
| Lotame Solutions, Inc. (2)(12) | Software | Preferred Stock Warrant | | | | |||||||||||
| Lytics, Inc. (2)(12) | Software | Preferred Stock Warrant | | | | |||||||||||
| Mirantis, Inc. (2)(12) | Software | Common Stock Warrant | | | | |||||||||||
| Noodle Partners, Inc. (2)(12) | Software | Preferred Stock Warrant | | | | |||||||||||
| Reputation Institute, Inc. (2)(12) | Software | Preferred Stock Warrant | | | | |||||||||||
| Revinate Holdings, Inc. (2)(12) | Software | Preferred Stock Warrant | | | | |||||||||||
| SIGNiX, Inc. (12) | Software | Preferred Stock Warrant | | | — | |||||||||||
| Slingshot Aerospace, Inc. (2)(12) | Software | Preferred Stock Warrant | | | | |||||||||||
| Supply Network Visibility Holdings LLC (2)(12) | Software | Preferred Stock Warrant | | | | |||||||||||
| Topia Mobility, Inc. (2)(12) | Software | Preferred Stock Warrant | | | — | |||||||||||
| Viken Detection Corporation (2)(12) | Software | Preferred Stock Warrant | | | | |||||||||||
| xAd, Inc. (2)(12) | Software | Preferred Stock Warrant | | | | |||||||||||
| Total Non-Affiliate Warrants — Technology | | | ||||||||||||||
See Notes to Consolidated Financial Statements
Consolidated Schedule of Investments
December 31, 2023
(Dollars in thousands)
| Cost of | Fair | |||||||||||||||
| Portfolio Company (1)(3) | Sector | Type of Investment (7) | Number of Shares | Investments (6)(9) | Value (9) | |||||||||||
| Non-Affiliate Warrants — Healthcare information and services — % (8) | ||||||||||||||||
| Hound Labs, Inc (2) (12) | Diagnostics | Preferred Stock Warrant | | | | |||||||||||
| Parse Biosciences, Inc. (2)(12) | Diagnostics | Common Stock Warrant | | | | |||||||||||
| Parse Biosciences, Inc. (2)(12) | Diagnostics | Preferred Stock Warrant | | | | |||||||||||
| Kate Farms, Inc. (2)(12) | Other Healthcare | Preferred Stock Warrant | | | | |||||||||||
| BrightInsight, Inc. (2)(12) | Software | Preferred Stock Warrant | | | — | |||||||||||
| Elligo Health Research, Inc. (2)(12) | Software | Preferred Stock Warrant | | | | |||||||||||
| Medsphere Systems Corporation (2)(12) | Software | Preferred Stock Warrant | | | | |||||||||||
| SafelyYou, Inc. (2)(12) | Software | Preferred Stock Warrant | | | | |||||||||||
| Total Non-Affiliate Warrants — Healthcare information and services | | | ||||||||||||||
| Total Non-Affiliate Warrants | | | ||||||||||||||
| Non-Affiliate Other Investments — Life Science — % (8) | ||||||||||||||||
| Lumithera, Inc. (12) | Medical Device | Royalty Agreement | | | ||||||||||||
| ZetrOZ, Inc. (12) | Medical Device | Royalty Agreement | — | — | ||||||||||||
| Total Non-Affiliate Other Investments | | | ||||||||||||||
| Non-Affiliate Equity — % (8) | ||||||||||||||||
| Cadrenal Therapeutics, Inc. (5) | Biotechnology | Common Stock | | — | | |||||||||||
| Castle Creek Biosciences, Inc. (12) | Biotechnology | Common Stock | | | | |||||||||||
| Emalex Biosciences, Inc. (12) | Biotechnology | Common Stock | | | | |||||||||||
| Axiom Space, Inc. (12) | Communication | Preferred Stock | | | | |||||||||||
| Getaround, Inc. (2)(5) | Consumer-related Technologies | Common Stock | | | | |||||||||||
| NextCar Holding Company, Inc. (2)(12) | Consumer-related Technologies | Preferred Stock | | | | |||||||||||
| SnagAJob.com, Inc. (12) | Consumer-related Technologies | Common Stock | | | | |||||||||||
| Lumithera, Inc. (12) | Medical Device | Common Stock | | | | |||||||||||
| Tigo Energy, Inc. (5) | Other Sustainability | Common Stock | | | | |||||||||||
| Decisyon, Inc. (12) | Software | Preferred Stock | | | | |||||||||||
| Lotame, Inc. (12) | Software | Preferred Stock | | | | |||||||||||
| Total Non-Affiliate Equity | | | ||||||||||||||
| Total Non-Affiliate Portfolio Investment Assets | $ | $ | ||||||||||||||
|
|
See Notes to Consolidated Financial Statements
Consolidated Schedule of Investments
December 31, 2023
(Dollars in thousands)
| Portfolio Company (1)(3) | Sector | Type of Investment (7) | Cash Rate (4) | Index | Margin | Floor | Ceiling | ETP (10) | Maturity Date | Principal Amount | Cost of Investments (6)(9) | Fair Value (9) | ||||||||||||||||||||||||||
| Non-Controlled Affiliate Investments — % (8) | ||||||||||||||||||||||||||||||||||||||
| Non-Controlled Affiliate Debt Investments — Life Sciences — % (8) | ||||||||||||||||||||||||||||||||||||||
| Evelo Biosciences, Inc. (2)(5)(12)(13) | Biotechnology | Term Loan | % (11) | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % (11) | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % (11) | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % (11) | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % (11) | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Term Loan | % (11) | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Total Non-Controlled Affiliate Debt Investments | ||||||||||||||||||||||||||||||||||||||
| Cost of | Fair | |||||||||||||||
| Portfolio Company (1)(3) | Sector | Type of Investment (7) | Number of Shares | Investments (6)(9) | Value (9) | |||||||||||
| Non-controlled Affiliate Equity — Life Sciences — % (8) | ||||||||||||||||
| Aulea Medical, Inc. (12)(16) | Medical Device | Common Stock | | — | — | |||||||||||
| Evelo Biosciences, Inc. (5) | Biotechnology | Common Stock | | | | |||||||||||
| Total Non-Controlled Affiliate Equity | | | ||||||||||||||
| Non-controlled Affiliate Warrants — Life Sciences — % (8) | ||||||||||||||||
| Evelo Biosciences, Inc. (2)(5)(12) | Biotechnology | Common Stock | | | — | |||||||||||
| Total Non-Controlled Affiliate Warrants | | — | ||||||||||||||
| Total Non-Controlled Affiliate Portfolio Investment Assets | $ | $ | ||||||||||||||
| Portfolio Company (1)(3) | Sector | Type of Investment (7) | Cash Rate (4) | Index | Margin | Floor | Ceiling | ETP (10) | Maturity Date | Principal Amount | Cost of Investments (6)(9) | Fair Value (9) | ||||||||||||||||||||||||||
| Controlled Affiliate Investments — % (8) | ||||||||||||||||||||||||||||||||||||||
| Controlled Affiliate Debt Investments — Technology — % (8) | ||||||||||||||||||||||||||||||||||||||
| Better Place Forests Co. (12) | Consumer-related Technologies | Term Loan | % (11) | Prime | % | % | % | | ||||||||||||||||||||||||||||||
| Term Loan | % (11) | Prime | % | % | % | | ||||||||||||||||||||||||||||||||
| Total Controlled Affiliate Debt Investments | ||||||||||||||||||||||||||||||||||||||
| Cost of | Fair | |||||||||||||||
| Portfolio Company (1)(3) | Sector | Type of Investment (7) | Number of Shares | Investments (6)(9) | Value (9) | |||||||||||
| Controlled Affiliate Equity — Technology — % (8) | ||||||||||||||||
| Better Place Forests Co. (12) | Consumer-related Technologies | Common Stock | | | | |||||||||||
| Better Place Forests Co. (12) | Consumer-related Technologies | Preferred Stock | | | | |||||||||||
| Total Controlled Affiliate Equity | | | ||||||||||||||
| Controlled Affiliate Other Investments — Life Sciences — % (8) | ||||||||||||||||
| HIMV LLC (12)(17) | Biotechnology | Other Investment | | | ||||||||||||
| Total Controlled Affiliate Other | | | ||||||||||||||
| Total Controlled Affiliate Portfolio Investment Assets | $ | $ | ||||||||||||||
| Total Portfolio Investment Assets — % (8) | $ | $ | ||||||||||||||
| Short Term Investments - Unrestricted Investments - % (8) | ||||||||
| US Bank Money Market Deposit Account | ||||||||
| Total Short Term Investments - Unrestricted Investments | $ | $ | ||||||
| Short Term Investments - Restricted Investments - % (8) | ||||||||
| US Bank Money Market Deposit Account | ||||||||
| Total Short Term Investments - Restricted Investments | $ | $ |
See Notes to Consolidated Financial Statements
Consolidated Schedule of Investments
December 31, 2023
(Dollars in thousands)
| (1) | All investments of the Company are in entities which are organized under the laws of the United States and have a principal place of business in the United States, unless otherwise noted. |
| (2) | Has been pledged as collateral under the Key Facility, the NYL Facility and/or the 2022 Asset-Backed Notes. |
| (3) | All non-affiliate investments are investments in which the Company owns less than 5% of the voting securities of the portfolio company. All non-controlled affiliate investments are investments in which the Company owns 5% or more of the voting securities of the portfolio company but not more than 25% of the voting securities of the portfolio company. All controlled affiliate investments are investments in which the Company owns more than 25% of the portfolio company’s outstanding voting securities or has the power to exercise control over management or policies of such portfolio company (including through a management agreement). |
| (4) | All interest is payable in cash due monthly in arrears, unless otherwise indicated, and applies only to the Company’s debt investments. Interest rate is the annual interest rate on the debt investment and does not include ETPs, and any additional fees related to the investments, such as deferred interest, commitment fees or prepayment fees. Debt investments are at variable rates for the term of the debt investment, unless otherwise indicated. For each debt investment, the current interest rate in effect as of December 31, 2023 is provided. |
| (5) | Portfolio company is a public company. |
| (6) | For debt investments, represents principal balance less unearned income. |
| (7) | Warrants, Equity and Other Investments are non-income producing. |
| (8) | Value as a percent of net assets. |
| (9) | As of December 31, 2023, |
| (10) | ETPs are contractual fixed-interest payments due in cash at the maturity date of the applicable debt investment, including upon any prepayment, and are a fixed percentage of the original principal balance of the debt investments unless otherwise noted. Interest will accrue during the life of the debt investment on each ETP and will be recognized as non-cash income until it is actually paid. Therefore, a portion of the incentive fee the Company may pay its Advisor will be based on income that the Company has not yet received in cash. |
| (11) | Debt investment has a PIK feature in which the accrued interest is added to the then-outstanding principal amount of the debt investment. |
| (12) | The fair value of the investment was valued using significant unobservable inputs. |
| (13) | Debt investment is on non-accrual status as of December 31, 2023. |
| (14) | Entity is organized under the laws of Canada and has a principal place of business in Canada. |
| (15) | On or about September 13, 2023, in connection with New Aerofarms, Inc.’s purchase of substantially all of the assets of Aerofarms, Inc. in a bankruptcy process, New Aerofarms, Inc. assumed all of the debt investments of the Company in Aerofarms, Inc.. |
| (16) | On July 31, 2023, pursuant to a certain Secured Party Bill of Sale and Transfer Agreement, the Company sold substantially all of the assets of Corinth MedTech, Inc., a borrower of the Company, to Aulea Medical Inc. (“Aulea”) in consideration of |
| (17) | By an Order of the Supreme Court of Nova Scotia made May 1, 2023, as amended and restated by an Order of the Court made May 5, 2023, IMV, Inc. (“IMV”) commenced proceedings (the “CCAA Proceedings”) under the Companies' Creditors Arrangement Act, R.S.C. 1985, c. C-36, as amended to seek creditor protection for IMV and on June 2, 2023, IMV obtained recognition of the CCAA Proceedings under Chapter 15 of the United States Bankruptcy Code in proceedings before the United States Bankruptcy Court for the District of Delaware. In September 2023, the Company, with its co-lender to IMV, credit-bid and acquired substantially all of the assets of IMV through HIMV LLC, an entity formed to acquire the assets of IMV. HIMV LLC is |
| (18) | On January 11, 2024, Nexii Building Solutions Inc., and its affiliates, obtained an Initial Order under the Companies’ Creditors Arrangement Act from the Supreme Court of British Columbia in Vancouver. The Initial Order provides for, among other things, a stay of proceedings in favour of Nexii, the approval of debtor-in-possession financing and the appointment of KSV Restructuring Inc. as monitor of Nexii. |
| (19) | Debt investment has a partial PIK feature in which (a) a portion of the accrued interest on the debt investment, in an amount equal to four and one half percent ( |
See Notes to Consolidated Financial Statements
Horizon Technology Finance Corporation (the “Company”) was organized as a Delaware corporation on March 16, 2010 and is an externally managed, non-diversified, closed-end investment company. The Company has elected to be regulated as a business development company (“BDC”) under the 1940 Act. In addition, for tax purposes, the Company has elected to be treated as a regulated investment company (“RIC”) as defined under Subchapter M of the Internal Revenue Code of 1986, as amended (the “Code”). As a RIC, the Company generally is not subject to corporate-level federal income tax on the portion of its taxable income (including net capital gains) the Company distributes to its stockholders. The Company primarily makes secured debt investments to development-stage companies in the technology, life science, healthcare information and services and sustainability industries. All of the Company’s debt investments consist of loans secured by all of, or a portion of, the applicable debtor company’s tangible and intangible assets.
On October 28, 2010, the Company completed an initial public offering (“IPO”) and its common stock trades on the Nasdaq Global Select Market under the symbol “HRZN”.
Horizon Credit II LLC (“Credit II”) was formed as a Delaware limited liability company on June 28, 2011, with the Company as its sole equity member. Credit II is a special purpose bankruptcy-remote entity and is a separate legal entity from the Company. Any assets conveyed to Credit II are not available to creditors of the Company or any other entity other than Credit II’s lenders. Credit II is consolidated in the financial statements of the Company.
The Company formed Horizon Funding 2019‑1 LLC (“2019‑1 LLC”) as a Delaware limited liability company on May 2, 2019 and Horizon Funding Trust 2019‑1 as a Delaware statutory trust on May 15, 2019 (“2019‑1 Trust” and, together with the 2019‑1 LLC, the “2019‑1 Entities”). The 2019‑1 Entities are special purpose bankruptcy remote entities and are separate legal entities from the Company. The Company formed the 2019‑1 Entities for purposes of securitizing the term debt securitization in connection with which an affiliate of the Company made an offering of $
Horizon Funding I, LLC (“HFI”) was formed as a Delaware limited liability company on May 9, 2018, with Horizon Secured Loan Fund I LLC, a Delaware limited liability company (“HSLFI”) as its sole member. HFI is a special purpose bankruptcy-remote entity and is a separate legal entity from HSLFI. Any assets conveyed to HFI are not available to creditors of HSLFI or any other entity other than HFI’s lenders. As of April 21, 2020, HSLFI and its subsidiary, HFI, are consolidated in the financial statements of the Company.
The Company formed Horizon Funding 2022‑1 LLC (“2022‑1 LLC”) as a Delaware limited liability company on September 30, 2022 and Horizon Funding Trust 2022‑1 as a Delaware statutory trust on October 18, 2022 (“2022‑1 Trust” and, together with the 2022‑1 LLC, the “2022‑1 Entities”). The 2022‑1 Entities are special purpose bankruptcy remote entities and are separate legal entities from the Company. The Company formed the 2022‑1 Entities for purposes of securitizing the 2022 Asset-Backed Notes. The 2022-1 Entities are consolidated in the financial statements of the Company.
Horizon Funding II, LLC (“HFII”) was formed as a Delaware limited liability company on May 13, 2024, with the Company as its sole equity member. HFII is a special purpose bankruptcy-remote entity and is a separate legal entity from the Company. Any assets conveyed to HFII are not available to creditors of the Company or any other entity other than HFII’s lenders. HFII is consolidated in the financial statements of the Company.
The Company has established wholly owned subsidiaries, which are structured as Delaware limited liability companies, either to hold assets of portfolio companies acquired in connection with a foreclosure or bankruptcy or to hold equity in portfolio companies which the Company may control. Such wholly-owned subsidiaries are separate legal entities from the Company and are consolidated in the financial statements of the Company.
The Company, together with its co-lender to IMV, established HIMV LLC, a Delaware limited liability company to purchase and sell the assets of IMV, a past borrower of the Company. The assets of IMV were sold for (i) the right to receive certain payments, if any, in connection with the potential future development and licensing of the assets sold and (ii) equity in the buyer of such assets. HIMV LLC is
The Company’s investment strategy is to maximize the investment portfolio’s return by generating current income from the debt investments the Company makes and capital appreciation from the warrants the Company receives when making such debt investments. The Company has entered into an investment management agreement with Horizon Technology Finance Management LLC (the “Advisor”) under which the Advisor manages the day-to-day operations of, and provides investment advisory services to, the Company.
Note 2. Basis of presentation and significant accounting policies
The consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and pursuant to the requirements for reporting on Form 10‑Q and Articles 6 and 10 of Regulation S-X (“Regulation S-X”) under the Securities Act of 1933, as amended (the “Securities Act”). In the opinion of management, the consolidated financial statements reflect all adjustments and reclassifications, consisting solely of normal recurring accruals, that are necessary for the fair presentation of financial results as of and for the periods presented. All intercompany balances and transactions have been eliminated. The current period’s results of operations are not necessarily indicative of results that ultimately may be achieved for the year. Therefore, the unaudited financial statements and notes should be read in conjunction with the audited financial statements and notes thereto as of and for the year ended December 31, 2023.
Principles of consolidation
As required under GAAP and Regulation S-X, the Company will generally consolidate its investment in a company that is an investment company subsidiary or a controlled operating company whose business consists of providing services to the Company. Accordingly, the Company consolidated the results of the Company’s wholly-owned subsidiaries in its consolidated financial statements.
Assets related to transactions that do not meet Accounting Standards Codification (“ASC”) Topic 860, Transfers and Servicing requirements for accounting sale treatment are reflected in the Company’s Consolidated Statements of Assets and Liabilities as investments. Those assets are owned by special purpose entities, including 2019‑1 Entities and 2022-1 Entities, that are consolidated in the Company’s consolidated financial statements. The creditors of the special purpose entities have received security interests in such assets, and such assets are not intended to be available to the creditors of the Company (or any affiliate of the Company).
Use of estimates
In preparing the consolidated financial statements in accordance with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosures of contingent assets and liabilities, as of the date of the balance sheet and income and expenses for the period. Actual results could differ from those estimates. Material estimates that are particularly susceptible to significant change in the near term relate to the valuation of investments.
Fair value
The Company records all of its investments at fair value in accordance with relevant GAAP, which establishes a framework used to measure fair value and requires disclosures for fair value measurements. The Company has categorized its investments carried at fair value, based on the priority of the valuation technique, into a three-level fair value hierarchy as more fully described in Note 6. Fair value is a market-based measure considered from the perspective of the market participant who holds the financial instrument rather than an entity specific measure. Therefore, when market assumptions are not readily available, the Company’s own assumptions are set to reflect those that management believes market participants would use in pricing the financial instrument at the measurement date.
The availability of observable inputs can vary depending on the financial instrument and is affected by a wide variety of factors, including, for example, the type of product, whether the product is new, whether the product is traded on an active exchange or in the secondary market and the current market conditions. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for financial instruments classified as Level 3.
See Note 6 for additional information regarding fair value.
Segments
The Company has determined that it has a single reporting segment and operating unit structure. The Company lends to and invests in portfolio companies in various technology, life science, healthcare information and services and sustainability industries. The Company separately evaluates the performance of each of its lending and investment relationships. However, because each of these debt investments and investment relationships has similar business and economic characteristics, they have been aggregated into a single lending and investment segment.
Investments
Investments are recorded at fair value. Pursuant to the amended SEC Rule 2a-5 of the 1940 Act, on July 29, 2022, the Company's board of directors (the “Board”) designated the Advisor as the Company’s “valuation designee.” The valuation designee determines the fair value of the Company’s portfolio investments and the Company's Board oversees the valuation designee. The Company has the intent to hold its debt investments for the foreseeable future or until maturity or payoff.
Interest on debt investments is accrued and included in income based on contractual rates applied to principal amounts outstanding. Interest income is determined using a method that results in a level rate of return on principal amounts outstanding. Generally, when a debt investment becomes 90 days or more past due, or if the Company otherwise does not expect to receive interest and principal repayments, the debt investment is placed on non-accrual status and the recognition of interest income may be discontinued. Interest payments received on non-accrual debt investments may be recognized as income, on a cash basis, or applied to principal depending upon management’s judgment at the time the debt investment is placed on non-accrual status. As of September 30, 2024, there were four investments on nonaccrual status with a cost of $
The Company has a limited number of debt investments that contain a PIK provision. Contractual PIK interest, which represents contractually deferred interest added to the loan balance that is generally due at the end of the loan term, is generally recorded on an accrual basis to the extent such amounts are expected to be collected. For the three months ended September 30, 2024 and 2023,
The Company receives a variety of fees from borrowers in the ordinary course of conducting its business, including advisory fees, commitment fees, amendment fees, non-utilization fees, success fees and prepayment fees. In a limited number of cases, the Company may also receive a non-refundable deposit earned upon the termination of a transaction. Debt investment origination fees, net of certain direct origination costs, are deferred and, along with unearned income, are amortized as a level-yield adjustment over the respective term of the debt investment. All other income is recognized when earned. Fees for counterparty debt investment commitments with multiple debt investments are allocated to each debt investment based upon each debt investment’s relative fair value. When a debt investment is placed on non-accrual status, the amortization of the related fees and unearned income is discontinued until the debt investment is returned to accrual status.
Certain debt investment agreements also require the borrower to make an ETP, that is accrued into interest receivable and taken into income over the life of the debt investment to the extent such amounts are expected to be collected. The Company will generally cease accruing the income if there is insufficient value to support the accrual or the Company does not expect the borrower to be able to pay the ETP when due. The proportion of the Company’s total investment income that resulted from the portion of ETPs not received in cash for the three months ended September 30, 2024 and 2023 was
In connection with substantially all lending arrangements, the Company receives warrants to purchase shares of stock from the borrower. The warrants are recorded as assets at estimated fair value on the grant date using the Black-Scholes valuation model. The warrants are considered loan fees and are recorded as unearned income on the grant date. The unearned income is recognized as interest income over the contractual life of the related debt investment in accordance with the Company’s income recognition policy. Subsequent to debt investment origination, the fair value of the warrants is determined using the Black-Scholes valuation model. Any adjustment to fair value is recorded through earnings as net unrealized appreciation or depreciation on investments. Gains and losses from the disposition of the warrants or stock acquired from the exercise of warrants are recognized as realized gains and losses on investments.
Realized gains or losses on the sale of investments, or upon the determination that an investment balance, or portion thereof, is not recoverable, are calculated using the specific identification method. The Company measures realized gains or losses by calculating the difference between the net proceeds from the repayment or sale and the amortized cost basis of the investment. Net change in unrealized appreciation or depreciation reflects the change in the fair values of the Company’s portfolio investments during the reporting period, including any reversal of previously recorded unrealized appreciation or depreciation when gains or losses are realized.
Debt issuance costs
Debt issuance costs are fees and other direct incremental costs incurred by the Company in obtaining debt financing from its lenders and issuing debt securities. The unamortized balance of debt issuance costs as of September 30, 2024 and December 31, 2023 was $
Income taxes
As a BDC, the Company has elected to be treated as a RIC under Subchapter M of the Code and operates in a manner so as to qualify for the tax treatment applicable to RICs. In order to qualify as a RIC and to avoid the imposition of corporate-level income tax on the portion of its taxable income distributed to stockholders, among other things, the Company is required to meet certain source of income and asset diversification requirements and to timely distribute dividends out of assets legally available for distribution to its stockholders of an amount generally at least equal to 90% of its investment company taxable income, as defined by the Code and determined without regard to any deduction for dividends paid, for each tax year. The Company, among other things, has made and intends to continue to make the requisite distributions to its stockholders, which generally relieves the Company from corporate-level U.S. federal income taxes. Accordingly, no provision for federal income tax has been recorded in the financial statements. Differences between taxable income and net increase in net assets resulting from operations either can be temporary, meaning they will reverse in the future, or permanent. In accordance with ASC Topic 946, Financial Services—Investment Companies, as amended, of the Financial Accounting Standards Board (“FASB”), permanent tax differences, such as non-deductible excise taxes paid, are reclassified from distributions in excess of net investment income and net realized loss on investments to paid-in-capital at the end of each fiscal year. These permanent book-to-tax differences are reclassified on the consolidated statements of changes in net assets to reflect their tax character but have no impact on total net assets.
Depending on the level of taxable income earned in a tax year, the Company may choose to carry forward taxable income in excess of current year distributions into the next tax year and incur a
The Company evaluates tax positions taken in the course of preparing the Company’s tax returns to determine whether the tax positions are “more-likely-than-not” to be sustained by the applicable tax authority in accordance with ASC Topic 740, Income Taxes, as modified by ASC Topic 946. Tax benefits of positions not deemed to meet the more-likely-than-not threshold, or uncertain tax positions, would be recorded as a tax expense in the current year. It is the Company’s policy to recognize accrued interest and penalties related to uncertain tax benefits in income tax expense. The Company had
Distributions
Distributions to common stockholders are recorded on the declaration date. The amount to be paid out as distributions is determined by the Board. Net realized capital gains, if any, may be distributed, although the Company may decide to retain such net realized gains for investment.
The Company has adopted a dividend reinvestment plan that provides for reinvestment of cash distributions on behalf of its stockholders, unless a stockholder elects to receive cash. As a result, if the Board declares a cash distribution, then stockholders who have not “opted out” of the dividend reinvestment plan will have their cash distributions automatically reinvested in additional shares of the Company’s common stock, rather than receiving the cash distribution. The Company may issue new shares or purchase shares in the open market to fulfill its obligations under the plan.
Stockholders’ Equity
On August 2, 2021, the Company entered into an At-The-Market (“ATM”) sales agreement (the “2021 Equity Distribution Agreement”), with Goldman Sachs & Co. LLC and B. Riley FBR, Inc. (each a “Sales Agent” and, collectively, the “Sales Agents”). The 2021 Equity Distribution Agreement provided that the Company may offer and sell its shares of common stock from time to time through the Sales Agents representing up to $
On September 22, 2023, the Company terminated the 2021 Equity Distribution Agreement and entered into a new ATM sales agreement (the “2023 Equity Distribution Agreement”), with the Sales Agents. The remaining shares available under the 2021 Equity Distribution Agreement are
During the three months ended September 30, 2024, the Company sold
During the three months ended September 30, 2023, the Company sold
During the nine months ended September 30, 2024, the Company sold
During the nine months ended September 30, 2023, the Company sold
The Company generally uses net proceeds from these offerings to make investments, to pay down liabilities and for general corporate purposes. As of September 30, 2024, shares representing approximately $
On June 2, 2023, the Company completed a follow-on public offering of
Stock Repurchase Program
On April 26, 2024, the Board extended a previously authorized stock repurchase program which allows the Company to repurchase up to $
Transfers of financial assets
Assets related to transactions that do not meet the requirements under ASC Topic 860, Transfers and Servicing for sale treatment under GAAP are reflected in the Company’s consolidated statements of assets and liabilities as investments. Those assets are owned by special purpose entities that are consolidated in the Company’s financial statements. The creditors of the special purpose entities have received security interests in such assets and such assets are not intended to be available to the creditors of the Company (or any other affiliate of the Company).
Transfers of financial assets are accounted for as sales when control over the assets has been surrendered. Control over transferred assets is deemed to be surrendered when (1) the assets have been isolated from the Company — put presumptively beyond the reach of the transferor and its creditors, even in bankruptcy or other receivership, (2) the transferee obtains the right (free of conditions that constrain it from taking advantage of that right) to pledge or exchange the transferred assets and (3) the transferor does not maintain effective control over the transferred assets through either (a) an agreement that both entitles and obligates the transferor to repurchase or redeem the assets before maturity or (b) the ability to unilaterally cause the holder to return specific assets, other than through a cleanup call.
Recently issued accounting pronouncement
In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”). ASU 2023-07 is intended to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses, allowing financial statement users to better understand the components of a segment's profit or loss and assess potential future cash flows for each reportable segment and the entity as a whole. The amendments expand a public entity's segment disclosures by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker, clarifying when an entity may report one or more additional measures to assess segment performance, requiring enhanced interim disclosures and providing new disclosure requirements for entities with a single reportable segment, among other new disclosure requirements. The amendments are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, and early adoption is permitted. The Company is currently evaluating the impact of adopting this guidance with respect to the consolidated financial statements and disclosures.
Recently adopted accounting pronouncement
In June 2022, the FASB issued Accounting Standards Update No. 2022-03, Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2022-03”). ASU 2022-03 clarifies the guidance when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of the security. The amendments in ASU 2022-03 were effective for public companies for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The adoption of ASU 2022-03 did not have a material impact on the Company’s consolidated financial statements.
Note 3. Related party transactions
Investment Management Agreement
At a meeting of the stockholders convened on May 25, 2023 and reconvened on June 28, 2023, the stockholders approved a new Investment Management Agreement which became effective on June 30, 2023 (the “Investment Management Agreement”) upon the closing of the acquisition of the Advisor by MCH Holdco LLC, an affiliate of Monroe Capital LLC. The new Investment Management Agreement replaced the previously effective Investment Management Agreement dated as of March 7, 2019. Under the terms of the Investment Management Agreement, the Advisor determines the composition of the Company’s investment portfolio, the nature and timing of the changes to the investment portfolio and the manner of implementing such changes; identifies, evaluates and negotiates the structure of the investments the Company makes (including performing due diligence on the Company’s prospective portfolio companies); and closes, monitors and administers the investments the Company makes, including the exercise of any voting or consent rights.
The Advisor’s services under the Investment Management Agreement are not exclusive to the Company, and the Advisor is free to furnish similar services to other entities so long as its services to the Company are not impaired. The Advisor is a registered investment adviser with the SEC. The Advisor receives fees for providing services to the Company under the Investment Management Agreement, consisting of two components, a base management fee and an incentive fee.
The base management fee is calculated at an annual rate of
The base management fee payable at September 30, 2024 and December 31, 2023 was $
The incentive fee has two parts, as follows:
The first part, which is subject to the Incentive Fee Cap and Deferral Mechanism, as defined below, is calculated and payable quarterly in arrears based on the Company’s Pre-Incentive Fee Net Investment Income for the immediately preceding calendar quarter. For this purpose, “Pre-Incentive Fee Net Investment Income” means interest income, dividend income and any other income (including any other fees (other than fees for providing managerial assistance), such as commitment, origination, structuring, diligence and consulting fees or other fees received from portfolio companies) accrued during the calendar quarter, minus expenses for the quarter (including the base management fee, expenses payable under the Administration Agreement (as defined below), and any interest expense and any dividends paid on any issued and outstanding preferred stock, but excluding the incentive fee). Pre-Incentive Fee Net Investment Income includes, in the case of investments with a deferred interest feature (such as original issue discount, debt instruments with PIK interest and zero coupon securities), accrued income the Company has not yet received in cash. The incentive fee with respect to the Pre-Incentive Fee Net Investment Income is
Pre-Incentive Fee Net Investment Income does not include any realized capital gains, realized capital losses or unrealized capital appreciation or depreciation. Because of the structure of the incentive fee, it is possible that the Company may pay an incentive fee in a quarter in which the Company incurs a loss. For example, if the Company receives Pre-Incentive Fee Net Investment Income in excess of the quarterly minimum hurdle rate, the Company will pay the applicable incentive fee up to the Incentive Fee Cap, defined below, even if the Company has incurred a loss in that quarter due to realized and unrealized capital losses. The Company’s net investment income used to calculate this part of the incentive fee is also included in the amount of the Company’s gross assets used to calculate the 2.00% base management fee. These calculations are appropriately prorated for any period of less than three months and adjusted for any share issuances or repurchases during the current quarter.
The incentive fee on Pre-Incentive Fee Net Investment Income is subject to a fee cap and deferral mechanism which is determined based upon a look-back period of up to three years and is expensed when incurred. For this purpose, the look-back period for the incentive fee based on Pre-Incentive Fee Net Investment Income (the “Incentive Fee Look-back Period”) includes the relevant calendar quarter and the 11 preceding full calendar quarters. Each quarterly incentive fee payable on Pre-Incentive Fee Net Investment Income is subject to a cap (the “Incentive Fee Cap”) and a deferral mechanism through which the Advisor may recoup a portion of such deferred incentive fees (collectively, the “Incentive Fee Cap and Deferral Mechanism”). The Incentive Fee Cap is equal to (a) 20.00% of Cumulative Pre-Incentive Fee Net Return (as defined below) during the Incentive Fee Look-back Period less (b) cumulative incentive fees of any kind paid to the Advisor during the Incentive Fee Look-back Period. To the extent the Incentive Fee Cap is zero or a negative value in any calendar quarter, the Company will not pay an incentive fee on Pre-Incentive Fee Net Investment Income to the Advisor in that quarter. To the extent that the payment of incentive fees on Pre-Incentive Fee Net Investment Income is limited by the Incentive Fee Cap, the payment of such fees will be deferred and paid in subsequent calendar quarters up to three years after their date of deferment, subject to certain limitations, which are set forth in the Investment Management Agreement. The Company only pays incentive fees on Pre-Incentive Fee Net Investment Income to the extent allowed by the Incentive Fee Cap and Deferral Mechanism. “Cumulative Pre-Incentive Fee Net Return” during any Incentive Fee Look-back Period means the sum of (a) Pre-Incentive Fee Net Investment Income and the base management fee for each calendar quarter during the Incentive Fee Look-back Period and (b) the sum of cumulative realized capital gains and losses, cumulative unrealized capital appreciation and cumulative unrealized capital depreciation during the applicable Incentive Fee Look-back Period.
The second part of the incentive fee is determined and payable in arrears as of the end of each calendar year (or, upon termination of the Investment Management Agreement, as of the termination date), and equals 20.00% of the Company’s realized capital gains, if any, on a cumulative basis from the date of the election to be a BDC through the end of each calendar year, computed net of all realized capital losses and unrealized capital depreciation on a cumulative basis through the end of such year, less all previous amounts paid in respect of the capital gain incentive fee. However, in accordance with GAAP, the Company is required to include the aggregate unrealized capital appreciation on investments in the calculation and accrue a capital gain incentive fee on a quarterly basis, as if such unrealized capital appreciation were realized, even though such unrealized capital appreciation is not permitted to be considered in calculating the fee actually payable under the Investment Management Agreement.
There was
The following table provides the expiration dates of the Company’s Incentive Fee Cap and Deferral Mechanism contingent future liability as of September 30, 2024:
| Expiration | Total | |||
| (In thousands) | ||||
| December 31, 2025 | $ | |||
| March 31, 2026 | ||||
| June 30, 2026 | ||||
| September 30, 2026 | ||||
| December 31, 2026 | ||||
| March 31, 2027 | ||||
| June 30, 2027 | ||||
| September 30, 2027 | ||||
| Total | $ | |||
There was
Administration Agreement
The Company entered into an administration agreement (the “Administration Agreement”) with the Advisor to provide administrative services to the Company. For providing these services, facilities and personnel, the Company reimburses the Advisor for the Company’s allocable portion of overhead and other expenses incurred by the Advisor in performing its obligations under the Administration Agreement, including rent, the fees and expenses associated with performing compliance functions and the Company’s allocable portion of the costs of compensation and related expenses of the Company’s Chief Financial Officer and Chief Compliance Officer and their respective staffs. The administrative fee expense was $
Note 4. Investments
The following table shows the Company’s investments as of September 30, 2024 and December 31, 2023:
| September 30, 2024 |
December 31, 2023 |
|||||||||||||||
| Cost |
Fair Value |
Cost |
Fair Value |
|||||||||||||
| (In thousands) |
||||||||||||||||
| Investments |
||||||||||||||||
| Debt |
$ | $ | $ | $ | ||||||||||||
| Warrants |
||||||||||||||||
| Other |
||||||||||||||||
| Equity |
||||||||||||||||
| Total investments |
$ | $ | $ | $ | ||||||||||||
The following table shows the Company’s investments by industry sector as of September 30, 2024 and December 31, 2023:
| September 30, 2024 |
December 31, 2023 |
|||||||||||||||
| Cost |
Fair Value |
Cost |
Fair Value |
|||||||||||||
| (In thousands) |
||||||||||||||||
| Life Science |
||||||||||||||||
| Biotechnology |
$ | $ | $ | $ | ||||||||||||
| Medical Device |
||||||||||||||||
| Technology |
||||||||||||||||
| Communications |
||||||||||||||||
| Consumer-Related |
||||||||||||||||
| Data Storage |
||||||||||||||||
| Internet and Media |
||||||||||||||||
| Networking |
||||||||||||||||
| Power Management |
||||||||||||||||
| Semiconductors |
||||||||||||||||
| Software |
||||||||||||||||
| Sustainability |
||||||||||||||||
| Energy Efficiency |
||||||||||||||||
| Other Sustainability |
||||||||||||||||
| Healthcare Information and Services |
||||||||||||||||
| Diagnostics |
||||||||||||||||
| Other |
||||||||||||||||
| Software |
||||||||||||||||
| Total investments |
$ | $ | $ | $ | ||||||||||||
Note 5. Transactions with affiliated companies
A non-controlled affiliated company is generally a portfolio company in which the Company owns 5% or more of such portfolio company’s voting securities but not more than 25% of such portfolio company’s voting securities.
Transactions related to investments in non-controlled affiliated companies for the three months ended September 30, 2024 were as follows:
| Three months ended September 30, 2024 |
||||||||||||||||||||||||||||||||
| Fair value at |
Transfers |
Net |
Fair value at |
|||||||||||||||||||||||||||||
| Portfolio |
June 30, |
Principal |
in/(out) at |
Discount |
unrealized |
Net realized |
September 30, |
|||||||||||||||||||||||||
| Company |
2024 |
Purchases |
payments |
fair value |
accretion |
gain/(loss) |
gain/(loss) |
2024 |
||||||||||||||||||||||||
| (In thousands) |
||||||||||||||||||||||||||||||||
| Aulea Medical, Inc. |
$ | $ | $ | $ | $ | $ | $ | $ | ||||||||||||||||||||||||
| Evelo Biosciences, Inc. |
( |
) | ( |
) | ||||||||||||||||||||||||||||
| ( |
) | ( |
) | |||||||||||||||||||||||||||||
| ( |
) | ( |
) | |||||||||||||||||||||||||||||
| ( |
) | ( |
) | |||||||||||||||||||||||||||||
| ( |
) | ( |
) | |||||||||||||||||||||||||||||
| ( |
) | ( |
) | |||||||||||||||||||||||||||||
| Total non-controlled affiliates |
$ | $ | $ | ( |
) | $ | $ | $ | ( |
) | $ | $ | ||||||||||||||||||||
Transactions related to investments in non-controlled affiliated companies for the three months ended September 30, 2023 were as follows:
| Three months ended September 30, 2023 |
||||||||||||||||||||||||||||||||||||
| Fair value at |
Transfers |
Net |
Fair value at |
|||||||||||||||||||||||||||||||||
| Portfolio |
June 30, | Principal | in/(out) at | Discount | unrealized | Net realized | September 30, | Interest | ||||||||||||||||||||||||||||
| Company |
2023 |
Purchases |
payments |
fair value |
accretion |
gain/(loss) |
gain/(loss) |
2023 |
income |
|||||||||||||||||||||||||||
| (In thousands) |
||||||||||||||||||||||||||||||||||||
| Aulea Medical, Inc. |
$ | $ | $ | $ | $ | $ | $ | $ | $ | |||||||||||||||||||||||||||
| Cadrenal Therapeutics, Inc. (1) |
( |
) | ||||||||||||||||||||||||||||||||||
| Evelo Biosciences, Inc. |
( |
) | ||||||||||||||||||||||||||||||||||
| ( |
) | |||||||||||||||||||||||||||||||||||
| ( |
) | |||||||||||||||||||||||||||||||||||
| ( |
) | |||||||||||||||||||||||||||||||||||
| ( |
) | |||||||||||||||||||||||||||||||||||
| ( |
) | |||||||||||||||||||||||||||||||||||
| Total non-controlled affiliates |
$ | $ | $ | $ | $ | $ | ( |
) | $ | $ | $ | |||||||||||||||||||||||||
| (1) |
As of September 30, 2023, the Company no longer owns |
Transactions related to investments in non-controlled affiliated companies for the nine months ended September 30, 2024 were as follows:
| Nine months ended September 30, 2024 |
||||||||||||||||||||||||||||||||||||
| Fair value at |
Transfers |
Net |
Fair value at |
|||||||||||||||||||||||||||||||||
| Portfolio |
December 31, |
Principal |
in/(out) at |
Discount |
unrealized |
Net realized |
September 30, |
Interest |
||||||||||||||||||||||||||||
| Company |
2023 |
Purchases |
payments |
fair value |
accretion |
gain/(loss) |
gain/(loss) |
2024 |
income |
|||||||||||||||||||||||||||
| (In thousands) |
||||||||||||||||||||||||||||||||||||
| Aulea Medical, Inc. |
$ | $ | $ | ( |
) | $ | $ | $ | $ | $ | $ | |||||||||||||||||||||||||
| Evelo Biosciences, Inc. |
( |
) | ||||||||||||||||||||||||||||||||||
| ( |
) | |||||||||||||||||||||||||||||||||||
| ( |
) | |||||||||||||||||||||||||||||||||||
| ( |
) | |||||||||||||||||||||||||||||||||||
| ( |
) | |||||||||||||||||||||||||||||||||||
| ( |
) | |||||||||||||||||||||||||||||||||||
| ( |
) | |||||||||||||||||||||||||||||||||||
| Total non-controlled affiliates |
$ | $ | $ | ( |
) | $ | $ | $ | $ | $ | $ | |||||||||||||||||||||||||
Transactions related to investments in non-controlled affiliated companies for the nine months ended September 30, 2023 were as follows:
| Nine months ended September 30, 2023 |
||||||||||||||||||||||||||||||||||||
| Fair value at |
Transfers |
Net |
Fair value at |
|||||||||||||||||||||||||||||||||
| Portfolio |
December 31, | Principal | in/(out) at | Discount | unrealized | Net realized | September 30, | Interest | ||||||||||||||||||||||||||||
| Company |
2022 |
Purchases |
payments |
fair value |
accretion |
gain/(loss) |
gain/(loss) |
2023 |
income |
|||||||||||||||||||||||||||
| (In thousands) |
||||||||||||||||||||||||||||||||||||
| Aulea Medical, Inc. |
$ | $ | $ | $ | $ | $ | $ | $ | $ | |||||||||||||||||||||||||||
| Cadrenal Therapeutics, Inc. (1) |
( |
) | ||||||||||||||||||||||||||||||||||
| Evelo Biosciences, Inc. |
( |
) | ||||||||||||||||||||||||||||||||||
| ( |
) | |||||||||||||||||||||||||||||||||||
| ( |
) | |||||||||||||||||||||||||||||||||||
| ( |
) | |||||||||||||||||||||||||||||||||||
| ( |
) | |||||||||||||||||||||||||||||||||||
| ( |
) | |||||||||||||||||||||||||||||||||||
| Total non-controlled affiliates |
$ | $ | $ | $ | $ | $ | ( |
) | $ | $ | $ | |||||||||||||||||||||||||
| (1) |
As of September 30, 2023, the Company no longer owns 5% or more of the portfolio company. |
A controlled affiliated company is generally a portfolio company in which the Company owns more than 25% of such portfolio company’s voting securities or has the power to exercise control over management or policies of such portfolio company (including through a management agreement).
Transactions related to investments in controlled affiliated companies for the three months ended September 30, 2024 were as follows:
| Three months ended September 30, 2024 |
||||||||||||||||||||||||||||||||||||||||
| Fair value at |
Transfers |
Net |
Fair value at |
|||||||||||||||||||||||||||||||||||||
| Portfolio |
June 30, |
Principal |
in/(out) at |
Discount |
unrealized |
Net realized |
September 30, |
Interest |
||||||||||||||||||||||||||||||||
| Company |
2024 |
Purchases |
payments |
PIK |
fair value |
accretion |
gain/(loss) |
gain/(loss) |
2024 |
income |
||||||||||||||||||||||||||||||
| (In thousands) |
||||||||||||||||||||||||||||||||||||||||
| Better Place Forests Co. |
$ | $ | $ | $ | $ | $ | $ | ( |
) | $ | $ | $ | ||||||||||||||||||||||||||||
| ( |
) | |||||||||||||||||||||||||||||||||||||||
| ( |
) | |||||||||||||||||||||||||||||||||||||||
| HIMV LLC |
( |
) | ||||||||||||||||||||||||||||||||||||||
| Nexii, Inc. |
( |
) | ||||||||||||||||||||||||||||||||||||||
| ( |
) | |||||||||||||||||||||||||||||||||||||||
| Total controlled affiliates |
$ | $ | $ | ( |
) | $ | $ | $ | $ | $ | $ | $ | ||||||||||||||||||||||||||||
Transactions related to investments in controlled affiliated companies for the three months ended September 30, 2023 were as follows:
| Three months ended September 30, 2023 |
||||||||||||||||||||||||||||||||||||||||
| Fair value at |
Transfers |
Net |
Fair value at |
|||||||||||||||||||||||||||||||||||||
| Portfolio |
June 30, |
Principal |
in/(out) at |
Discount |
unrealized |
Net realized |
September 30, |
Interest |
||||||||||||||||||||||||||||||||
| Company |
2023 |
Purchases |
payments |
PIK |
fair value |
accretion |
gain/(loss) |
gain/(loss) |
2023 |
income |
||||||||||||||||||||||||||||||
| (In thousands) |
||||||||||||||||||||||||||||||||||||||||
| Better Place Forests Co. |
$ | $ | $ | $ | $ | $ | $ | $ | $ | $ | ||||||||||||||||||||||||||||||
| ( |
) | |||||||||||||||||||||||||||||||||||||||
| HIMV LLC |
||||||||||||||||||||||||||||||||||||||||
| Total controlled affiliates |
$ | $ | $ | $ | $ | $ | $ | $ | $ | $ | ||||||||||||||||||||||||||||||
Transactions related to investments in controlled affiliated companies for the nine months ended September 30, 2024 were as follows:
| Nine months ended September 30, 2024 |
||||||||||||||||||||||||||||||||||||||||
| Fair value at |
Transfers |
Net |
Fair value at |
|||||||||||||||||||||||||||||||||||||
| Portfolio |
December 31, |
Principal |
in/(out) at |
Discount |
unrealized |
Net realized |
September 30, |
Interest |
||||||||||||||||||||||||||||||||
| Company |
2023 |
Purchases |
payments |
PIK |
fair value |
accretion |
gain/(loss) |
gain/(loss) |
2024 |
income |
||||||||||||||||||||||||||||||
| (In thousands) |
||||||||||||||||||||||||||||||||||||||||
| Better Place Forests Co. |
$ | $ | $ | $ | $ | $ | $ | ( |
) | $ | $ | $ | ||||||||||||||||||||||||||||
| ( |
) | |||||||||||||||||||||||||||||||||||||||
| ( |
) | |||||||||||||||||||||||||||||||||||||||
| ( |
) | |||||||||||||||||||||||||||||||||||||||
| ( |
) | |||||||||||||||||||||||||||||||||||||||
| ( |
) | |||||||||||||||||||||||||||||||||||||||
| HIMV LLC |
( |
) | ( |
) | ||||||||||||||||||||||||||||||||||||
| Nexii, Inc. |
( |
) | ||||||||||||||||||||||||||||||||||||||
| ( |
) | |||||||||||||||||||||||||||||||||||||||
| Total controlled affiliates |
$ | $ | $ | ( |
) | $ | $ | $ | $ | ( |
) | $ | $ | $ | ||||||||||||||||||||||||||
Transactions related to investments in controlled affiliated companies for the nine months ended September 30, 2023 were as follows:
| Nine months ended September 30, 2023 |
||||||||||||||||||||||||||||||||||||||||
| Fair value at |
Transfers |
Net |
Fair value at |
|||||||||||||||||||||||||||||||||||||
| Portfolio |
December 31, |
Principal |
in/(out) at |
Discount |
unrealized |
Net realized |
September 30, |
Interest |
||||||||||||||||||||||||||||||||
| Company |
2022 |
Purchases |
payments |
PIK |
fair value |
accretion |
gain/(loss) |
gain/(loss) |
2023 |
income |
||||||||||||||||||||||||||||||
| (In thousands) |
||||||||||||||||||||||||||||||||||||||||
| Better Place Forests Co. |
$ | $ | $ | $ | $ | $ | $ | $ | $ | $ | ||||||||||||||||||||||||||||||
| ( |
) | |||||||||||||||||||||||||||||||||||||||
| HIMV LLC |
||||||||||||||||||||||||||||||||||||||||
| Total controlled affiliates |
$ | $ | $ | $ | $ | $ | $ | $ | $ | $ | ||||||||||||||||||||||||||||||
Note 6. Fair value
Prior to July 30, 2022, the Board determined the fair value of the Company’s investments. Pursuant to the amended SEC Rule 2a-5 of the 1940 Act, on July 29, 2022, the Board designated the Advisor as the Company’s “valuation designee.” The Board is responsible for oversight of the valuation designee. The valuation designee has established a Valuation Committee to determine in good faith the fair value of the Company’s investments, based on input from the Advisor’s management and personnel and independent valuation firms which are engaged at the direction of the Valuation Committee to assist in the valuation of certain portfolio investments lacking a readily available market quotation at least once during a trailing twelve-month period. The Valuation Committee determines fair values pursuant to a valuation policy approved by the Board and pursuant to a consistently applied valuation process. This valuation process is conducted at the end of each fiscal quarter, with at least
The Company uses fair value measurements made by the valuation designee to record fair value adjustments to certain assets and liabilities and to determine fair value disclosures. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is best determined based upon quoted market prices. However, in certain instances, there are no quoted market prices for certain assets or liabilities. In cases where quoted market prices are not available, fair values are based on estimates using present value or other valuation techniques. Those techniques are significantly affected by the assumptions used, including the discount rate and estimates of future cash flows. Accordingly, the fair value estimates may not be realized in an immediate settlement of the asset or liability.
Fair value measurements focus on exit prices in an orderly transaction (that is, not a forced liquidation or distressed sale) between market participants at the measurement date under current market conditions. If there has been a significant decrease in the volume and level of activity for the asset or liability, a change in valuation technique or the use of multiple valuation techniques may be appropriate. In such instances, determining the price at which willing market participants would transact at the measurement date under current market conditions depends on the facts and circumstances and requires the use of significant judgment.
The Company’s fair value measurements are classified into a fair value hierarchy in accordance with ASC Topic 820, Fair Value Measurement, based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to determine fair value. The three categories within the hierarchy are as follows:
| Level 1 |
Quoted prices in active markets for identical assets and liabilities. |
| Level 2 |
Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities in active markets, quoted prices in markets that are not active, and model-based valuation techniques for which all significant inputs are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. |
| Level 3 |
Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation. |
Due to the inherent uncertainty of determining the fair value of investments that do not have a readily available market value, the fair value of the Company’s investments may fluctuate from period to period. Additionally, the fair value of the Company’s investments may differ significantly from the values that would have been used had a ready market existed for such investments and may differ materially from the values that the Company may ultimately realize. Further, such investments are generally subject to legal and other restrictions on resale or otherwise are less liquid than publicly traded securities. If the Company was required to liquidate a portfolio investment in a forced or liquidation sale, the Company could realize significantly less than the value at which the Company has recorded such portfolio investment.
Cash and interest receivable: The carrying amount is a reasonable estimate of fair value. These financial instruments are not recorded at fair value on a recurring basis and are categorized as Level 1 within the fair value hierarchy described above.
Money market funds: The carrying amounts are valued at their net asset value as of the close of business on the day of valuation. These financial instruments are recorded at fair value on a recurring basis and are categorized as Level 2 within the fair value hierarchy described above as these funds can be redeemed daily.
Debt investments: The fair value of debt investments is estimated by discounting the expected future cash flows using the period end rates at which similar debt investments would be made to borrowers with similar credit ratings and for the same remaining maturities. Significant increases (decreases) in this unobservable input would result in a significantly lower (higher) fair value measurement. These assets are recorded at fair value on a recurring basis and are categorized as Level 3 within the fair value hierarchy described above.
Under certain circumstances, the Company may use an alternative technique to value debt investments that better reflects its fair value such as the use of multiple probability weighted cash flow models when the expected future cash flows contain elements of variability.
Warrant investments: The Company values its warrants using the Black-Scholes valuation model incorporating the following material assumptions:
| ● |
Underlying asset value of the issuer is estimated based on information available, including any information regarding the most recent rounds of borrower funding. Significant increases (decreases) in this unobservable input would result in a significantly higher (lower) fair value measurement. |
| ● |
Volatility, or the amount of uncertainty or risk about the size of the changes in the warrant price, is based on indices of publicly traded companies similar in nature to the underlying company issuing the warrant. A total of seven such indices are used. Significant increases (decreases) in this unobservable input would result in a significantly higher (lower) fair value measurement. |
| ● |
The risk-free interest rates are derived from the U.S. Treasury yield curve. The risk-free interest rates are calculated based on a weighted average of the risk-free interest rates that correspond closest to the expected remaining life of the warrant. |
| ● |
Other adjustments, including a marketability discount on private company warrants, are estimated based on management’s judgment about the general industry environment. |
| ● |
Historical portfolio experience on cancellations and exercises of the Company’s warrants are utilized as the basis for determining the estimated time to exit of the warrants in each financial reporting period. Warrants may be exercised in the event of acquisitions, mergers or initial public offerings, and cancelled due to events such as bankruptcies, restructuring activities or additional financings. These events cause the expected remaining life assumption to be shorter than the contractual term of the warrants. Significant increases (decreases) in this unobservable input would result in significantly higher (lower) fair value measurement. |
Under certain circumstances the Company may use an alternative technique to value warrants that better reflects the warrants’ fair value, such as an expected settlement of a warrant in the near term or a model that incorporates a put feature associated with the warrant. The fair value may be determined based on the expected proceeds to be received from such settlement or based on the net present value of the expected proceeds from the put option.
The fair value of the Company’s warrants held in publicly traded companies is determined based on inputs that are readily available in public markets or can be derived from information available in public markets. Therefore, the Company has categorized these warrants as Level 2 within the fair value hierarchy described above. The fair value of the Company’s warrants held in private companies is determined using both observable and unobservable inputs and represents management’s best estimate of what market participants would use in pricing the warrants at the measurement date. Therefore, the Company has categorized these warrants as Level 3 within the fair value hierarchy described above. These assets are recorded at fair value on a recurring basis.
Equity investments: The fair value of an equity investment in a privately held company is initially the face value of the amount invested. The Company adjusts the fair value of equity investments in private companies upon the completion of a new third-party round of equity financing. The Company may make adjustments to fair value, absent a new equity financing event, based upon positive or negative changes in a portfolio company’s financial or operational performance. Significant increases (decreases) in this unobservable input would result in a significantly higher (lower) fair value measurement. The Company has categorized these equity investments as Level 3 within the fair value hierarchy described above. The fair value of an equity investment in a publicly traded company is based upon the closing public share price on the date of measurement. Therefore, the Company has categorized these equity investments as Level 1 within the fair value hierarchy described above. These assets are recorded at fair value on a recurring basis.
Other investments: Other investments are valued based on the facts and circumstances of the underlying contractual agreement. The Company currently values these contractual agreements using a multiple probability weighted cash flow model as the contractual future cash flows contain elements of variability. Significant changes in the estimated cash flows and probability weightings would result in a significantly higher or lower fair value measurement. The Company has categorized these other investments as Level 3 within the fair value hierarchy described above. These other investments are recorded at fair value on a recurring basis.
The following tables detail the assets that are carried at fair value and measured at fair value on a recurring basis as of September 30, 2024 and December 31, 2023 and indicate the fair value hierarchy of the valuation techniques utilized by the Company to determine the fair value:
| September 30, 2024 |
||||||||||||||||
| Level 1 |
Level 2 |
Level 3 |
Total |
|||||||||||||
| (In thousands) |
||||||||||||||||
| Debt investments |
$ | $ | $ | $ | ||||||||||||
| Warrant investments |
||||||||||||||||
| Other investments |
||||||||||||||||
| Equity investments |
||||||||||||||||
| Total investments |
$ | $ | $ | $ | ||||||||||||
| December 31, 2023 |
||||||||||||||||
| Level 1 |
Level 2 |
Level 3 |
Total |
|||||||||||||
| (In thousands) |
||||||||||||||||
| Debt investments |
$ | $ | $ | $ | ||||||||||||
| Warrant investments |
||||||||||||||||
| Other investments |
||||||||||||||||
| Equity investments |
||||||||||||||||
| Total investments |
$ | $ | $ | $ | ||||||||||||
The following tables provide a summary of quantitative information about the Company’s Level 3 fair value measurements of the Company’s investments as of September 30, 2024 and December 31, 2023. In addition to the techniques and inputs noted in the table below, according to the Company’s valuation policy, the Company may also use other valuation techniques and methodologies when determining its fair value measurements.
The following table is not intended to be all-inclusive, but rather provides information on the significant Level 3 inputs as they relate to the Company’s fair value measurements as of September 30, 2024:
| September 30, 2024 |
|||||||||||||
| Fair |
Valuation Techniques/ |
Unobservable |
Weighted |
||||||||||
| Investment Type |
Value |
Methodologies |
Input |
Range |
Average(1) |
||||||||
| (Dollars in thousands, except per share data) |
|||||||||||||
| Debt investments |
$ | Discounted Expected Future Cash Flows |
Hypothetical Market Yield |
|
% | ||||||||
| Multiple Probability Weighted Cash Flow Model |
Probability Weighting |
|
% | ||||||||||
| Warrant investments |
Black-Scholes Valuation Model |
Price Per Share |
|
$ | |||||||||
| Average Industry Volatility |
|
% | |||||||||||
| Marketability Discount |
|
% | |||||||||||
| Estimated Time to Exit (in years) |
|||||||||||||
| Other investments |
Multiple Probability Weighted Cash Flow Model |
Discount Rate |
|
% | |||||||||
| Probability Weighting |
|
% | |||||||||||
| Equity investments |
Last Equity Financing |
Price Per Share |
0 –60 |
$ | |||||||||
| Total Level 3 investments |
$ | ||||||||||||
| (1) |
Weighted average is calculated by multiplying (a) the unobservable input for each investment in the investment type by (b) (1) the fair value of the related investment in the investment type divided by (2) the total fair value of the investment type. |
The following table is not intended to be all-inclusive, but rather provides information on the significant Level 3 inputs as they relate to the Company’s fair value measurements as of December 31, 2023:
| December 31, 2023 |
|||||||||||||
| Fair |
Valuation Techniques/ |
Unobservable |
Weighted |
||||||||||
| Investment Type |
Value |
Methodologies |
Input |
Range |
Average(1) |
||||||||
| (Dollars in thousands, except per share data) |
|||||||||||||
| Debt investments |
$ | Discounted Expected Future Cash Flows |
Hypothetical Market Yield |
% | |||||||||
| Multiple Probability Weighted Cash Flow Model |
Probability Weighting |
% | |||||||||||
| Warrant investments |
Black-Scholes Valuation Model |
Price Per Share |
|
$ | |||||||||
| Average Industry Volatility |
% | ||||||||||||
| Marketability Discount |
% | ||||||||||||
| Estimated Time to Exit (in years) |
|||||||||||||
| Expected Proceeds |
Price Per Share |
$ |
$ | ||||||||||
| Other investments |
Multiple Probability Weighted Cash Flow Model |
Discount Rate |
% | ||||||||||
| Probability Weighting |
% | ||||||||||||
| Equity investments |
Last Equity Financing |
Price Per Share |
6 –03 |
$ | |||||||||
| Total Level 3 investments |
$ | ||||||||||||
| (1) |
Weighted average is calculated by multiplying (a) the unobservable input for each investment in the investment type by (b) (1) the fair value of the related investment in the investment type divided by (2) the total fair value of the investment type. |
Borrowings: The Credit Facilities approximate fair value due to the variable interest rate of the facilities and are categorized as Level 2 within the fair value hierarchy described above. Additionally, the Company considers its creditworthiness in determining the fair value of such borrowings. The fair value of the fixed-rate 2026 Notes (as defined in Note 7) is based on the closing public share price on the date of measurement. On September 30, 2024, the closing price of the 2026 Notes on the New York Stock Exchange was $
Off-balance-sheet instruments: Fair values for off-balance-sheet lending commitments are based on fees currently charged to enter into similar agreements, taking into account the remaining terms of the agreements and the counterparties’ credit standings. Therefore, the Company has categorized these instruments as Level 3 within the fair value hierarchy described above.
The following table shows a reconciliation of the beginning and ending balances for Level 3 assets measured at fair value on a recurring basis for the three months ended September 30, 2024:
| Three months ended September 30, 2024 |
||||||||||||||||||||
| Debt |
Warrant |
Equity |
Other |
|||||||||||||||||
| Investments |
Investments |
Investments |
Investments |
Total |
||||||||||||||||
| (In thousands) |
||||||||||||||||||||
| Level 3 assets, beginning of period |
$ | $ | $ | $ | $ | |||||||||||||||
| Purchase of investments |
||||||||||||||||||||
| Warrants received and classified as Level 3 |
||||||||||||||||||||
| Principal payments received on investments |
( |
) | ( |
) | ( |
) | ||||||||||||||
| Payment-in-kind interest on investments |
||||||||||||||||||||
| Proceeds from sale of investments |
( |
) | ( |
) | ||||||||||||||||
| Net realized loss on investments |
( |
) | ( |
) | ( |
) | ||||||||||||||
| Unrealized appreciation (depreciation) included in earnings |
( |
) | ( |
) | ( |
) | ||||||||||||||
| Transfer out of warrant investments |
( |
) | ( |
) | ||||||||||||||||
| Other |
( |
) | ( |
) | ||||||||||||||||
| Level 3 assets, end of period |
$ | $ | $ | $ | $ | |||||||||||||||
During the three months ended September 30, 2024, there were
The following table shows a reconciliation of the beginning and ending balances for Level 3 assets measured at fair value on a recurring basis for the three months ended September 30, 2023:
| Three months ended September 30, 2023 |
||||||||||||||||||||
| Debt |
Warrant |
Equity |
Other |
|||||||||||||||||
| Investments |
Investments |
Investments |
Investments |
Total |
||||||||||||||||
| (In thousands) |
||||||||||||||||||||
| Level 3 assets, beginning of period |
$ | $ | $ | $ | $ | |||||||||||||||
| Purchase of investments |
||||||||||||||||||||
| Warrants received and classified as Level 3 |
||||||||||||||||||||
| Principal payments received on investments |
( |
) | ( |
) | ||||||||||||||||
| Payment-in-kind interest on investments |
||||||||||||||||||||
| Proceeds from sale of investments |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||
| Net realized (loss) gain on investments |
( |
) | ( |
) | ( |
) | ||||||||||||||
| Unrealized depreciation included in earnings |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||
| Transfer out of Level 3 |
( |
) | ( |
) | ||||||||||||||||
| Transfer out of debt investments |
( |
) | ||||||||||||||||||
| Other |
( |
) | ( |
) | ||||||||||||||||
| Level 3 assets, end of period |
$ | $ | $ | $ | $ | |||||||||||||||
During the three months ended September 30, 2023, there was one transfer out of Level 3. The one transfer out of Level 3 related to debt investments held in one portfolio company with an aggregate fair value of $
The following table shows a reconciliation of the beginning and ending balances for Level 3 assets measured at fair value on a recurring basis for the nine months ended September 30, 2024:
| Nine months ended September 30, 2024 |
||||||||||||||||||||
| Debt |
Warrant |
Equity |
Other |
|||||||||||||||||
| Investments |
Investments |
Investments |
Investments |
Total |
||||||||||||||||
| (In thousands) |
||||||||||||||||||||
| Level 3 assets, beginning of period |
$ | $ | $ | $ | $ | |||||||||||||||
| Purchase of investments |
||||||||||||||||||||
| Warrants received and classified as Level 3 |
||||||||||||||||||||
| Principal payments received on investments |
( |
) | ( |
) | ( |
) | ||||||||||||||
| Payment-in-kind interest on investments |
||||||||||||||||||||
| Proceeds from sale of investments |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||
| Net realized (loss) gain on investments |
( |
) | ( |
) | ||||||||||||||||
| Unrealized appreciation (depreciation) included in earnings |
( |
) | ( |
) | ( |
) | ||||||||||||||
| Transfer out of debt and warrant investments |
( |
) | ( |
) | ||||||||||||||||
| Other |
||||||||||||||||||||
| Level 3 assets, end of period |
$ | $ | $ | $ | $ | |||||||||||||||
During the nine months ended September 30, 2024, there were
The change in unrealized appreciation included in the consolidated statement of operations attributable to Level 3 investments still held at September 30, 2024 includes $
The following table shows a reconciliation of the beginning and ending balances for Level 3 assets measured at fair value on a recurring basis for the nine months ended September 30, 2023:
| Nine months ended September 30, 2023 |
||||||||||||||||||||
| Debt |
Warrant |
Equity |
Other |
|||||||||||||||||
| Investments |
Investments |
Investments |
Investments |
Total |
||||||||||||||||
| (In thousands) |
||||||||||||||||||||
| Level 3 assets, beginning of period |
$ | $ | $ | $ | $ | |||||||||||||||
| Purchase of investments |
||||||||||||||||||||
| Warrants and equity received and classified as Level 3 |
||||||||||||||||||||
| Principal payments received on investments |
( |
) | ( |
) | ||||||||||||||||
| Payment-in-kind interest on investments |
||||||||||||||||||||
| Proceeds from sale of investments |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||
| Net realized (loss) gain on investments |
( |
) | ( |
) | ( |
) | ||||||||||||||
| Unrealized depreciation included in earnings |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||
| Transfer out of Level 3 |
( |
) | ( |
) | ( |
) | ||||||||||||||
| Transfer out of debt investments |
( |
) | ( |
) | ||||||||||||||||
| Other |
||||||||||||||||||||
| Level 3 assets, end of period |
$ | $ | $ | $ | $ | |||||||||||||||
During the nine months ended September 30, 2023, there were two transfers out of Level 3. One transfer out of Level 3 related to equity held in one portfolio company with an aggregate fair value of $
The change in unrealized depreciation included in the consolidated statement of operations attributable to Level 3 investments still held at September 30, 2023 includes $
The Company discloses fair value information about financial instruments, whether or not recognized in the consolidated statement of assets and liabilities, for which it is practicable to estimate that value. Certain financial instruments are excluded from the disclosure requirements. Accordingly, the aggregate fair value amounts presented do not represent the underlying value of the Company.
The fair value amounts have been measured as of the reporting date and have not been reevaluated or updated for purposes of these financial statements subsequent to that date. As such, the fair values of these financial instruments subsequent to the reporting date may be different than amounts reported.
As of September 30, 2024 and December 31, 2023, all of the balances of all the Company’s financial instruments were recorded at fair value, except for the Company’s borrowings, as previously described.
Market risk
The Company assumes interest rate risk (the risk that general interest rate levels will change) as a result of its normal operations. As a result, the fair values of the Company’s financial instruments may change when interest rate levels change, and that change may be either favorable or unfavorable to the Company. Management attempts to match maturities of assets and liabilities to the extent believed necessary to minimize interest rate risk. Management monitors rates and maturities of assets and liabilities and attempts to minimize interest rate risk by adjusting terms of new debt investments and by investing in securities with terms that mitigate the Company’s overall interest rate risk.
Note 7. Borrowings
The following table shows the Company’s borrowings as of September 30, 2024 and December 31, 2023:
| September 30, 2024 | December 31, 2023 | |||||||||||||||||||||||
| Total | Balance | Unused | Total | Balance | Unused | |||||||||||||||||||
| Commitment | Outstanding | Commitment | Commitment | Outstanding | Commitment | |||||||||||||||||||
| (In thousands) | ||||||||||||||||||||||||
| Key Facility | $ | $ | $ | $ | $ | $ | ||||||||||||||||||
| NYL Facility | ||||||||||||||||||||||||
| Nuveen Facility | ||||||||||||||||||||||||
| 2022 Asset-Backed Notes | ||||||||||||||||||||||||
| 2027 Notes | ||||||||||||||||||||||||
| 2026 Notes | ||||||||||||||||||||||||
| Total before debt issuance costs | ||||||||||||||||||||||||
| Unamortized debt issuance costs attributable to term borrowings | — | ( | ) | — | — | ( | ) | — | ||||||||||||||||
| Total borrowings outstanding, net | $ | $ | $ | $ | $ | $ | ||||||||||||||||||
As of September 30, 2024, with certain limited exceptions, the Company, as a BDC, is only allowed to borrow amounts such that the Company’s asset coverage, as defined in the 1940 Act, is at least
Credit Facilities
Key Facility
The Company entered into the Key Facility with Key effective November 4, 2013. On June 20, 2024, the Company amended the Key Facility, among other things, (i) to extend the date on which the Company may request advances under the Key Facility to June 20, 2027 and to extend the maturity date to June 20, 2029 and (ii) to amend the interest rate to be based on the rate of interest published in The Wall Street Journal as the prime rate in the United States plus
NYL Facility
HFI entered into the NYL Facility with the NYL Noteholders for an aggregate purchase price of up to $
On May 24, 2023, the Company amended its NYL Facility to, among other things, increase the commitment by $
On May 6, 2024, the Company amended its NYL Facility to, among other things, extend the investment period to June 2025 and the maturity date of all advances to June 2030. In addition, the amendment amended the interest rate for advances made after May 6, 2024, fixing the interest rate at the greater of (i)
There were $
Under the terms of the NYL Facility, the Company is required to maintain a reserve cash balance, which may be used to pay monthly interest and principal payments on the NYL Facility. The Company has segregated these funds and classified them as restricted investments in money market funds. At September 30, 2024 and December 31, 2023, there were approximately $
Nuveen Facility
HFII entered into the Nuveen Facility with the Nuveen Noteholders for an aggregate purchase price of up to $
There were $
Under the terms of the Nuveen Facility, the Company is required to maintain a reserve cash balance, which may be used to pay monthly interest and principal payments on the Nuveen Facility. The Company has segregated these funds and classified them as restricted investments in money market funds. At September 30, 2024, there were approximately $
Securitizations
2019 Asset-Backed Notes
On August 13, 2019, the Company completed a term debt securitization in connection with which an affiliate of the Company made an offering of the 2019 Asset-Backed Notes. The 2019 Asset-Backed Notes were rated A+(sf) by Morningstar Credit Ratings, LLC. There was no change in the rating since August 13, 2019. The 2019 Asset-Backed Notes were repaid in full on November 22, 2023.
The 2019 Asset-Backed Notes were issued by the 2019‑1 Trust pursuant to a note purchase agreement, dated as of August 13, 2019, by and among the Company and Keybanc Capital Markets Inc. as Initial Purchaser, and were backed by a pool of loans made to certain portfolio companies of the Company and secured by certain assets of those portfolio companies and were to be serviced by the Company. Interest on the 2019 Asset-Backed Notes was paid, to the extent of funds available, at a fixed rate of
As of December 31, 2023, the 2019 Asset-Backed Notes were repaid in full.
2022 Asset-Backed Notes
On November 9, 2022, the Company completed a term debt securitization in connection with which an affiliate of the Company made an offering of the 2022 Asset-Backed Notes. The 2022 Asset-Backed Notes were rated A by DBRS, Inc. There has been no change in the rating since November 9, 2022.
The 2022 Asset-Backed Notes were issued by the 2022‑1 Trust pursuant to a note purchase agreement, dated as of November 9, 2022, by and among the Company and Keybanc Capital Markets Inc. as Initial Purchaser, and are backed by a pool of loans made to certain portfolio companies of the Company and secured by certain assets of those portfolio companies and are to be serviced by the Company. Interest on the 2022 Asset-Backed Notes will be paid, to the extent of funds available, at a fixed rate of
As of September 30, 2024 and December 31, 2023, the 2022 Asset-Backed Notes had an outstanding principal balance of $
Under the terms of the 2022 Asset-Backed Notes, the Company is required to maintain a reserve cash balance, funded through proceeds from the sale of the 2022 Asset-Backed Notes, which may be used to pay monthly interest and principal payments on the 2022 Asset-Backed Notes. The Company has segregated these funds and classified them as restricted investments in money market funds. At September 30, 2024 and December 31, 2023, there were approximately $
Unsecured Notes
2026 Notes
On March 30, 2021, the Company issued and sold an aggregate principal amount of $
2027 Notes
On June 15, 2022, the Company issued and sold an aggregate principal amount of $
Note 8. Financial instruments with off-balance-sheet risk
In the normal course of business, the Company is party to financial instruments with off-balance-sheet risk to meet the financing needs of its borrowers. These financial instruments include commitments to extend credit and involve, to varying degrees, elements of credit risk in excess of the amount recognized in the consolidated statement of assets and liabilities. The Company attempts to limit its credit risk by conducting extensive due diligence and obtaining collateral where appropriate.
The balance of unfunded commitments to extend credit was $
The following table provides the Company’s unfunded commitments by portfolio company as of September 30, 2024 and December 31, 2023:
| September 30, 2024 |
December 31, 2023 |
|||||||||||||||
| Fair Value of |
Fair Value of |
|||||||||||||||
| Unfunded |
Unfunded |
|||||||||||||||
| Commitment |
Commitment |
Commitment |
Commitment |
|||||||||||||
| Amount |
Liability |
Amount |
Liability |
|||||||||||||
| (In thousands) |
(In thousands) |
|||||||||||||||
| Better Place Forests Co. |
$ | $ | $ | $ | ||||||||||||
| BrightInsight, Inc. |
||||||||||||||||
| Britecore Holdings, Inc. |
||||||||||||||||
| Candesant Biomedical Corporation |
||||||||||||||||
| Ceribell, Inc. |
||||||||||||||||
| Divergent Technologies, Inc. |
||||||||||||||||
| Elligo Healthcare Research, Inc. |
||||||||||||||||
| Fictiv, Inc. |
||||||||||||||||
| GT Medical Technologies, Inc. |
||||||||||||||||
| Hometeam Technologies, Inc. |
||||||||||||||||
| MicroTransponder, Inc. |
||||||||||||||||
| Mirantis, Inc. |
||||||||||||||||
| Optoro, Inc. |
||||||||||||||||
| Parse Biosciences, Inc. |
||||||||||||||||
| Pivot Bio, Inc. |
||||||||||||||||
| SafelyYou, Inc. |
||||||||||||||||
| Sonex Health, Inc. |
||||||||||||||||
| Standvast Holdings, LLC |
||||||||||||||||
| Supply Network Visibility Holdings, LLC |
||||||||||||||||
| Swift Health Systems, Inc. |
||||||||||||||||
| Tallac Therapeutics, Inc. |
||||||||||||||||
| Viken Detection Corporation |
||||||||||||||||
| Total |
$ | $ | $ | $ | ||||||||||||
The table above also provides the fair value of the Company’s unfunded commitment liability as of September 30, 2024 and December 31, 2023, which totaled $
Note 9. Concentrations of credit risk
The Company’s debt investments consist primarily of loans to development-stage companies at various stages of development in the technology, life science, healthcare information and services and sustainability industries. Many of these companies may have relatively limited operating histories and also may experience variation in operating results. Many of these companies conduct business in regulated industries and could be affected by changes in government regulations. Most of the Company’s borrowers will need additional capital to satisfy their continuing working capital needs and other requirements, and in many instances, to service the interest and principal payments on the loans.
The Company’s largest debt investments may vary from period to period as new debt investments are recorded and existing debt investments are repaid. The Company’s five largest debt investments at cost represented
Note 10. Distributions
The Company’s distributions are recorded on the declaration date. The following table summarizes the Company’s distribution activity for the nine months ended September 30, 2024 and for the year ended December 31, 2023:
| DRIP | DRIP | |||||||||||||||||||
| Date | Amount | Cash | Shares | Share | ||||||||||||||||
| Declared | Record Date | Payment Date | Per Share | Distribution | Issued | Value | ||||||||||||||
| (In thousands, except share and per share data) | ||||||||||||||||||||
| Nine Months Ended September 30, 2024 | ||||||||||||||||||||
| July 26, 2024 | | | $ | $ | $ | |||||||||||||||
| July 26, 2024 | | | ||||||||||||||||||
| July 26, 2024 | | | ||||||||||||||||||
| April 26, 2024 | | | ||||||||||||||||||
| April 26, 2024 | | | ||||||||||||||||||
| April 26, 2024 | | | ||||||||||||||||||
| February 23, 2024 | | | ||||||||||||||||||
| February 23, 2024 | | | ||||||||||||||||||
| February 23, 2024 | | | ||||||||||||||||||
| February 23, 2024 | | | ||||||||||||||||||
| $ | $ | $ | ||||||||||||||||||
| Year Ended December 31, 2023 | ||||||||||||||||||||
| October 27, 2023 | | | $ | $ | $ | |||||||||||||||
| October 27, 2023 | | | ||||||||||||||||||
| October 27, 2023 | | | ||||||||||||||||||
| October 27, 2023 | | | ||||||||||||||||||
| July 28, 2023 | | | ||||||||||||||||||
| July 28, 2023 | | | ||||||||||||||||||
| July 28, 2023 | | | ||||||||||||||||||
| April 28, 2023 | | | ||||||||||||||||||
| April 28, 2023 | | | ||||||||||||||||||
| April 28, 2023 | | | ||||||||||||||||||
| February 23, 2023 | | | ||||||||||||||||||
| February 23, 2023 | | | ||||||||||||||||||
| February 23, 2023 | | | ||||||||||||||||||
| $ | $ | $ | ||||||||||||||||||
On October 25, 2024, the Board declared monthly distributions per share, payable as set forth in the following table:
Monthly distributions
| Ex-Dividend Date | Record Date | Payment Date | Distributions Declared | |||||
| February 18, 2025 | | | $ | |||||
| January 16, 2025 | | | $ | |||||
| December 16, 2024 | | | $ | |||||
After paying distributions of $
Note 11. Financial highlights
The following table shows financial highlights for the Company:
| Nine months ended September 30, |
||||||||||
| 2024 |
2023 |
|||||||||
| (In thousands, except share and per share data) |
||||||||||
| Per share data: |
||||||||||
| Net asset value at beginning of period |
$ | $ | ||||||||
| Net investment income |
||||||||||
| Realized loss |
( |
) | ( |
) | ||||||
| Unrealized appreciation (depreciation) on investments |
( |
) | ||||||||
| Net increase (decrease) in net assets resulting from operations |
( |
) | ||||||||
| Distributions declared (1) |
( |
) | ( |
) | ||||||
| From net investment income |
( |
) | ( |
) | ||||||
| From net realized gain on investments |
||||||||||
| Return of capital |
||||||||||
| Other(2) |
||||||||||
| Net asset value at end of period |
$ | $ | ||||||||
| Per share market value, beginning of period |
$ | $ | ||||||||
| Per share market value, end of period |
$ | $ | ||||||||
| Total return based on a market value (3) |
( |
)% | % | |||||||
| Shares outstanding at end of period |
||||||||||
| Ratios to average net assets: |
||||||||||
| Expenses without incentive fee (4) |
% | % | ||||||||
| Incentive fees (4) |
% | |||||||||
| Net expenses (4) |
% | % | ||||||||
| Net investment income with incentive fee (4) |
% | % | ||||||||
| Net assets at the end of the period |
$ | $ | ||||||||
| Average net asset value |
$ | $ | ||||||||
| Average debt per share |
$ | $ | ||||||||
| Portfolio turnover ratio |
% | (5) |
% | (5) |
||||||
| (1) |
Distributions are determined based on taxable income calculated in accordance with income tax regulations, which may differ from amounts determined under GAAP due to (i) changes in unrealized appreciation and depreciation, (ii) temporary and permanent differences in income and expense recognition, and (iii) the amount of spillover income carried over from a given tax year for distribution in the following tax year. The final determination of taxable income for each tax year, as well as the tax attributes for distributions in such tax year, will be made after the close of the tax year. |
| (2) |
Includes the impact of the different share amounts as a result of calculating per share data based on the weighted average basic shares outstanding during the period and certain per share data based on the shares outstanding as of a period end or transaction date. The issuance of common stock on a per share basis reflects the incremental net asset value changes as a result of the issuance of common stock in the Company’s continuous public offering and pursuant to the Company’s distribution reinvestment plan. The issuance of common stock at an offering price, net of sales commissions and dealer manager fees, that is greater than the net asset value per share results in an increase in net asset value per share. |
| (3) |
The total return equals the change in the ending market value over the beginning of period price per share plus distributions paid per share during the period, divided by the beginning price. |
| (4) |
Annualized. |
| (5) |
Calculated by dividing (A) the lesser of purchases or sales of portfolio securities for the fiscal year by (B) the monthly average of the value of portfolio securities owned by the Company during the fiscal year, with certain securities excluded from the numerator and denominator pursuant to applicable federal securities laws. |
Note 12. Subsequent Events
On October 7, 2024, the Company funded a $
On October 15, 2025, the Company funded a $
On October 17, 2024, the Company entered into a note purchase agreement, by and among the Company, each purchaser named therein, and the investment adviser named therein, in connection with the issuance and sale of $
The Convertible Notes mature on , unless earlier converted or repurchased in accordance with their terms. The Convertible Notes bear interest at a rate of
On October 18, 2025, the Company funded a $
On October 22, 2024, Monroe Capital LLC (“Monroe Capital”), an affiliate of the Company and the Advisor, announced that Monroe Capital has entered into a definitive agreement with Wendel Group (Euronext: MF:FP) (“Wendel”) relating to Wendel’s strategic investment in Monroe Capital. The transaction is expected to close in the first quarter of 2025, subject to the satisfaction of customary closing conditions, including the receipt of regulatory clearances and approvals and client consents. In connection with the transaction, the Company expects to seek approval of a new investment management agreement between the Company and the Advisor, from the Board and its shareholders, the terms of which are expected to remain substantively similar to the current investment management agreement.
On October 23, 2024, CAMP NYC, Inc. (“CAMP”) prepaid its outstanding principal balance of $
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
In this quarterly report on Form 10‑Q, except where the context suggests otherwise, the terms “we,” “us,” “our” and “Horizon Technology Finance” refer to Horizon Technology Finance Corporation and its consolidated subsidiaries. The information contained in this section should be read in conjunction with our consolidated financial statements and related notes thereto appearing elsewhere in this quarterly report on Form 10‑Q.
Forward-looking statements
This quarterly report on Form 10‑Q, including the Management’s Discussion and Analysis of Financial Condition and Results of Operations, contains statements that constitute forward-looking statements, which relate to future events or our future performance or financial condition. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our industry, our beliefs and our assumptions. The forward-looking statements contained in this quarterly report on Form 10‑Q involve risks and uncertainties, including statements as to:
| ● |
our future operating results, including the performance of our existing debt investments, warrants and other investments; |
| ● |
the introduction, withdrawal, success and timing of business initiatives and strategies; |
| ● |
general economic and political trends and other external factors, including continuing supply chain disruptions, increased inflation and a general slowdown in economic activity; |
| ● |
the relative and absolute investment performance and operations of our Advisor; |
| ● |
the impact of increased competition; |
| ● |
the impact of investments we intend to make and future acquisitions and divestitures; |
| ● |
the unfavorable resolution of legal proceedings; |
| ● |
our business prospects and the prospects of our portfolio companies; |
| ● |
geopolitical turmoil and the potential for volatility in energy prices and disruptions to global supply chains resulting from such turmoil and its impact on the industries in which we invest; |
| ● |
the impact, extent and timing of technological changes and the adequacy of intellectual property protection; |
| ● |
our regulatory structure and tax status; |
| ● |
changes in the general interest rate environment; |
| ● |
our ability to qualify and maintain qualification as a RIC and as a BDC; |
| ● |
the adequacy of our cash resources and working capital; |
| ● |
any losses or operations disruptions caused by us, our Advisor or our portfolio companies holding cash balances at financial institutions that exceed federally insured limits or by disruptions in the financial services industry; |
| ● |
the timing of cash flows, if any, from the operations of our portfolio companies, and the resulting effect on our portfolio companies' decisions to make payment-in-kind (“PIK”) interest payments or ability to make end of term payments; |
| ● |
the impact of interest rate volatility on our results, particularly if we use leverage as part of our investment strategy; |
| ● |
the ability of our portfolio companies to achieve their objective; |
| ● |
the impact of legislative and regulatory actions and reforms and regulatory supervisory or enforcement actions of government agencies relating to us or our Advisor; |
| ● |
our contractual arrangements and relationships with third parties; |
| ● |
our ability to access capital and any future financings by us; |
| ● |
our use of financial leverage; |
| ● |
the ability of our Advisor to attract and retain highly talented professionals; |
| ● |
the impact of changes to tax legislation and, generally, our tax position; and |
| ● |
our ability to fund unfunded commitments. |
We use words such as “anticipates,” “believes,” “expects,” “intends,” “seeks” and similar expressions to identify forward-looking statements. Undue influence should not be placed on the forward looking statements as our actual results could differ materially from those projected in the forward-looking statements for any reason, including the factors in “Risk Factors” and elsewhere in our annual report on Form 10‑K for the year ended December 31, 2023, and elsewhere in this quarterly report on Form 10‑Q.
We have based the forward-looking statements included in this quarterly report on Form 10-Q on information available to us on the date of this quarterly report on Form 10-Q, and we assume no obligation to update any such forward-looking statements. Although we undertake no obligation to revise or update any forward-looking statements in this quarterly report on Form 10‑Q, whether as a result of new information, future events or otherwise, you are advised to consult any additional disclosures that we may make directly to you or through reports that we in the future may file with the U.S. Securities and Exchange Commission, or the SEC, including periodic reports on Form 10‑Q and Form 10‑K and current reports on Form 8‑K.
You should understand that under Sections 27A(b)(2)(B) and (D) of the Securities Act and Sections 21E(b)(2)(B) and (D) of the Exchange Act, the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 do not apply to statements made in connection with any annual or quarterly reports we file under the Exchange Act.
Overview
We are a specialty finance company that lends to and invests in development-stage companies in the technology, life science, healthcare information and services and sustainability industries, which we refer to as our “Target Industries.” Our investment objective is to maximize our investment portfolio’s total return by generating current income from the debt investments we make and capital appreciation from the warrants we receive when making such debt investments. We are focused on making secured debt investments, which we refer to collectively as “Venture Loans,” to venture capital and private equity backed companies and publicly traded companies in our Target Industries, which we refer to as “Venture Lending.” Our debt investments are typically secured by first liens or first liens behind a secured revolving line of credit, or collectively “Senior Term Loans.” Some of our debt investments may also be subordinated to term debt provided by third parties. As of September 30, 2024, 86.2%, or $546.0 million, of our debt investment portfolio at fair value consisted of Senior Term Loans. Venture Lending is typically characterized by (1) the making of a secured debt investment after a venture capital or equity investment in the portfolio company has been made, which investment provides a source of cash to fund the portfolio company’s debt service obligations under the Venture Loan, (2) the senior priority of the Venture Loan which requires repayment of the Venture Loan prior to the equity investors realizing a return on their capital, (3) the amortization of the Venture Loan and (4) the lender’s receipt of warrants or other success fees with the making of the Venture Loan.
We are an externally managed, closed-end, non-diversified management investment company that has elected to be regulated as a BDC under the Investment Company Act of 1940, as amended, or the 1940 Act. In addition, for U.S. federal income tax purposes, we have elected to be treated as a RIC under Subchapter M of the Code. As a BDC, we are required to comply with regulatory requirements, including limitations on our use of debt. We are permitted to, and expect to, finance our investments through borrowings subject to a 150% asset coverage test. As defined in the 1940 Act, asset coverage of 150% means that for every $100 of net assets a BDC holds, it may raise up to $200 from borrowing and issuing senior securities. The amount of leverage that we may employ will depend on our assessment of market conditions and other factors at the time of any proposed borrowing. As a RIC, we generally are not subject to corporate-level income taxes on our investment company taxable income, determined without regard to any deductions for dividends paid, and our net capital gain that we distribute as dividends for U.S. federal income tax purposes to our stockholders as long as we meet certain source-of-income, distribution, asset diversification and other requirements.
We were formed in March 2010 and completed an initial public offering.
Our investment activities, and our day-to-day operations, are managed by our Advisor and supervised by our Board, of which a majority of the members are independent of us. Under the Investment Management Agreement, we have agreed to pay our Advisor a base management fee and an incentive fee for its advisory services to us. We have also entered into the Administration Agreement with our Advisor under which we have agreed to reimburse our Advisor for our allocable portion of overhead and other expenses incurred by our Advisor in performing its obligations under the Administration Agreement.
Portfolio composition and investment activity
The following table shows our portfolio by type of investment as of September 30, 2024 and December 31, 2023:
| September 30, 2024 |
December 31, 2023 |
|||||||||||||||||||||
| Percentage of |
Percentage of |
|||||||||||||||||||||
| Number of |
Fair |
Total |
Number of |
Fair |
Total |
|||||||||||||||||
| Investments |
Value |
Portfolio |
Investments |
Value |
Portfolio |
|||||||||||||||||
| (Dollars in thousands) |
||||||||||||||||||||||
| Debt investments |
53 | $ | 633,284 | 92.6 | % |
56 | $ | 670,172 | 94.5 | % |
||||||||||||
| Warrants |
86 | 18,735 | 2.7 | 85 | 24,594 | 3.5 | ||||||||||||||||
| Other investments |
5 | 17,944 | 2.6 | 3 | 6,430 | 0.9 | ||||||||||||||||
| Equity |
17 | 14,037 | 2.1 | 14 | 7,889 | 1.1 | ||||||||||||||||
| Total |
$ | 684,000 | 100.0 | % |
$ | 709,085 | 100.0 | % |
||||||||||||||
The following table shows total portfolio investment activity as of and for the three and nine months ended September 30, 2024 and 2023:
| For the three months ended |
For the nine months ended |
|||||||||||||||
| September 30, |
September 30, |
|||||||||||||||
| 2024 |
2023 |
2024 |
2023 |
|||||||||||||
| (In thousands) |
||||||||||||||||
| Beginning portfolio |
$ | 646,862 | $ | 715,391 | $ | 709,085 | $ | 720,026 | ||||||||
| New debt and equity investments |
94,117 | 89,435 | 140,751 | 186,988 | ||||||||||||
| Less refinanced debt balances |
(8,290 | ) | (22,500 | ) | (19,540 | ) | (32,500 | ) | ||||||||
| Net new debt and equity investments |
85,827 | 66,935 | 121,211 | 154,488 | ||||||||||||
| Principal payments received on investments |
(12,502 | ) | (9,121 | ) | (34,805 | ) | (22,011 | ) | ||||||||
| Early pay-offs and principal paydowns |
(31,890 | ) | (16,605 | ) | (85,643 | ) | (68,211 | ) | ||||||||
| Payment-in-kind interest on investments |
379 | 3,934 | 2,114 | 6,088 | ||||||||||||
| Accretion of debt investment fees |
1,474 | 1,925 | 4,470 | 5,018 | ||||||||||||
| New debt investment fees |
(1,522 | ) | (1,595 | ) | (2,089 | ) | (2,397 | ) | ||||||||
| Warrants and equity received in settlement of fee income |
— | 80 | 359 | 169 | ||||||||||||
| Proceeds from sale of investments |
(69 | ) | (2,557 | ) | (157 | ) | (11,063 | ) | ||||||||
| Net realized loss on investments |
(33,894 | ) | (11,816 | ) | (31,422 | ) | (28,513 | ) | ||||||||
| Net unrealized appreciation (depreciation) on investments |
29,335 | (17,518 | ) | 864 | (24,448 | ) | ||||||||||
| Other |
— | — | 13 | (93 | ) | |||||||||||
| Ending portfolio |
$ | 684,000 | $ | 729,053 | $ | 684,000 | $ | 729,053 | ||||||||
We receive payments on our debt investments based on scheduled amortization of the outstanding balances. In addition, we receive repayments of some of our debt investments prior to their scheduled maturity date. The frequency or volume of these repayments may fluctuate significantly from period to period.
The following table shows our debt investments by industry sector as of September 30, 2024 and December 31, 2023:
| September 30, 2024 |
December 31, 2023 |
|||||||||||||||
| Debt |
Percentage of |
Debt |
Percentage of |
|||||||||||||
| Investments at |
Total |
Investments at |
Total |
|||||||||||||
| Fair Value |
Portfolio |
Fair Value |
Portfolio |
|||||||||||||
| (Dollars in thousands) |
||||||||||||||||
| Life Science |
||||||||||||||||
| Biotechnology |
$ | 89,830 | 14.2 | % |
$ | 108,448 | 16.2 | % |
||||||||
| Medical Device |
170,347 | 26.9 | 137,367 | 20.5 | ||||||||||||
| Technology |
||||||||||||||||
| Communications |
13,060 | 2.1 | 18,654 | 2.8 | ||||||||||||
| Consumer-Related |
47,358 | 7.5 | 93,002 | 13.9 | ||||||||||||
| Networking |
9,641 | 1.5 | 5,087 | 0.8 | ||||||||||||
| Software |
130,256 | 20.6 | 158,016 | 23.6 | ||||||||||||
| Sustainability |
||||||||||||||||
| Energy Efficiency |
9,687 | 1.5 | — | — | ||||||||||||
| Other Sustainability |
58,921 | 9.3 | 79,828 | 11.8 | ||||||||||||
| Healthcare Information and Services |
||||||||||||||||
| Diagnostics |
14,052 | 2.2 | 19,453 | 2.9 | ||||||||||||
| Other Healthcare |
39,323 | 6.2 | — | — | ||||||||||||
| Software |
50,809 | 8.0 | 50,317 | 7.5 | ||||||||||||
| Total |
$ | 633,284 | 100.0 | % |
$ | 670,172 | 100.0 | % |
||||||||
The largest debt investments in our portfolio may vary from period to period as new debt investments are originated and existing debt investments are repaid. Our five largest debt investments at cost represented 22% and 23% of total debt investments outstanding as of September 30, 2024 and December 31, 2023, respectively. Our five largest debt investments at fair value represented 23% and 22% of total debt investments outstanding as of September 30, 2024 and December 31, 2023, respectively. No single debt investment at cost or fair value represented more than 10% of our total debt investments as of September 30, 2024 and December 31, 2023.
Debt investment asset quality
We use an internal credit rating system which rates each debt investment on a scale of 4 to 1, with 4 being the highest credit quality rating and 3 being the rating for a standard level of risk. A rating of 2 represents an increased level of risk and, while no loss is currently anticipated for a 2‑rated debt investment, there is potential for future loss of principal. A rating of 1 represents a deteriorating credit quality and a high degree of risk of loss of principal. Our internal credit rating system is not a national credit rating system. As of September 30, 2024 and December 31, 2023, our debt investments had a weighted average credit rating of 3.1. The following table shows the classification of our debt investment portfolio by credit rating as of September 30, 2024 and December 31, 2023:
| September 30, 2024 |
December 31, 2023 |
|||||||||||||||||||||||
| Debt |
Percentage |
Debt |
Percentage |
|||||||||||||||||||||
| Number of |
Investments at |
of Debt |
Number of |
Investments at |
of Debt |
|||||||||||||||||||
| Investments |
Fair Value |
Investments |
Investments |
Fair Value |
Investments |
|||||||||||||||||||
| (Dollars in thousands) |
||||||||||||||||||||||||
| Credit Rating |
||||||||||||||||||||||||
| 4 |
10 | $ | 129,508 | 20.5 | % |
11 | $ | 150,367 | 22.4 | % |
||||||||||||||
| 3 |
34 | 449,085 | 70.9 | 39 | 452,911 | 67.6 | ||||||||||||||||||
| 2 |
6 | 33,465 | 5.3 | 2 | 39,343 | 5.9 | ||||||||||||||||||
| 1 |
3 | 21,226 | 3.3 | 4 | 27,551 | 4.1 | ||||||||||||||||||
| Total |
53 | $ | 633,284 | 100.0 | % |
56 | $ | 670,172 | 100.0 | % |
||||||||||||||
As of September 30, 2024, there were three debt investments with an internal credit rating of 1, with an aggregate cost of $36.5 million and an aggregate fair value of $21.2 million and there were six debt investments with an internal credit rating of 2, with an aggregate cost of $36.9 million and an aggregate fair value of $33.5 million. As of December 31, 2023, there were four debt investments with an internal credit rating of 1, with an aggregate cost of $72.5 million and an aggregate fair value of $27.6 million and there were two debt investments with an internal credit rating of 2, with an aggregate cost of $43.8 million and an aggregate fair value of $39.3 million. The increase in the number of investments with internal credit ratings of 1 or 2 was principally a result of the increase in the risk of loss of principal caused by the portfolio companies low cash positions and the difficult equity fundraising market and/or the underperformance of certain portfolio companies.
Consolidated results of operations
As a BDC and a RIC, we are subject to certain constraints on our operations, including limitations imposed by the 1940 Act and the Code. The consolidated results of operations described below may not be indicative of the results we report in future periods.
Comparison of the three months ended September 30, 2024 and 2023
The following table shows consolidated results of operations for the three months ended September 30, 2024 and 2023:
| For the three months ended |
||||||||
| September 30, |
||||||||
| 2024 |
2023 |
|||||||
| (In thousands) |
||||||||
| Total investment income |
$ | 24,563 | $ | 29,138 | ||||
| Total expenses |
12,353 | 11,605 | ||||||
| Net investment income before excise tax |
12,210 | 17,533 | ||||||
| Provision for excise tax |
373 | 179 | ||||||
| Net investment income |
11,837 | 17,354 | ||||||
| Net realized loss |
(33,894 | ) | (11,816 | ) | ||||
| Net unrealized appreciation (depreciation) on investments |
29,335 | (17,518 | ) | |||||
| Net increase (decrease) in net assets resulting from operations |
$ | 7,278 | $ | (11,980 | ) | |||
| Average debt investments, at fair value |
$ | 611,924 | $ | 679,763 | ||||
| Average earning debt investments |
$ | 598,522 | $ | 685,107 | ||||
| Average gross assets less cash |
$ | 684,620 | $ | 740,836 | ||||
| Average borrowings outstanding |
$ | 441,723 | $ | 417,220 | ||||
Net increase (decrease) in net assets resulting from operations can vary substantially from period to period for various reasons, including, without limitation, the recognition of realized gains and losses and unrealized appreciation and depreciation on investments. As a result, quarterly comparisons of net increase in net assets resulting from operations may not be meaningful.
Investment income
Total investment income decreased by $4.6 million, or 15.7%, to $24.6 million for the three months ended September 30, 2024 as compared to the three months ended September 30, 2023. For the three months ended September 30, 2024, total investment income consisted primarily of $22.8 million in interest income from investments, which included $3.3 million in income from the accretion of origination fees and end of term payments (“ETPs”), $1.4 million in fee income and $0.4 million in PIK income. Interest income on debt investments decreased by $2.3 million, or 9.1%, to $22.8 million, for the three months ended September 30, 2024 compared to the three months ended September 30, 2023. Interest income on debt investments for the three months ended September 30, 2024 as compared to the three months ended September 30, 2023 decreased primarily due to a decrease of $86.6 million, or 12.6%, in the average earning debt investments. The proportion of total investment income that resulted from the portion of ETPs not received in cash for the three months ended September 30, 2024 and 2023 was 4.6% and 5.1%, respectively. The decrease in the proportion of total investment income that resulted from the portion of ETPs not received in cash was a result of a decrease in final payments received in cash from prepayments for the three months ended September 30, 2024 compared to the three months ended September 30, 2023.
Fee income, which includes success fee, other fee and prepayment fee income on debt investments, increased by $1.3 million, or 1014.5%, to $1.4 million for the three months ended September 30, 2024 compared to the three months ended September 30, 2023 primarily due to higher fee income earned on prepayments for the three months ended September 30, 2024 compared to the three months ended September 30, 2023.
PIK income decreased by $3.6 million for the three months ended September 30, 2024 compared to the three months ended September 30, 2023. For the three months ended September 30, 2024 and 2023, 1.5% and 13.5%, respectively, of total investment income was attributable to non-cash PIK interest. The decrease in PIK income for the three months ended September 30, 2024 compared to the three months ended September 30, 2023 was primarily due to a decrease in earning assets that contain a PIK feature for the three months ended September 30, 2024 compared to the three months ended September 30, 2023.
The following table shows our dollar-weighted annualized yield for the three months ended September 30, 2024 and 2023:
| For the three months ended |
||||||||
| September 30, |
||||||||
| Investment type: |
2024 |
2023 |
||||||
| Debt investments(1) |
15.9 | % | 17.1 | % | ||||
| All investments(1) |
14.8 | % | 16.1 | % | ||||
| (1) |
We calculate the dollar-weighted annualized yield on average investment type for any period as (1) total related investment income during the period divided by (2) the average of the fair value of the investment type outstanding on (a) the last day of the calendar month immediately preceding the first day of the period and (b) the last day of each calendar month during the period. The dollar-weighted annualized yield on average investment type is higher than what investors will realize because it does not reflect our expenses or any sales load paid by investors. |
Investment income, consisting of interest income and fees on debt investments, can fluctuate significantly upon repayment of large debt investments. Interest income from the five largest debt investments at cost in the aggregate accounted for 21% and 24% of investment income for the three months ended September 30, 2024 and 2023, respectively. Interest income from the five largest debt investments at fair value in the aggregate accounted for 25% and 22% of investment income for the three months ended September 30, 2024 and 2023, respectively.
Expenses
Total expenses increased by $0.7 million, or 6.4%, to $12.4 million for the three months ended September 30, 2024 as compared to the three months ended September 30, 2023. Total expenses for each period consisted of interest expense, base management fee, incentive and administrative fees, professional fees and general and administrative expenses.
Interest expense increased by $0.8 million, or 11.8%, to $7.9 million for the three months ended September 30, 2024 as compared to the three months ended September 30, 2023. Interest expense, which includes the amortization of debt issuance costs, increased primarily due to an increase in average borrowings of $24.5 million, or 5.9%, for the three months ended September 30, 2024 as compared to the three months ended September 30, 2023 and an increase in our effective cost of debt for the three months ended September 30, 2024 as compared to the three months ended September 30, 2023.
Base management fee expense decreased by $0.2 million, or 7.0%, to $3.0 million for the three months ended September 30, 2024 as compared to the three months ended September 30, 2023. Base management fee decreased primarily due to a decrease of $56.2 million, or 7.6%, in average gross assets less cash for the three months ended September 30, 2024 as compared to the three months ended September 30, 2023.
There was no performance based incentive fee expense for the three months ended September 30, 2024 and 2023. The incentive fee on pre-incentive fee net investment income was subject to an Incentive Fee Cap and Deferral Mechanism in our Investment Management Agreement of $2.4 million for the three months ended September 30, 2024 compared to $3.5 million for the three months ended September 30, 2023. The Incentive Fee Cap and Deferral Mechanism resulted in $2.4 million of reduced incentive fee expense and increased net investment income for the three months ended September 30, 2024. The incentive fee on pre-incentive fee net investment income was subject to the Incentive Fee Cap for the three months ended September 30, 2024 due to the cumulative incentive fees paid exceeding 20% of cumulative pre-incentive fee net return during the applicable quarter and the 11 preceding full calendar quarters.
Administrative fee expense, professional fees and general and administrative expenses were $1.4 million and $1.3 million for the three months ended September 30, 2024 and 2023, respectively.
Net realized gains and losses and net unrealized appreciation and depreciation
Realized gains or losses on investments are measured by the difference between the net proceeds from the repayment or sale and the cost basis of our investments without regard to unrealized appreciation or depreciation previously recognized. Realized gains or losses on investments include investments charged off during the period, net of recoveries. The net change in unrealized appreciation or depreciation on investments primarily reflects the change in portfolio investment fair values during the reporting period, including the reversal of previously recorded unrealized appreciation or depreciation when gains or losses are realized.
During the three months ended September 30, 2024, we realized net losses on investments totaling $33.9 million primarily due to the settlement of one of our debt investments. During the three months ended September 30, 2023, we realized net losses on investments totaling $11.8 million primarily due to the settlement of one of our debt investments. Such net realized losses were primarily the result of portfolio companies ceasing operations due to their inability to raise additional capital and the sale of their assets for less than the cost of their debt investments.
During the three months ended September 30, 2024, net unrealized appreciation on investments totaled $29.3 million which was primarily due to (1) the reversal of previously recorded unrealized depreciation from the settlement of one of our debt investments and (2) the unrealized appreciation on one of our debt investments offset by (1) the unrealized depreciation on one of our other investments and (2) the unrealized depreciation on our warrant investments. During the three months ended September 30, 2023, net unrealized depreciation on investments totaled $17.5 million which was primarily due to the unrealized depreciation on two of our debt investments offset by (1) the reversal of previously recorded unrealized depreciation from the settlement of one of our debt investments and (2) the unrealized appreciation on one of our equity investments. The difficult equity fundraising market and under performance of certain portfolio companies, among other factors, resulted in us reducing the fair market value of the debt investments in such portfolio companies, thus increasing the unrealized depreciation on such debt investments.
Comparison of the nine months ended September 30, 2024 and 2023
The following table shows consolidated results of operations for the nine months ended September 30, 2024 and 2023:
| For the nine months ended |
||||||||
| September 30, |
||||||||
| 2024 |
2023 |
|||||||
| (In thousands) |
||||||||
| Total investment income |
$ | 76,370 | $ | 85,292 | ||||
| Total expenses |
37,904 | 38,313 | ||||||
| Net investment income before excise tax |
38,466 | 46,979 | ||||||
| Provision for excise tax |
1,109 | 542 | ||||||
| Net investment income |
37,357 | 46,437 | ||||||
| Net realized loss |
(31,422 | ) | (28,513 | ) | ||||
| Net unrealized appreciation (depreciation) on investments |
864 | (24,448 | ) | |||||
| Net increase (decrease) in net assets resulting from operations |
$ | 6,799 | $ | (6,524 | ) | |||
| Average debt investments, at fair value |
$ | 641,287 | $ | 685,171 | ||||
| Average earning debt investments |
$ | 621,463 | $ | 692,991 | ||||
| Average gross assets less cash |
$ | 702,312 | $ | 739,268 | ||||
| Average borrowings outstanding |
$ | 447,009 | $ | 430,974 | ||||
Net increase (decrease) in net assets resulting from operations can vary substantially from period to period for various reasons, including, without limitation, the recognition of realized gains and losses and unrealized appreciation and depreciation on investments. As a result, quarterly comparisons of net increase in net assets resulting from operations may not be meaningful.
Investment income
Total investment income decreased by $8.9 million, or 10.5%, to $76.4 million for the nine months ended September 30, 2024 as compared to the nine months ended September 30, 2023. For the nine months ended September 30, 2024, total investment income consisted primarily of $71.6 million in interest income from investments, which included $10.8 million in income from the accretion of origination fees and end of term payments, $2.7 million in fee income and $2.1 million in PIK income. Interest income on debt investments decreased by $5.4 million, or 7.0%, to $71.6 million, for the nine months ended September 30, 2024 compared to the nine months ended September 30, 2023. Interest income on debt investments for the nine months ended September 30, 2024 as compared to the nine months ended September 30, 2023 decreased primarily due to a decrease of $71.5 million, or 10.3%, in the average earning debt investments, offset by an increase in the Prime Rate which is the base rate for most of our variable rate debt investments. The proportion of total investment income that resulted from the portion of ETPs not received in cash for the nine months ended September 30, 2024 and 2023 was 6.0% and 4.9%, respectively. The increase in the proportion of total investment income that resulted from the portion of ETPs not received in cash was a result of a decrease in earning assets for the nine months ended September 30, 2024 compared to the nine months ended September 30, 2023.
Fee income, which includes success fee, other fee and prepayment fee income on debt investments, increased by $0.4 million, or 18.0%, to $2.7 million for the nine months ended September 30, 2024 compared to the nine months ended September 30, 2023 primarily due to higher fee income earned on prepayments for the nine months ended September 30, 2024 compared to the nine months ended September 30, 2023.
PIK income decreased by $3.9 million for the nine months ended September 30, 2024 compared to the nine months ended September 30, 2023. For the nine months ended September 30, 2024 and 2023, 2.8% and 7.1%, respectively, of total investment income was attributable to non-cash PIK interest. The decrease in PIK interest as a percentage of total investment income was principally the result of a decrease in earning assets that contain a PIK feature for the nine months ended September 30, 2024 compared to the nine months ended September 30, 2023.
The following table shows our dollar-weighted annualized yield for the nine months ended September 30, 2024 and 2023:
| For the nine months ended |
||||||||
| September 30, |
||||||||
| Investment type: |
2024 |
2023 |
||||||
| Debt investments(1) |
15.8 | % | 16.5 | % | ||||
| All investments(1) |
14.8 | % | 15.7 | % | ||||
| (1) |
We calculate the dollar-weighted annualized yield on average investment type for any period as (1) total related investment income during the period divided by (2) the average of the fair value of the investment type outstanding on (a) the last day of the calendar month immediately preceding the first day of the period and (b) the last day of each calendar month during the period. The dollar-weighted annualized yield on average investment type is higher than what investors will realize because it does not reflect our expenses or any sales load paid by investors. |
Investment income, consisting of interest income and fees on debt investments, can fluctuate significantly upon repayment of large debt investments. Interest income from the five largest debt investments at cost in the aggregate accounted for 21% and 23% of investment income for the nine months ended September 30, 2024 and 2023, respectively. Interest income from the five largest debt investments at fair value in the aggregate accounted for 23% and 21% of investment income for the nine months ended September 30, 2024 and 2023, respectively.
Expenses
Total expenses decreased by $0.4 million, or 1.1%, to $37.9 million for the nine months ended September 30, 2024 as compared to the nine months ended September 30, 2023. Total expenses for each period consisted of interest expense, base management fee, incentive and administrative fees, professional fees and general and administrative expenses.
Interest expense increased by $2.6 million, or 12.3%, to $24.0 million for the nine months ended September 30, 2024 as compared to the nine months ended September 30, 2023. Interest expense, which includes the amortization of debt issuance costs, increased primarily due to an increase in average borrowings of $16.0 million, or 3.7%, for the nine months ended September 30, 2024 as compared to the nine months ended September 30, 2023 and an increase in our effective cost of debt for the nine months ended September 30, 2024 as compared to the nine months ended September 30, 2023.
Base management fee expense decreased by $0.4 million, or 4.6%, to $9.2 million for the nine months ended September 30, 2024 as compared to the nine months ended September 30, 2023. Base management fee decreased primarily due to a decrease of $37.0 million, or 5.0%, in average gross assets less cash for the nine months ended September 30, 2024 as compared to the nine months ended September 30, 2023.
Performance based incentive fee expense decreased by $2.8 million, or 90.5%, to $0.3 million for the nine months ended September 30, 2024 as compared to the nine months ended September 30, 2023. This decrease was due to an Incentive Fee Cap and Deferral Mechanism in our Investment Management Agreement of $7.2 million for the nine months ended September 30, 2024 compared to $6.8 million for the nine months ended September 30, 2023. The Incentive Fee Cap and Deferral Mechanism resulted in $7.2 million and $6.8 million of reduced incentive fee expense and increased net investment income for the nine months ended September 30, 2024 and 2023, respectively. The incentive fee on pre-incentive fee net investment income was subject to the Incentive Fee Cap for the nine months ended September 30, 2024 due to the cumulative incentive fees paid exceeding 20% of cumulative pre-incentive fee net return during the applicable quarter and the 11 preceding full calendar quarters.
Administrative fee expense, professional fees and general and administrative expenses were $4.4 million and $4.2 million for the nine months ended September 30, 2024 and 2023, respectively.
Net realized gains and losses and net unrealized appreciation and depreciation
Realized gains or losses on investments are measured by the difference between the net proceeds from the repayment or sale and the cost basis of our investments without regard to unrealized appreciation or depreciation previously recognized. Realized gains or losses on investments include investments charged off during the period, net of recoveries. The net change in unrealized appreciation or depreciation on investments primarily reflects the change in portfolio investment fair values during the reporting period, including the reversal of previously recorded unrealized appreciation or depreciation when gains or losses are realized.
During the nine months ended September 30, 2024, we realized net losses on investments totaling $31.4 million primarily due to the settlement of one of our debt investments. During the nine months ended September 30, 2023, we realized net losses on investments totaling $28.5 million primarily due to the settlement of four of our debt investments. Such net realized losses were primarily the result of portfolio companies ceasing operations due to their inability to raise additional capital and the sale of their assets for less than the cost of their debt investments.
During the nine months ended September 30, 2024, net unrealized appreciation on investments totaled $0.9 million which was primarily due to (1) the reversal of previously recorded unrealized depreciation from the settlement of one of our debt investments and (2) the unrealized appreciation on one of our other investments partially offset by (1) the unrealized depreciation on four of our debt investments and (2) the unrealized depreciation on our warrant and equity investments. During the nine months ended September 30, 2023, net unrealized depreciation on investments totaled $24.4 million which was primarily due to (1) the unrealized depreciation on four of our debt investments and (2) the unrealized depreciation on two of our equity investments offset by (1) the reversal of previously recorded unrealized depreciation from the settlement of three of our debt investments and (2) the unrealized appreciation on one of our equity investments. The difficult equity fundraising market and under performance of certain portfolio companies, among other factors, resulted in us reducing the fair market value of the debt investments in such portfolio companies, thus increasing the unrealized depreciation on such debt investments.
Liquidity and capital resources
As of September 30, 2024 and December 31, 2023, we had cash and investments in money market funds of $83.4 million and $73.1 million, respectively. Cash and investments in money market funds are available to fund new investments, reduce borrowings, pay expenses, repurchase common stock and pay distributions. In addition, as of September 30, 2024 and December 31, 2023, we had $3.3 million and $2.6 million, respectively, of restricted investments in money market funds. Restricted investments in money market funds may be used to make monthly interest and principal payments on our 2022 Asset-Backed Notes, our NYL Facility or our Nuveen Facility. Our primary sources of capital have been from our public equity offerings, use of our revolving credit facility (the “Key Facility”) with KeyBank National Association (“Key”), the Note Funding Agreement (the “NYL Facility”), with several entities owned or affiliated with New York Life Insurance Company and the Nuveen Note Funding Agreement (the “Nuveen Facility”, together with the Key Facility and the NYL Facility, the “Credit Facilities”) with several entities owned or affiliated with Nuveen Alternative Advisors LLC, and issuance of our public and private debt securities.
On August 2, 2021, we entered into an At-The-Market (“ATM”) sales agreement (the “2021 Equity Distribution Agreement”) with Goldman Sachs & Co. LLC and B. Riley FBR, Inc., (each a “Sales Agent” and, collectively, the “Sales Agents”). The 2021 Equity Distribution Agreement provided that we may offer and sell shares of our common stock from time to time through the Sales Agents up to $100.0 million worth of our common stock, in amounts and at times to be determined by us.
On September 22, 2023, we terminated the 2021 Equity Distribution Agreement and entered into a new ATM sales agreement (the “2023 Equity Distribution Agreement”) with the Sales Agents. The remaining shares available under the 2021 Equity Distribution Agreement are no longer available for issuance. The 2023 Equity Distribution Agreement provides that we may offer and sell shares of our common stock from time to time through the Sales Agents up to $150.0 million worth of our common stock, in amounts and at times to be determined by us. Sales of our common stock, if any, may be made in negotiated transactions or transactions that are deemed to be “at-the-market,” as defined in Rule 415 under the Securities Act, including sales made directly on the NASDAQ or similar securities exchange or sales made to or through a market maker other than on an exchange, at prices related to the prevailing market prices or at negotiated prices.
During the three months ended September 30, 2024, we sold 1,709,096 shares of common stock under the 2023 Equity Distribution Agreement. For the same period, we received total accumulated net proceeds of approximately $18.4 million, including $0.4 million of offering expenses, from these sales.
During the three months ended September 30, 2023, we sold 1,186,303 shares of common stock under the 2023 Equity Distribution Agreement and 2021 Equity Distribution Agreement. For the same period, we received total accumulated net proceeds of approximately $13.9 million, including $0.4 million of offering expenses, from these sales.
During the nine months ended September 30, 2024, we sold 4,279,141 shares of common stock under the 2023 Equity Distribution Agreement. For the same period, we received total accumulated net proceeds of approximately $47.5 million, including $1.0 million of offering expenses, from these sales.
During the nine months ended September 30, 2023, we sold 2,240,326 shares of common stock under the 2023 Equity Distribution Agreement and 2021 Equity Distribution Agreement. For the same period, we received total accumulated net proceeds of approximately $26.1 million, including $0.7 million of offering expenses, from these sales.
On June 2, 2023, we completed a follow-on public offering of 3,250,000 shares of our common stock at a public offering price of $12.50 per share, for total net proceeds to us of $38.9 million, after deducting underwriting commission and discounts and other offering expenses.
On April 26, 2024, our Board extended a previously authorized stock repurchase program which allows us to repurchase up to $5.0 million of our common stock at prices below our net asset value (“NAV”) per share as reported in our most recent consolidated financial statements. Under the repurchase program, we may, but are not obligated to, repurchase shares of our outstanding common stock in the open market or in privately negotiated transactions from time to time. Any repurchases by us will comply with the requirements of Rule 10b‑18 under the Exchange Act and any applicable requirements of the 1940 Act. Unless extended by our Board, the repurchase program will terminate on the earlier of June 30, 2025 or the repurchase of $5.0 million of our common stock. During the three and nine months ended September 30, 2024 and 2023, we did not make any repurchases of our common stock. From the inception of the stock repurchase program through September 30, 2024, we repurchased 167,465 shares of our common stock at an average price of $11.22 on the open market at a total cost of $1.9 million.
At September 30, 2024 there was no outstanding principal balance under our Key Facility. At December 31, 2023, the outstanding principal balance under our Key Facility was $70.0 million. As of September 30, 2024 and December 31, 2023, we had borrowing capacity under the Key Facility of $150.0 million and $80.0 million, respectively. At September 30, 2024 and December 31, 2023, $13.3 million and $25.0 million, respectively, was available for borrowing under the Key Facility, subject to existing terms and advance rates.
At September 30, 2024 and December 31, 2023, the outstanding principal balance under the NYL Facility was $181.0 million. As of September 30, 2024 and December 31, 2023, we had borrowing capacity under the NYL Facility of $69.0 million. At September 30, 2024 and December 31, 2023, $8.2 million and $17.4 million, respectively, was available for borrowing under the NYL Facility, subject to existing terms and advance rates.
At September 30, 2024, the outstanding principal balance under the Nuveen Facility was $50.0 million. As of September 30, 2024, we had borrowing capacity under the Nuveen Facility of $50.0 million. At September 30, 2024, $29.9 million was available for borrowing under the Nuveen Facility, subject to existing terms and advance rates. The Nuveen Facility was not outstanding at December 31, 2023.
Our operating activities provided cash of $30.1 million for the nine months ended September 30, 2024, and our financing activities used cash of $19.1 million for the same period. Our operating activities provided cash from principal payments received on our debt investments partially offset by cash used to purchase investments in portfolio companies. Our financing activities used cash primarily to repay our Key Facility, to repay our 2022 Asset-Backed Notes and to pay distributions to our stockholders, partially offset from an advance on our Nuveen Facility and the sale of shares through our ATM for net proceeds of $47.5 million.
Our operating activities used cash of $16.5 million for the nine months ended September 30, 2023, and our financing activities provided cash of $36.1 million for the same period. Our operating activities used cash to purchase investments in portfolio companies partially offset by principal payments received on our debt investments. Our financing activities provided cash primarily from the completion of a follow-on public offering of 3.25 million shares of common stock for net proceeds of $38.9 million, after deducting underwriting commission and discounts and other offering expenses, the sale of shares through our ATM for net proceeds of $26.1 million, and advances on our Credit Facilities, partially offset by cash used to repay our 2019 Asset-Backed Notes, to repay the outstanding principal balance under our Key Facility and to pay distributions to our stockholders.
Our primary use of available funds is to make debt investments in portfolio companies and for general corporate purposes. We expect to raise additional equity and debt capital opportunistically as needed and, subject to market conditions, to support our future growth to the extent permitted by the 1940 Act.
In order to remain subject to taxation as a RIC, we intend to distribute to our stockholders all or substantially all of our investment company taxable income. In addition, as a BDC, we are required to maintain asset coverage of at least 150%. This requirement limits the amount that we may borrow.
We believe that our current cash, cash generated from operations, and funds available from our Credit Facilities will be sufficient to meet our working capital and capital expenditure commitments for at least the next 12 months.
Current borrowings
The following table shows our borrowings as of September 30, 2024 and December 31, 2023:
| September 30, 2024 |
December 31, 2023 |
|||||||||||||||||||||||
| Total |
Balance |
Unused |
Total |
Balance |
Unused |
|||||||||||||||||||
| Commitment |
Outstanding |
Commitment |
Commitment |
Outstanding |
Commitment |
|||||||||||||||||||
| (In thousands) |
||||||||||||||||||||||||
| Key Facility |
$ | 150,000 | $ | — | $ | 150,000 | $ | 150,000 | $ | 70,000 | $ | 80,000 | ||||||||||||
| NYL Facility |
250,000 | 181,000 | 69,000 | 250,000 | 181,000 | 69,000 | ||||||||||||||||||
| Nuveen Facility |
100,000 | 50,000 | 50,000 | — | — | — | ||||||||||||||||||
| 2022 Asset-Backed Notes |
90,970 | 90,970 | — | 100,000 | 100,000 | — | ||||||||||||||||||
| 2027 Notes |
57,500 | 57,500 | — | 57,500 | 57,500 | — | ||||||||||||||||||
| 2026 Notes |
57,500 | 57,500 | — | 57,500 | 57,500 | — | ||||||||||||||||||
| Total before debt issuance costs |
705,970 | 436,970 | 269,000 | 615,000 | 466,000 | 149,000 | ||||||||||||||||||
| Unamortized debt issuance costs attributable to term borrowings |
— | (3,001 | ) | — | — | (3,765 | ) | — | ||||||||||||||||
| Total borrowings outstanding, net |
$ | 705,970 | $ | 433,969 | $ | 269,000 | $ | 615,000 | $ | 462,235 | $ | 149,000 | ||||||||||||
Credit Facilities
Key Facility
We entered into the Key Facility effective November 4, 2013. On June 20, 2024, we amended the Key Facility, among other things, (i) to extend the date on which we may request advances under the Key Facility to June 20, 2027 and to extend the maturity date to June 20, 2029 and (ii) to amend the interest rate to be based on the rate of interest published in The Wall Street Journal as the prime rate in the United States plus 0.10%, with a prime rate floor of 4.10%. Prior to June 20, 2024, the interest rate on the Key Facility was based on Prime plus 0.25%, with a prime rate floor of 4.25%. The prime rate was 8.00% and 8.50% as of September 30, 2024 and December 31, 2023, respectively. The interest rate in effect was 8.10% and 8.75% as of September 30, 2024 and December 31, 2023, respectively. The Key Facility requires the payment of an unused line fee in an amount up to 0.50% of any unborrowed amount available under the facility annually.
On June 29, 2023, we amended the Key Facility to, among other things, increase the commitment amount to $150 million and to increase the amount of the accordion feature which now allows the potential increase in the total commitment amount to $300 million. The Key Facility is collateralized by debt investments held by Credit II and permits an advance rate of up to sixty percent (60%) of eligible debt investments held by Credit II. The Key Facility contains covenants that, among other things, require us to maintain a minimum net worth, to restrict the debt investments securing the Key Facility to certain criteria for qualified debt investments and to comply with portfolio company concentration limits as defined in the related loan agreement. After the period during which we may request advances under the Key Facility (or the “Revolving Period”), we may not request new advances, and we must repay the outstanding advances under the Key Facility as of such date, at such times and in such amounts as are necessary to maintain compliance with the terms and conditions of the Key Facility, particularly the condition that the principal balance of the Key Facility not exceed sixty percent (60%) of the aggregate principal balance of our eligible debt investments to our portfolio companies.
NYL Facility
HFI is a wholly-owned subsidiary of HSLFI. HFI entered into the NYL Facility with the NYL Noteholders for an aggregate purchase price of up to $100.0 million, with an accordion feature of up to $200.0 million at the mutual discretion and agreement of HSLFI and the NYL Noteholders. On June 1, 2018, HSLFI sold or contributed to HFI certain secured loans made to certain portfolio companies pursuant to the Sale and Servicing Agreement. Any notes issued by HFI are collateralized by all investments held by HFI and permit an advance rate of up to 67% of the aggregate principal amount of eligible debt investments.
On May 24, 2023, we amended the NYL Facility to, among other things, increase the commitment by $50.0 million to enable our wholly-owned subsidiary to issue up to $250.0 million of secured notes. In addition, the amendment amended the interest rate for advances made after May 24, 2023, fixing the interest rate at the greater of (i) 4.60% and (ii) the Three Year I-Curve plus 3.50% with the interest rate to be reset on any advance date.
On May 6, 2024, we amended the NYL Facility to, among other things, extend the investment period to June 2025 and the maturity date of all advances to June 2030. In addition, the amendment amended the interest rate for advances made after May 6, 2024, fixing the interest rate at the greater of (i) 4.60% and (ii) the Three Year I Curve plus 3.20%, with the interest rate to be reset on any advance date.
Under the terms of the NYL Facility, we are required to maintain a reserve cash balance, which may be used to pay monthly interest and principal payments on the NYL Facility. We have segregated these funds and classified them as restricted investments in money market funds. At September 30, 2024 and December 31, 2023, there were approximately $1.4 million of such restricted investments.
There were $181.0 million in notes issued to the NYL Noteholders as of September 30, 2024 and December 31, 2023 at an interest rate of 6.43% and 5.96%, respectively. As of September 30, 2024 and December 31, 2023, we had borrowing capacity under the NYL Facility of $69.0 million. At September 30, 2024 and December 31, 2023, $8.2 million and $17.4 million, respectively, was available for borrowing, subject to existing terms and advance rates.
Nuveen Facility
HFII entered into the Nuveen Facility with the Nuveen Noteholders for an aggregate purchase price of up to $100.0 million, with an accordion feature of up to $200.0 million at the mutual discretion and agreement us and the Nuveen Noteholders. On June 21, 2024, we sold or contributed to HFII certain secured loans made to certain portfolio companies pursuant to the Sale and Servicing Agreement. Any notes issued by HFII are collateralized by all investments held by HFII and permit an advance rate of up to 67.5% of the aggregate principal amount of eligible debt investments. The Nuveen Facility bears interest, payable monthly, determined at a rate per annum equal to the greater of (i) the yield for the United States Treasury constant maturity 3-year and 5-year in the most recent statistical release published by the Board of Governors of the Federal Reserve System designated as “Selected Interest Rates (Daily) – H.15” interpolated to a 4.88-year weighted average life plus 3.15% and (ii) 5.00%. We may request advances under the Nuveen Facility through June 21, 2027 and the Nuveen Facility is scheduled to mature on June 10, 2033.
Under the terms of the Nuveen Facility, we are required to maintain a reserve cash balance, which may be used to pay monthly interest and principal payments on the Nuveen Facility. We have segregated these funds and classified them as restricted investments in money market funds. At September 30, 2024, there were approximately $0.9 million of such restricted investments.
There were $50.0 million in notes issued to the Nuveen Noteholders as of September 30, 2024 at an interest rate of 7.38%. As of September 30, 2024, we had borrowing capacity under the Nuveen Facility of $50.0 million. At September 30, 2024, $29.9 million, was available for borrowing, subject to existing terms and advance rates.
Securitizations
2019 Asset-Backed Notes
On August 13, 2019, the 2019 Asset-Backed Notes were issued by the 2019‑1 Trust pursuant to a note purchase agreement, dated as of August 13, 2019, by and among us and Keybanc Capital Markets Inc. as Initial Purchaser, and were backed by a pool of loans made to certain portfolio companies of ours and secured by certain assets of those portfolio companies. The 2019 Asset-Backed Notes were rated A+(sf) by Morningstar Credit Ratings, LLC on August 13, 2019. The 2019 Asset-Backed Notes bore interest at a fixed rate of 4.21% per annum and had a stated maturity of September 15, 2027. As of December 31, 2023, the 2019 Asset-Backed Notes were repaid in full.
2022 Asset-Backed Notes
On November 9, 2022, the 2022 Asset-Backed Notes were issued by the 2022‑1 Trust pursuant to a note purchase agreement, dated as of November 9, 2022, by and among us and Keybanc Capital Markets Inc. as Initial Purchaser, and are backed by a pool of loans made to certain portfolio companies of ours and secured by certain assets of those portfolio companies and are to be serviced by us. Interest on the 2022 Asset-Backed Notes will be paid, to the extent of funds available, at a fixed rate of 7.56% per annum. The 2022 Asset-Backed Notes have a two-year reinvestment period and a stated maturity of November 15, 2030. The 2022 Asset-Backed Notes were rated A by Morningstar Credit Ratings, LLC on November 9, 2022. There has been no change in the rating since November 9, 2022.
At September 30, 2024 and December 31, 2023, the 2022 Asset-Backed Notes had an outstanding principal balance of $91.0 million and $100.0 million, respectively.
Under the terms of the 2022 Asset-Backed Notes, we are required to maintain a reserve cash balance, funded through proceeds from the sale of the 2022 Asset-Backed Notes, which may be used to pay monthly interest and principal payments on the 2022 Asset-Backed Notes. We have segregated these funds and classified them as restricted investments in money market funds. At September 30, 2024, and December 31, 2023, there were approximately $1.0 million and $1.3 million, respectively, of such restricted investments.
Unsecured Notes
2026 Notes
On March 30, 2021, we issued and sold an aggregate principal amount of $57.5 million of 4.875% notes due in 2026 (the “2026 Notes”). The amount of 2026 Notes issued and sold included the full exercise by the underwriters of their option to purchase $7.5 million in aggregate principal of additional notes. The 2026 Notes have a stated maturity of March 30, 2026 and may be redeemed in whole or in part at our option at any time or from time to time on or after March 30, 2023 at a redemption price of $25 per security plus accrued and unpaid interest. The 2026 Notes bear interest at a rate of 4.875% per year, payable quarterly on March 30, June 30, September 30 and December 30 of each year. The 2026 Notes are our direct unsecured obligations and (i) rank equally in right of payment with our current and future unsecured indebtedness; (ii) are senior in right of payment to any of our future indebtedness that expressly provides it is subordinated to the 2026 Notes; (iii) are effectively subordinated to all of our existing and future secured indebtedness (including indebtedness that is initially unsecured to which we subsequently grant security), to the extent of the value of the assets securing such indebtedness, and (iv) are structurally subordinated to all existing and future indebtedness and other obligations of any of our subsidiaries. As of September 30, 2024, we were in material compliance with the terms of the 2026 Notes. The 2026 Notes are listed on the New York Stock Exchange under the symbol “HTFB”.
2027 Notes
On June 15, 2022, we issued and sold an aggregate principal amount of $50.0 million of 6.25% notes due in 2027 and on July 11, 2022, pursuant to the underwriters’ 30 day option to purchase additional notes, we sold an additional $7.5 million of such notes (collectively, the “2027 Notes”). The 2027 Notes have a stated maturity of June 15, 2027 and may be redeemed in whole or in part at our option at any time or from time to time on or after June 15, 2024 at a redemption price of $25 per security plus accrued and unpaid interest. The 2027 Notes bear interest at a rate of 6.25% per year, payable quarterly on March 30, June 30, September 30 and December 30 of each year, commencing on September 30, 2022. The 2027 Notes are our direct unsecured obligations and (i) rank equally in right of payment with our current and future unsecured indebtedness; (ii) are senior in right of payment to any of our future indebtedness that expressly provides it is subordinated to the 2027 Notes; (iii) are effectively subordinated to all of our existing and future secured indebtedness (including indebtedness that is initially unsecured to which we subsequently grant security), to the extent of the value of the assets securing such indebtedness, and (iv) are structurally subordinated to all existing and future indebtedness and other obligations of any of our subsidiaries. As of September 30, 2024, we were in material compliance with the terms of the 2027 Notes. The 2027 Notes are listed on the New York Stock Exchange under the symbol “HTFC”.
Other assets
As of September 30, 2024 and December 31, 2023, other assets were $6.6 million and $3.6 million, respectively, which was primarily comprised of debt issuance costs and prepaid expenses.
Contractual obligations and off-balance sheet arrangements
The following table shows our significant contractual payment obligations and off-balance sheet arrangements as of September 30, 2024:
| Payments due by period |
||||||||||||||||||||
| Less than |
1 – 3 | 3 – 5 | After 5 |
|||||||||||||||||
| Total |
1 year |
Years |
Years |
years |
||||||||||||||||
| (In thousands) |
||||||||||||||||||||
| Borrowings |
$ | 436,970 | $ | 70,284 | $ | 284,255 | $ | 82,431 | $ | — | ||||||||||
| Unfunded commitments |
189,875 | 122,375 | 67,500 | — | — | |||||||||||||||
| Incentive fee deferral |
18,084 | — | 18,084 | — | — | |||||||||||||||
| Total |
$ | 644,929 | $ | 192,659 | $ | 369,839 | $ | 82,431 | $ | — | ||||||||||
In the normal course of business, we are party to financial instruments with off-balance sheet risk. These consist primarily of unfunded commitments to extend credit, in the form of loans, to our portfolio companies. Unfunded commitments to provide funds to portfolio companies are not reflected on our balance sheet. Our unfunded commitments may be significant from time to time. As of September 30, 2024, we had unfunded commitments of $189.9 million. This includes $20.0 million of undrawn revolver commitments. These commitments are subject to the same underwriting and ongoing portfolio maintenance requirements as are the financial instruments that we hold on our balance sheet. In addition, these commitments are often subject to financial or non-financial milestones and other conditions to borrowing that must be achieved before the commitment can be drawn. Since these commitments may expire without being drawn upon, the total commitment amount does not necessarily represent future cash requirements. We regularly monitor our unfunded commitments and anticipated refinancings, maturities and capital raising, to ensure that we have sufficient liquidity to fund unfunded commitments. As of September 30, 2024, we reasonably believed that our assets would provide adequate financial resources to satisfy all of our unfunded commitments.
In addition to the Credit Facilities, we have certain commitments pursuant to our Investment Management Agreement entered into with our Advisor. We have agreed to pay a fee for investment advisory and management services consisting of two components (1) a base management fee equal to a percentage of the value of our gross assets less cash or cash equivalents, and (2) a two-part incentive fee. We have also entered into a contract with our Advisor to serve as our administrator. Payments under the Administration Agreement are equal to an amount based upon our allocable portion of our Advisor’s overhead in performing its obligations under the agreement, including rent, fees and other expenses inclusive of our allocable portion of the compensation of our Chief Financial Officer and Chief Compliance Officer and their respective staffs. See Note 3 to our consolidated financial statements for additional information regarding our Investment Management Agreement and our Administration Agreement.
The incentive fee on Pre-Incentive Fee Net Investment Income is subject to a fee cap and deferral mechanism which is determined based upon a look-back period of up to three years and is expensed when incurred. For this purpose, the Incentive Fee Look-back Period includes the relevant calendar quarter and the 11 preceding full calendar quarters. Each quarterly incentive fee payable on Pre-Incentive Fee Net Investment Income is subject to the Incentive Fee Cap and Deferral Mechanism. The Incentive Fee Cap is equal to (a) 20.00% of Cumulative Pre-Incentive Fee Net Return during the Incentive Fee Look-back Period less (b) cumulative incentive fees of any kind paid to our Advisor during the Incentive Fee Look-back Period. To the extent the Incentive Fee Cap is zero or a negative value in any calendar quarter, we will not pay an incentive fee on Pre-Incentive Fee Net Investment Income to our Advisor in that quarter. To the extent that the payment of incentive fees on Pre-Incentive Fee Net Investment Income is limited by the Incentive Fee Cap, the payment of such fees will be deferred and paid in subsequent calendar quarters up to three years after their date of deferment, subject to certain limitations, which are set forth in the Investment Management Agreement. During the three months ended September 30, 2024 and 2023, the Incentive Fee Cap and Deferral Mechanism resulted in deferral of $2.4 million and $3.5 million, respectively, of incentive fee which may become subject to payment up to three years after the date of deferment. During the nine months ended September 30, 2024 and 2023, the Incentive Fee Cap and Deferral Mechanism resulted in deferral of $7.2 million and $6.8 million, respectively, of incentive fee which may become subject to payment up to three years after the date of deferment. As of September 30, 2024 and December 31, 2023, the total amount subject to recoupment was $18.1 million and $10.8 million, respectively.
Distributions
In order to qualify and be subject to tax as a RIC, we must meet certain source-of-income, asset diversification and annual distribution requirements. Generally, in order to qualify as a RIC, we must derive at least 90% of our gross income for each tax year from dividends, interest, payments with respect to certain securities, loans, gains from the sale or other disposition of stock, securities or foreign currencies, income derived from certain publicly traded partnerships, or other income derived with respect to our business of investing in stock or other securities. We must also meet certain asset diversification requirements at the end of each quarter of each tax year. Failure to meet these diversification requirements on the last day of a quarter may result in us having to dispose of certain investments quickly in order to prevent the loss of RIC status. Any such dispositions could be made at disadvantageous prices or times, and may cause us to incur substantial losses.
In addition, in order to be subject to tax as a RIC and to avoid the imposition of corporate-level tax on the income and gains we distribute to our stockholders in respect of any tax year, we are required under the Code to distribute as dividends to our stockholders out of assets legally available for distribution each tax year an amount generally at least equal to 90% of the sum of our net ordinary income and net short-term capital gains in excess of net long-term capital losses, if any. Additionally, in order to avoid the imposition of a U.S. federal excise tax, we are required to distribute, in respect of each calendar year, dividends to our stockholders of an amount at least equal to the sum of 98% of our calendar year net ordinary income (taking into account certain deferrals and elections); 98.2% of our capital gain net income (adjusted for certain ordinary losses) for the one year period ending on October 31 of such calendar year; and any net ordinary income and capital gain net income for preceding calendar years that were not distributed during such calendar years and on which we previously did not incur any U.S. federal income tax. If we fail to qualify as a RIC for any reason and become subject to corporate tax, the resulting corporate taxes could substantially reduce our net assets, the amount of income available for distribution and the amount of our distributions. Such a failure would have a material adverse effect on us and our stockholders. In addition, we could be required to recognize unrealized gains, incur substantial taxes and interest and make substantial distributions in order to re-qualify as a RIC. We cannot assure stockholders that they will receive any distributions.
To the extent our taxable earnings in a tax year fall below the total amount of our distributions made to stockholders in respect of such tax year, a portion of those distributions may be deemed a return of capital to our stockholders for U.S. federal income tax purposes. Thus, the source of a distribution to our stockholders may be the original capital invested by the stockholder rather than our income or gains. Stockholders should review any written disclosure accompanying a distribution payment carefully and should not assume that the source of any distribution is our ordinary income or gains.
We have adopted an “opt out” dividend reinvestment plan, or DRIP, for our common stockholders. As a result, if we declare a distribution, then stockholders’ cash distributions will be automatically reinvested in additional shares of our common stock unless a stockholder specifically “opts out” of our DRIP. If a stockholder opts out, that stockholder will receive cash distributions. Although distributions paid in the form of additional shares of our common stock will generally be subject to U.S. federal, state and local taxes, stockholders participating in our DRIP will not receive any corresponding cash distributions with which to pay any such applicable taxes. If our common stock is trading above NAV, a stockholder receiving distributions in the form of additional shares of our common stock will be treated as receiving a distribution of an amount equal to the fair market value of such shares of our common stock. We may use newly issued shares to implement the DRIP, or we may purchase shares in the open market in connection with our obligations under the DRIP.
Related party transactions
We have entered into the Investment Management Agreement with our Advisor. Our Advisor is registered as an investment adviser under the Investment Advisers Act of 1940, as amended. Our investment activities are managed by our Advisor and supervised by our Board, the majority of whom are independent directors. Under the Investment Management Agreement, we have agreed to pay our Advisor a base management fee as well as an incentive fee. During the three months ended September 30, 2024 and 2023, our Advisor earned $3.0 million and $3.2 million, respectively, pursuant to the Investment Management Agreement. During the nine months ended September 30, 2024 and 2023, our Advisor earned $9.5 million and $12.7 million, respectively, pursuant to the Investment Management Agreement.
On February 22, 2023, our Advisor, Horizon Technology Finance Principals LLC f/k/a Horizon Technology Finance, LLC (“HTF Principals”) and Horizon Technology Finance Employees LLC (“HTF Employees”) entered into a Membership Interest Purchase Agreement (the “Purchase Agreement”) with MCH Holdco LLC (“MCH Holdco”), an affiliate of Monroe Capital LLC (“Monroe Capital”), and Monroe Capital Investment Holdings, L.P., an affiliate of Monroe Capital and the sole stockholder of MCH Holdco. On June 30, 2023, pursuant to the Purchase Agreement, HTF Principals and HTF Employees sold all of their membership interests in our Advisor (which constitute one hundred percent (100%) of the membership interests of our Advisor) to MCH Holdco and our Advisor became a direct wholly owned subsidiary of MCH Holdco and an affiliate of Monroe Capital. Pursuant to the Purchase Agreement, a significant portion of the consideration payable by Monroe Capital to HTF Principals and HTF Employees is in the form of earnout payments contingent upon our performance in 2023, 2024, and 2025, aligning the incentives of our Advisor’s current officers with our stockholders.
We have also entered into the Administration Agreement with our Advisor. Under the Administration Agreement, we have agreed to reimburse our Advisor for our allocable portion of overhead and other expenses incurred by our Advisor in performing its obligations under the Administration Agreement, including rent and our allocable portion of the costs of compensation and related expenses of our Chief Financial Officer and Chief Compliance Officer and their respective staffs. In addition, pursuant to the terms of the Administration Agreement our Advisor provides us with the office facilities and administrative services necessary to conduct our day-to-day operations. During the three months ended September 30, 2024 and 2023, our Advisor earned $0.4 million pursuant to the Administration Agreement. During the nine months ended September 30, 2024 and 2023, our Advisor earned $1.3 million and $1.2 million, respectively, pursuant to the Administration Agreement.
In connection with the Purchase Agreement, HTF Principals sold its trademark interest in “Horizon Technology Finance”, and granted us a royalty-free license to use the name “Horizon Technology Finance.”
We believe that we derive substantial benefits from our relationship with our Advisor. Our Advisor or its affiliates may manage other investment vehicles (the “Advisor Funds”), with the same investment strategy as us, which now may include investment vehicles managed by affiliates of Monroe Capital. Our Advisor may provide us an opportunity to co-invest with the Advisor Funds. Under the 1940 Act, absent receipt of exemptive relief from the SEC, we and our affiliates are precluded from co-investing in negotiated investments. Monroe Capital's exemptive relief to permit joint transactions granted by the SEC on October 15, 2014, as amended, permits us to co-invest with the Advisor Funds, subject to certain conditions.
Critical accounting policies
The discussion of our financial condition and results of operation is based upon our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP. The preparation of these consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. Changes in the economic environment, financial markets and any other parameters used in determining such estimates could cause actual results to differ. In addition to the discussion below, we describe our significant accounting policies in the notes to our consolidated financial statements.
We have identified the following items as critical accounting policies.
Valuation of investments
Investments are recorded at fair value. Prior to July 30, 2022, our Board determined the fair value of our investments. Pursuant to the amended SEC Rule 2a-5 of the 1940 Act, on July 29, 2022, our Board designated our Advisor as the “valuation designee.” Our Board is responsible for oversight of the valuation designee. The valuation designee has established a Valuation Committee to determine in good faith the fair value of our investments, based on input of our Advisor’s management and personnel and independent valuation firms which are engaged at the direction of the Valuation Committee to assist in the valuation of certain portfolio investments lacking a readily available market quotation at least once during a trailing twelve-month period. The Valuation Committee determines fair values pursuant to a valuation policy approved by our Board and pursuant to a consistently applied valuation process. This valuation process is conducted at the end of each fiscal quarter, with at least 25% (based on fair value) of our valuation of portfolio companies lacking readily available market quotations subject to review by an independent valuation firm. We apply fair value to substantially all of our investments in accordance with Topic 820, Fair Value Measurement, of the Financial Accounting Standards Board’s, or FASB’s, Accounting Standards Codification as amended, or ASC, which establishes a framework used to measure fair value and requires disclosures for fair value measurements. We have categorized our investments carried at fair value, based on the priority of the valuation technique, into a three-level fair value hierarchy. Fair value is a market-based measure considered from the perspective of the market participant who holds the financial instrument rather than an entity specific measure. Therefore, when market assumptions are not readily available, our own assumptions are set to reflect those that we believe market participants would use in pricing the financial instrument at the measurement date.
The availability of observable inputs can vary depending on the financial instrument and is affected by a wide variety of factors, including, for example, the type of product, whether the product is new, whether the product is traded on an active exchange or in the secondary market and the current market conditions. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. The three categories within the hierarchy are as follows:
| Level 1 |
Quoted prices in active markets for identical assets and liabilities. |
| Level 2 |
Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities in active markets, quoted prices in markets that are not active and model-based valuation techniques for which all significant inputs are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. |
| Level 3 |
Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation. |
Income recognition
Interest on debt investments is accrued and included in income based on contractual rates applied to principal amounts outstanding. Interest income is determined using a method that results in a level rate of return on principal amounts outstanding. Generally, when a debt investment becomes 90 days or more past due, or if we otherwise do not expect to receive interest and principal repayments, the debt investment is placed on non-accrual status and the recognition of interest income may be discontinued. Interest payments received on non-accrual debt investments may be recognized as income, on a cash basis, or applied to principal depending upon management’s judgment at the time the debt investment is placed on non-accrual status. For the three and nine months ended September 30, 2024, we recognized in interest income $0.2 million from debt investments while on non-accrual status. For the three and nine months ended September 30, 2023, we did not recognize any interest income from debt investments while on non-accrual status.
We receive a variety of fees from borrowers in the ordinary course of conducting our business, including advisory fees, commitment fees, amendment fees, non-utilization fees, success fees and prepayment fees. In a limited number of cases, we may also receive a non-refundable deposit earned upon the termination of a transaction. Debt investment origination fees, net of certain direct origination costs, are deferred, and along with unearned income, are amortized as a level yield adjustment over the respective term of the debt investment. All other income is recorded into income when earned. Fees for counterparty debt investment commitments with multiple debt investments are allocated to each debt investment based upon each debt investment’s relative fair value. When a debt investment is placed on non-accrual status, the amortization of the related fees and unearned income is discontinued until the debt investment is returned to accrual status.
Certain debt investment agreements also require the borrower to make an ETP that is accrued into income over the life of the debt investment to the extent such amounts are expected to be collected. We will generally cease accruing the income if there is insufficient value to support the accrual or if we do not expect the borrower to be able to pay the ETP when due.
In connection with substantially all lending arrangements, we receive warrants to purchase shares of stock from the borrower. We record the warrants as assets at estimated fair value on the grant date using the Black-Scholes valuation model. We consider the warrants as loan fees and record them as unearned income on the grant date. The unearned income is recognized as interest income over the contractual life of the related debt investment in accordance with our income recognition policy. Subsequent to origination, the warrants are also measured at fair value using the Black-Scholes valuation model. Any adjustment to fair value is recorded through earnings as net unrealized gain or loss on investments. Gains and losses from the disposition of the warrants or stock acquired from the exercise of warrants are recognized as realized gains and losses on investments.
Realized gains or losses on the sale of investments, or upon the determination that an investment balance, or portion thereof, is not recoverable, are calculated using the specific identification method. We measure realized gains or losses by calculating the difference between the net proceeds from the repayment or sale and the amortized cost basis of the investment. Net change in unrealized appreciation or depreciation reflects the change in the fair values of our portfolio investments during the reporting period, including any reversal of previously recorded unrealized appreciation or depreciation, when gains or losses are realized.
Income taxes
We have elected to be treated as a RIC under Subchapter M of the Code and operate in a manner so as to qualify for the tax treatment applicable to RICs. In order to qualify as a RIC and to avoid the imposition of corporate-level U.S. federal income tax on the amounts we distribute to our stockholders, among other things, we are required to meet certain source of income and asset diversification requirements, and we must timely distribute dividends to our stockholders out of assets legally available for distribution each tax year of an amount generally equal to at least 90% of our investment company taxable income, as defined by the Code and determined without regard to any deduction for dividends paid. We, among other things, have made and intend to continue to make the requisite distributions to our stockholders, which will generally relieve us from incurring any material liability for U.S. federal income taxes.
Depending on the level of taxable income earned in a tax year, we may choose to carry forward taxable income in excess of current year distributions into the next tax year and incur a 4% excise tax on such income, as required. To the extent that we determine that our estimated current year annual taxable income will be in excess of estimated current year distributions, we will accrue excise tax, if any, on estimated excess taxable income as taxable income is earned.
We evaluate tax positions taken in the course of preparing our tax returns to determine whether the tax positions are “more-likely-than-not” to be sustained by the applicable tax authority in accordance with ASC Topic 740, Income Taxes, as modified by ASC Topic 946, Financial Services — Investment Companies. Tax benefits of positions not deemed to meet the more-likely-than-not threshold, or uncertain tax positions, are recorded as a tax expense in the current year. It is our policy to recognize accrued interest and penalties related to uncertain tax benefits in income tax expense. We had no material uncertain tax positions at September 30, 2024 and December 31, 2023.
Recent developments
On October 7, 2024, we funded a $2.5 million debt investment to an existing portfolio company, Standvast Holdings, LLC.
On October 15, 2025, we funded a $0.6 million debt investment to an existing portfolio company, Swift Health Systems, Inc.
On October 17, 2024, we entered into a note purchase agreement, by and among us, each purchaser named therein, and the investment adviser named therein, in connection with the issuance and sale of $20,000,000 aggregate principal of our 7.125% Convertible Notes due 2031, par value $25.00 per share (the “Convertible Notes”), in a transaction exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933. We received net proceeds (before expenses) from the sale of the Convertible Notes of approximately $18.6 million.
The Convertible Notes mature on October 16, 2031, unless earlier converted or repurchased in accordance with their terms. The Convertible Notes bear interest at a rate of 7.125% per year, subject to additional interest or a repurchase obligation upon certain events, payable quarterly in arrears on March 31, June 30, September 30 and December 31 of each year, beginning on December 31, 2024. The Convertible Notes may be converted into common stock by the holders of the Convertible Notes at any time after April 17, 2025 at a conversion price equal to the greater of: (i) volume-weighted average closing sale price for the five trading days immediately prior to the relevant conversion date and (ii) the most recently report net asset value per share of our common stock.
On October 18, 2025, we funded a $0.5 million debt investment to an existing portfolio company, Better Place Forests Co.
On October 22, 2024, Monroe Capital, an affiliate of us and our Advisor, announced that Monroe Capital has entered into a definitive agreement with Wendel Group (Euronext: MF:FP) (“Wendel”) relating to Wendel’s strategic investment in Monroe Capital. The transaction is expected to close in the first quarter of 2025, subject to the satisfaction of customary closing conditions, including the receipt of regulatory clearances and approvals and client consents. In connection with the transaction, we expect to seek approval of a new investment management agreement between us and our Advisor, from our Board and its shareholders, the terms of which are expected to remain substantively similar to the current investment management agreement.
On October 23, 2024, CAMP NYC, Inc. (“CAMP”) prepaid its outstanding principal balance of $2.0 million on its venture loan, plus interest and end-of-term payment. We continue to hold warrants in CAMP.
Recently issued accounting pronouncement
In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”). ASU 2023-07 is intended to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses, allowing financial statement users to better understand the components of a segment's profit or loss and assess potential future cash flows for each reportable segment and the entity as a whole. The amendments expand a public entity's segment disclosures by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker, clarifying when an entity may report one or more additional measures to assess segment performance, requiring enhanced interim disclosures and providing new disclosure requirements for entities with a single reportable segment, among other new disclosure requirements. The amendments are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, and early adoption is permitted. We are currently evaluating the impact of adopting this guidance with respect to our consolidated financial statements and disclosures.
Recently adopted accounting pronouncement
In June 2022, the FASB issued Accounting Standards Update No. 2022-03, Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2022-03”). ASU 2022-03 clarifies the guidance when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of the security. The amendments in ASU 2022-03 were effective for public companies for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The adoption of ASU 2022-03 did not have a material impact on our consolidated financial statements.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
We are subject to financial market risks, including changes in interest rates. During the periods covered by our financial statements, the interest rates on the debt investments within our portfolio were primarily at floating rates. We expect that our debt investments in the future will primarily have floating interest rates. As of September 30, 2024 and December 31, 2023, 99% and 94%, respectively, of the outstanding principal amount of our debt investments bore interest at floating rates. Contractual interest rates on our commitments to lend to our portfolio companies are typically based on the Prime Rate as published in the Wall Street Journal.
Based on our September 30, 2024 consolidated statement of assets and liabilities (without adjustment for potential changes in the credit market, credit quality, size and composition of assets on the consolidated statement of assets and liabilities or other business developments that could affect net income) and the base index rates at September 30, 2024, the following table shows the annual impact on the change in net assets resulting from operations of changes in interest rates, which assumes no changes in our investments and borrowings:
| Investment |
Interest |
Change in Net |
||||||||||
| Change in basis points |
Income |
Expense |
Assets(1) |
|||||||||
| (In thousands) |
||||||||||||
| Up 300 basis points |
$ | 17,060 | $ | — | $ | 17,060 | ||||||
| Up 200 basis points |
$ | 11,230 | $ | — | $ | 11,230 | ||||||
| Up 100 basis points |
$ | 5,399 | $ | — | $ | 5,399 | ||||||
| Down 300 basis points |
$ | (8,685 | ) | $ | — | $ | (8,685 | ) | ||||
| Down 200 basis points |
$ | (6,030 | ) | $ | — | $ | (6,030 | ) | ||||
| Down 100 basis points |
$ | (3,206 | ) | $ | — | $ | (3,206 | ) | ||||
| (1) |
Excludes the impact of incentive fees based on Pre-Incentive Fee Net Investment Income. |
While our 2027 Notes, our 2026 Notes, and our 2022 Asset-Backed Notes bear interest at a fixed rate, our Credit Facilities have floating interest rate provisions. The Key Facility is subject to an interest rate floor of 0.10% per annum, based on a prime rate index which resets monthly. The interest payable on the NYL Facility is based on the Three Year I Curve rate plus a margin of 3.20% with an interest rate floor and resets on any advance date. The interest payable on the Nuveen Facility is based on the United States Treasury constant maturity 3-year and 5-year rates plus a margin of 3.15% with an interest rate floor and resets on any advance date. Any other credit facilities into which we enter in the future may have floating interest rate provisions. We have used hedging instruments in the past to protect us against interest rate fluctuations, and we may use them in the future. Such instruments may include caps, swaps, futures, options and forward contracts. While hedging activities may insulate us against adverse changes in interest rates, they may also limit our ability to participate in the benefits of lower interest rates with respect to the investments in our portfolio with fixed interest rates. Engaging in commodity interest transactions such as swap transactions or futures contracts on our behalf may cause our Advisor to fall within the definition of “commodity pool operator” under the Commodity Exchange Act (the “CEA”), and related Commodity Futures Trading Commission (the “CFTC”), regulations. On January 31, 2020, our Advisor claimed an exclusion from the definition of the term “commodity pool operator” under the CEA and the CFTC regulations in connection with its management of us and, therefore, is not subject to CFTC registration or regulation under the CEA as a commodity pool operator with respect to its management of us.
Because we currently fund, and expect to continue to fund, our investments with borrowings, our net income is dependent upon the difference between the rate at which we borrow funds and the rate at which we invest the funds borrowed. Accordingly, there can be no assurance that a significant change in market interest rates will not have a material adverse effect on our net income. In periods of rising interest rates, our cost of funds could increase, which would reduce our net investment income.
Inflation and Supply Chain Risk
Economic activity has continued to accelerate across sectors and regions. Nevertheless, due to global supply chain issues, geopolitical events, a rise in energy prices and strong consumer demand as economies continue to reopen, inflation is showing signs of acceleration in the U.S. and globally. Inflation is likely to continue in the near to medium-term, particularly in the U.S., with the possibility that monetary policy may tighten in response. Persistent inflationary pressures could affect our portfolio companies’ profit margins.
Item 4. Controls and Procedures
(a) Evaluation of disclosure controls and procedures
As of September 30, 2024, we, including our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a‑15(e) under the Exchange Act). Based on that evaluation, our management, including our Chief Executive Officer and Chief Financial Officer, concluded that our disclosure controls and procedures were effective and provided reasonable assurance that information required to be disclosed in our periodic SEC filings is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. However, in evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated can provide only reasonable assurance of achieving the desired control objectives, and management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of such possible controls and procedures.
(b) Changes in internal controls over financial reporting.
There have been no material changes in our internal control over financial reporting (as defined in Rules 13a‑15(f) and 15d‑15(f) under the Exchange Act) during our most recently completed fiscal quarter, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
We are not currently subject to any material legal proceedings, nor, to our knowledge, are any material legal proceeding threatened against us. From time to time, we may be a party to certain legal proceedings in the ordinary course of business, including proceedings relating to the enforcement of our rights under contracts with our portfolio companies. Our business is also subject to extensive regulation, which may result in regulatory proceedings against us. While the outcome of any such future legal or regulatory proceedings cannot be predicted with certainty, we do not expect that any such future proceedings will have a material effect upon our financial condition or results of operations.
In addition to other information set forth in this quarterly report on Form 10-Q, you should carefully consider the factors set forth in “Item 1A Risk Factors” in our annual report on Form 10‑K for the year ended December 31, 2023, which could materially affect our business, financial condition and/or operating results. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially affect our business, financial condition and/or operating results. There have been no material changes during the nine months ended September 30, 2024 to the risk factors set forth in “Item 1A. Risk Factors” of our annual report on Form 10-K for the year ended December 31, 2023.
Item 2: Unregistered Sales of Equity Securities and Use of Proceeds
None.
Item 3: Defaults Upon Senior Securities
None.
Item 4: Mine Safety Disclosures
Not applicable
Rule 10b5-1 Trading Plans
During the fiscal quarter ended September 30, 2024, of our directors or executive officers adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement”.
EXHIBIT INDEX
| Exhibit |
Description |
|
| 31.1* |
||
| 31.2* |
||
| 32.1* |
||
| 32.2* |
||
| 101.INS | Inline XBRL Instance Document (the Instance Document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document) | |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |
* Filed herewith
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Quarterly Report on Form 10‑Q to be signed on its behalf by the undersigned, thereunto duly authorized.
| HORIZON TECHNOLOGY FINANCE CORPORATION |
||
| Date: October 29, 2024 |
By: |
/s/ Robert D. Pomeroy, Jr. |
| Name: |
Robert D. Pomeroy, Jr. |
|
| Title: |
Chief Executive Officer and Chairman of the Board |
|
| Date: October 29, 2024 |
By: |
/s/ Daniel R. Trolio |
| Name: |
Daniel R. Trolio |
|
| Title: |
Chief Financial Officer |
|